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ABSTRACT 
In an attempt to bridge the widely acknowledged gap between research and clinical 
practice, this thesis examined the feasibility of benchmarking outcomes for published 
psychological treatments of chronic pain for application within routine clinical settings. 
Benchmarking outcomes is relatively common for psychological treatments in the mental 
health field, but in spite of the prevalence of chronic pain and its known impact on many areas 
of functioning, the chronic pain literature has previously only considered the generic 
application of benchmarks for developing services and considering standards for waiting times.   
Four studies of mixed methodological approaches were conducted. The first aimed to 
ascertain the extent of similarities between published psychological treatments of chronic pain 
and treatments delivered in routine clinical settings. This was to ensure that the application of 
benchmarks from the published literature to routine clinical settings would be meaningful. The 
second study examined whether the published literature was likely to facilitate the 
development of benchmarks, and the third sought clarification in terms of outcome domains 
within which useful benchmarks could be generated. The final study was a meta-analysis of 
data extracted from the published literature within specified outcome domains.  
The results suggested that it would be meaningful to apply benchmarks produced from 
the published literature to routine clinical settings, and that the literature would facilitate the 
development of benchmarks within several outcome domains. The meta-analysis led to the 
generation of four benchmarks. These were in the outcome domains of pain experience and 
physical functioning when compared with waiting list controls, and coping and cognitive 
appraisal and emotional functioning when compared with active controls. The impact of the 
design of each study and properties inherent within the literature on the benchmarks 
generated and their application within routine clinical settings was then considered, prior to 
suggestions for future research and clinical applications. 
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INTRODUCTION 
The clinical psychology profession is based on the ‘scientist-practitioner’ model; 
developed in a drive to overcome the conflict between clinical practice and research 
(Barkham & Mellor-Clark, 2003) by ensuring the ability of practitioners to function 
competently as both clinicians and researchers (Barker, Pistrang & Elliott, 2002). The 
accreditation of clinical psychology training courses aims to facilitate the development of 
such competencies, in insisting that in addition to clinical skills, psychologists in clinical 
training (PICTs) are taught how to digest research and apply findings to clinical practice, 
and are supervised in conducting advanced applied research within a doctoral level thesis 
(British Psychological Society, 2007). This thesis aimed to both demonstrate the author’s 
ability to function as a researcher, and attempt to bridge a gap between research and 
clinical practice by considering the published research data into psychological treatments 
of chronic pain and its potential application to clinical practice. The overall aim was to use 
the published literature to benchmark outcomes for psychological treatments of chronic 
pain which could be applied within clinical settings, and a number of steps were taken in 
order to achieve this. These included determining whether the application of research data 
to clinical settings would be meaningful and if the published literature would facilitate such 
application; considering the outcome domains within which benchmarks could be 
generated; and finally, ascertaining what the benchmarks suggested about the impact of 
psychological treatments of chronic pain and considering how they could be used within 
clinical practice.  
Research and Clinical Practice  
The National Institute for Health and Clinical Excellence considers the best 
available evidence in its clinical guidance, and because Randomised Controlled Trials (RCTs) 
and systematic reviews and meta-analyses of RCTs are considered to provide evidence of 
the highest quality (Greenhalgh, 2006), they tend to have the greatest impact on clinical 
guidance. RCTs produce ‘efficacy’ data about treatments, and the application of such data 
to routine clinical settings is referred to as ‘evidence-based practice’. Although this 
paradigm is often assumed to be sufficient to support practice in routine clinical settings, 
the controlled conditions reported in efficacy studies mean that data is not necessarily 
externally valid to clinical settings. This has resulted in a ‘gap’ between research and clinical 
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practice, and explains why it has been argued that the move towards evidence-based 
practice has essentially re-emphasised the research-practice division within the clinical 
psychology profession (Kazdin, 2008). In contrast to evidence-based practice, ‘practice-
based evidence’ comprises data about therapeutic effectiveness obtained from clinical 
settings, and as such is regarded as externally valid. Whilst the methodological quality of 
effectiveness studies is not considered to be comparable to that of RCTs, effectiveness 
findings are at least representative of the populations to which they will be applied 
(Seligman, 1995; Shadish, Matt, Navarro & Phillips, 2000).  
Efficacy and effectiveness studies have their own strengths and weaknesses, but it 
has long been recognised that research into the efficacy as well as effectiveness of 
treatments is essential to ensure that the evidence-base directing practice does not 
suppress innovation (NHS Executive, 1996). Green and Glasgow (2006) have recently 
acknowledged that that ‘if we want more evidence-based practice, we need more practice-
based evidence’ (p. 126),and there is therefore a need to acknowledge both RCT and 
clinical setting data, and to attempt to overcome the inherent difficulties in translating 
findings across these settings (Kazdin, 2008).  
Bridging the Gap between Research and Clinical Practice: Benchmarking 
One way in which efficacy data can be translated to clinical settings is through the 
use of ‘benchmarking’ (Barkham, Mellor-Clark, Connell & Cahill, 2006; Minami, Wampold, 
Serlin, Kircher & Brown, 2007; Weersing & Weisz, 2002). Benchmarking allows 
professionals within clinical settings to consider research evidence (Goodheart, et al., 
2006), and reflect on its application to clinical practice within a comprehensible format 
(Minami, Serlin, Wampold, Kircher & Brown, 2008; Wampold, Goodheart & Levant, 2007). 
Clinical governance requires the effectiveness of routine clinical practice to be measured 
(Department of Health, 1999), and benchmarking allows this in terms of the extent to 
which clinical outcomes are comparable to research outcomes (Minami, et al., 2008; Wade, 
Treat & Stuart, 1998); a comparison which can also facilitate an understanding of ‘what 
works for whom’ (Roth & Fonagy, 1996).  
Benchmarking Psychological Treatments 
Whether or not benchmarks aggregate efficacy data to compare with aggregated 
effectiveness data or utilise single studies to compare outcomes, benchmarking can 
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enhance the knowledge base for psychological treatments within a process considered to 
be a 'virtuous circle' (Barkham, Mellor-Clark, Connell & Cahill, 2006). This process not only 
informs clinical practice, but is also congruent with the clinical psychology profession's 
scientist-practitioner role (Barkham & Mellor-Clark, 2003). Additionally, the ability of 
benchmarking to accommodate for the limitations of effectiveness designs was first 
acknowledged three decades ago (T. Cook & Campbell, 1979), and more recently it has also 
been credited with helping to overcome the limitations of efficacy data (Wade et al.,1998).  
There are a number of psychological therapies and diagnostic categories across 
which benchmarking has been applied. The seminal study of Wade et al. (1998) focused on 
panic disorder, and the magnitude of treatment effects was estimated within an 
effectiveness study which was comparable with two efficacy studies. The measure of 
effectiveness within this study was 'relative' in that it was determined by the proportion of 
participants meeting pre-set criteria, relative to the proportion of participants 
demonstrating similar improvements within the efficacy studies. Wade et al. (1998) found 
that the magnitude of effectiveness was on a par with those found in the efficacy studies, 
with the vast majority of participants (87%) describing themselves as 'panic free' post-
treatment. Similar levels of improvement were seen in terms of anticipatory and general 
anxiety and levels of depression.  
Wade et al. (1998) can be considered to have set the precedent for subsequent 
benchmarking studies, which have in the main been conducted within the depression 
literature in examining eclectic services with adolescent (Weersing & Weisz, 2002) and 
adult populations (Barkham, Rees, Leach, Shapiro, Hardy & Lucock, 2005; Barkham, Stiles, 
Connell, Twigg, Leach, Lucock, et al., 2008); and adults receiving a variety of standardised 
therapies (Minami, et al., 2007). Benchmarking has more commonly been applied within 
the adult mental health field, but has also been used within health psychology to 
determine the relative effectiveness of a pilot programme of Cognitive Behavioural 
Therapy (CBT) for clients with Chronic Fatigue Syndrome (CFS) to RCT outcomes (Scheeres, 
Wensing, Knoop & Bleijenberg, 2008) and to produce quality guidelines for standards of 
care for people with epilepsy (Pugh, et al., 2007).  
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Chronic Pain 
Pain is subjective, and has been defined by Merskey and Bogduk (1994) as ‘an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage’ (p. 210). Chronic pain is technically pain 
which has lasted for six months or longer (APA, 2004), although most literature considers 
pain that does not resolve, is unresponsive to treatment and lasts for longer than three 
months to be an indicator of chronicity (Tunks, Crook & Weir, 2008).  
The Impact of Chronic Pain 
The estimated prevalence of chronic pain in adults is between 12% and 30% 
(Breivik, Collett, Ventafridda, Cohen & Gallacher, 2006). It is associated with significant 
distress and disability in all domains of life (Turk, Swanson & Tunks, 2008); contributing to 
somatic complaints and problems with social and emotional well-being and abilities to 
manage daily activities (Breivik, et al., 2006). Chronic pain has negative implications for 
employment and work related roles (Boersma & Linton, 2006; Breivik, et al., 2006; Morley 
& Eccleston, 2008), and is associated with fatigue, poor sleep, reliance on support systems, 
loss of social and familial roles, anger and frustration (Morley & Eccleston, 2008) and 
depression (Boersma & Linton, 2006; Breivik, et al., 2006; Morley & Eccleston, 2008; Tunks, 
Weir & Crook, 2008). People with chronic pain also frequently report sexual dysfunction 
associated with depression, poor coping skills and inadequate social support, with indirect 
effects of medication on impairment (Kwan, Roberts & Swalm, 2005).  
Pathology does not predict an individual’s perceptions of and responses to pain but 
evidence suggests that cognitive, emotional, behavioural and social factors impact on both 
pain experience and response to treatment (Adams, Poole & Richardson, 2006; Turk, 1999; 
Turk & Okifuji, 2002); with employment, coping styles (Tunks, Weir, et al., 2008), marital 
satisfaction, spousal responses to pain (Cano, Gillis, Heinz, Geisser & Foran, 2004), feelings 
of control over pain, resilience (Karoly & Ruehlman, 2006), and fear-avoidance and pain 
beliefs (Boersma & Linton, 2006) all being identified as moderators of outcome.  
Treatments of Chronic Pain  
Given the detrimental effects of chronic pain on multiple areas of an individual’s 
life and the many moderators of outcome, a biopsychosocial model is essential in 
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understanding the experience and ensuring that effective treatments are provided (Adams, 
et al., 2006; Philips & Rachman, 1996; Tunks, Crook, et al., 2008; Turk & Okifuji, 2002; Turk, 
Swanson, et al., 2008). This is acknowledged within recommendations that multi-
disciplinary treatments are provided for people with chronic pain (British Pain Society, 
2007; Tunks, Weir, et al., 2008; Turk & Okifuji, 2002). 
Treatments for chronic pain include psychodynamically informed insight-oriented 
approaches, motivational interviewing, biofeedback, guided imagery and hypnosis (Turk, 
Swanson, et al., 2008); and treatments such as behavioural therapy, biofeedback and 
relaxation are all associated with improvements to pain experience, affect, coping and 
social role functioning when compared with control groups (Morley, Eccleston & Williams, 
1999). Evidence also suggests that mindfulness meditation is associated with reduced 
physical and psychological pathology, with many changes being maintained at follow-up 
(Kabat-Zinn, Lipworth & Burney, 1985). Mindfulness meditation also accounts for 
significant proportions of variance in terms of pain, physical, social, emotional and 
cognitive functioning, overall disability and medication use (McCracken, Gauntlett-Gilbert 
& Vowles, 2007). Similarly, acceptance-based approaches have been associated with 
reduced healthcare use and improvements to levels of social, physical and emotional 
functioning (McCracken, Vowles & Eccleston, 2005). 
  More than fifty published RCTs have examined the efficacy of psychological 
treatments of chronic pain, with CBT demonstrating the greatest empirical support on a 
significant number of pain related domains including pain, affect and disability (Eccleston, 
Williams & Morley, 2009; Morley, et al., 1999) and coping strategies (Morley, et al., 1999). 
There is also emerging evidence for the effectiveness of CBT within routine clinical settings 
(Morley, Williams & Hussain, 2008). 
Benchmarking Psychological Treatments of Chronic Pain  
The meaningful application of benchmarking has been demonstrated across a 
number of treatment settings. However, this does not challenge the intuitive argument 
that benchmarking is of greatest utility when treatments delivered are standardised and 
available in clinical and research settings, such as Beck’s model of cognitive therapy for 
depression (Beck, Ward, Mendelson, Mock & Erbaugh, 1961), and the same outcome 
measures are employed within both settings. Benchmarking may also be of greatest use 
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when treated populations are similar enough to one another to ensure that research and 
clinical comparisons are meaningful. Psychological treatments of chronic pain, in clinical or 
research settings, do not lend themselves to such comparisons however. Rather, the 
literature reports myriad psychological treatments, methods of delivery, levels of therapist 
training and experience, treatment populations and outcome measures. It has been 
acknowledged that the comparison of data generated within RCT and clinical settings is not 
ideal given that the settings are unlikely to be identical, but that until an alternative 
becomes available, benchmarking efficacy data is the best available option (Minami, et al., 
2009).  
Prior to considering benchmarking for psychological treatments of chronic pain, 
the existing benchmarking literature and ways in which it has overcome heterogeneity 
obstacles warrants consideration, in order that the feasibility of producing benchmarks 
within an imperfect context can be explored. It demonstrates that studies have varied, for 
example, in terms of whether they chose to focus on single or multiple psychological 
treatments. Wade et al. (1998) focused on CBT but aggregated data from trials regardless 
of whether delivery had been individual or in groups, and Weersing and Weisz (2002) 
examined the same broad psychological treatment as deemed to be the 'research standard 
of care' regardless of eclectic modes of delivery. Other studies used data from any 
treatments that were evidence-based (Pugh, et al., 2007), or those which had been 
identified as the primary treatment within a recent literature review (Scheeres, et al., 
2008). Outcomes from different therapies have also been aggregated (Barkham, Rees, et 
al., 2005; Barkham, et al., 2008; Minami, et al., 2007), and this mode of benchmarking is 
permitted given the reported equivalent effects of different psychological treatments that 
are based on psychological principles and delivered by qualified therapists (Wampold, et 
al., 1997).  
Another factor worthy of consideration is the observed heterogeneity of levels of 
experience and professional backgrounds of therapists delivering treatments within the 
chronic pain literature (Eccleston, et al., 2009; Morley, et al., 1999). This also requires 
consideration in terms of both the way in which benchmarking is conducted and the 
external validity of the findings. 
With reference to treatment populations, the chronic pain literature tends to 
categorise clients by presentation to services rather than diagnosis (Morley, 2008; Morley 
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& Eccleston, 2008) as both anecdotal and research findings suggest that diagnosis does not 
account for a great deal of variance in treatment outcome (Van Tulder, Assendelft, Koes & 
Bouter, 1997). Most benchmarking studies have considered populations with a 
homogeneous diagnosis, however, with the exception of Barkham et al. (2008) who 
included more heterogeneous groups, and such methods are likely to possess greater 
external validity and be more valuable within the chronic pain literature.  
The benchmarking literature has also demonstrated variations in terms of methods 
employed. For example, Scheeres et al. (2008) reported the proportion of patients within 
their study who demonstrated clinically significant levels of improvement. This reflects a 
recent trend towards more sophisticated methods of demonstrating change in terms of 
whether post-treatment scores were within normative ranges; methods also employed by 
Barkham et al. (2008) and Wade et al. (1998).  As Scheeres et al. (2008) were unable to 
access similar data within efficacy studies, however, they also calculated the magnitude of 
the treatment effect within all studies using effect sizes and confidence intervals (CIs); 
therefore enabling them to make relative comparisons between each treatment. Barkham, 
Rees et al. (2005) and Barkham et al. (2008) made similar relative treatment comparisons, 
but chose to transform scores between homogeneous measures used in clinical settings 
and compare these with a standard measure used in research settings; methods that are 
unfortunately irrelevant to the chronic pain literature given the heterogeneity of measures 
employed (Eccleston, et al., 2009; Morley, et al., 1999). Weersing and Weisz (2002) 
additionally compared their outcomes with treatments described in the efficacy literature, 
and, like Minami et al. (2007), reported the relative effectiveness of their treatment to 
control groups. Such relative methods are of great utility, as if comparisons are not made 
with a control group, the magnitude of the treatment effect is likely to be overestimated as 
there is no allowance for spontaneous remission.  
Whilst matters of treatments, therapist and population factors and outcome 
measures require considerable forethought, it is reasonable to assume that chronic pain is 
another field of health psychology within which benchmarking may be feasible. It has 
previously been considered in terms of designing services (Donovan, Evers, Jacobs & 
Mandleblatt, 1999) and specifying waiting times within this field (Lynch, et al., 2008) and a 
recent consultation exercise aims to generate general best practice benchmarks for the 
treatment of pain (Department of Health, 2009). However, benchmarking has yet to be 
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considered as one way of bridging the gap between research and clinical practice 
concerning outcomes for psychological treatments of chronic pain. Bridging this gap is 
important for a number of reasons, not least to ensure that treatments provided in clinical 
settings are evidence based and facilitate realistic treatment expectations. Research 
suggests that whilst patient reported levels of satisfaction with treatments provided for 
chronic pain, whether medical, physical or psychological, are generally good (George & 
Hirsh, 2005; Hirsh, et al., 2005; McCracken, Evon & Karapas, 2002), levels of satisfaction 
with the effects of treatment vary between 40% (Breivik, et al., 2006) and 55% (Hirsh, et 
al., 2005). This may be related to recent findings that patients often have unrealistic 
expectations of the effects of psychological treatments (Thorne & Morley, 2009). Though it 
is recognised that expectations often change as treatments progress, unrealistic 
expectations are somewhat understandable given that neither clinicians nor researchers 
are currently able to convey realistic outcomes. Expectations are known to impact on 
psychological outcomes and pain experience however (Kirsch, 1985, 1999; Price, et al., 
1999), and chronic pain is admittedly a relatively common condition which can have a 
detrimental impact on many aspects of functioning. There is therefore a clear argument for 
at least attempting to build a bridge between research and clinical practice; aiming to both 
provide effective treatments and generate realistic outcomes as a result.  
Research Questions 
 The literature reviewed led to the development of a number of research questions 
related to the issue of benchmarking outcomes for psychological treatments of chronic 
pain:  
1. Is it meaningful to use the efficacy literature to develop benchmarks which can 
be applied to routine clinical settings?  
This was explored within study 1, which aimed to determine whether routine 
clinical practice is evidence-based, and subsequently, whether it would be 
meaningful to compare it with published efficacy data from RCTs (see pages 20-
30). 
2. Does the published literature contain data which facilitates the development of 
benchmarks?  
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This question was examined within study 2, which aimed to determine whether the 
aggregation of data from published RCTs is likely to produce benchmarks (see 
pages 31-44).  
3. Are there particular outcome domains within which it is useful to produce 
benchmarks for use in clinical settings? 
Study 3 aimed to answer this question in generating a consensus opinion of 
clinicians working in routine clinical practice as to useful domains to benchmark 
(see pages 45-56).  
4. What do the benchmarks suggest about the impact of psychological treatments 
of chronic pain within particular outcome domains?   
This question was examined within study 4: a meta-analysis of the data identified 
in study 2 within the domains identified within study 3 (pages 57-81).  
 
As there were a number of research questions to be explored within four separate 
studies, a mixed methodological approach was taken. Each study has been described 
sequentially in terms of its aims, methods, results and a study-specific discussion prior to a 
final overall discussion. It is worth noting, however, that as several of the procedures were 
conducted concurrently, some studies make reference to data obtained in later studies. 
With this in mind, every effort has been taken to ensure that such references are both 
logical and necessary. 
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STUDY 1: IS IT MEANINGFUL TO USE THE EFFICACY LITERATURE TO DEVELOP BENCHMARKS 
WHICH CAN BE APPLIED TO ROUTINE CLINICAL SETTINGS?  
AIMS  
This study aimed to determine whether there are enough similarities with the 
published literature to ensure that benchmarks developed in efficacy contexts could be 
meaningfully applied to clinical settings.  
METHOD  
Design 
This study employed a mixed quantitative and qualitative design which focused on the 
staff, patients, treatments and outcome measures within UK based Pain Management 
Programmes (PMPs).  
Ethical Clearance 
This study did not require ethical approval, as confirmed in Appendix 1.  
Participants 
Participants were members of staff working in PMPs across the UK.  
Measures 
A survey was designed in order to determine whether routine clinical practice is 
evidence-based (see Appendix 2). The survey questions were based on a form for extracting 
data from RCTs for chronic pain. This form had been previously approved by the Cochrane 
Collaboration and used within a recent systematic review of the chronic pain literature 
(Eccleston, et al., 2009).  
Procedure 
Participants were invited to participate by several methods. Professor Stephen Morley 
(SM) introduced the study and invited participation following his plenary session at the British 
Pain Society’s Annual Scientific Meeting in April 2009. Additionally, an email was sent to 
approximately 200 people; seventy-six of whom were members of the British Pain Society’s 
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PMP Special Interest Group (SIG) (British Pain Society, 2009) and the rest of whom had 
attended the most recent PMP SIG conference and volunteered their contact details. 
The survey was developed and deployed using the ‘Bristol Online Survey’ method; a 
widely accessible internet-based survey method used by over one-hundred higher education 
institutes and public and private sector companies (University of Bristol, 2009). An electronic 
link to the survey was sent to potential participants, who were invited to respond within a 
reasonable time frame. Responses were summarised and to ensure that the anonymity of 
participants was maintained, a summary of the preliminary results was forwarded to the 
original email list, whether or not they had chosen to participate (see Appendix 3). The results 
were then compared with preliminary data extracted from the published literature identified 
within study 2, with specific reference to the psychological treatment within each RCT that had 
been classified as primary for the purposes of this research.  
RESULTS 
Thirty-six separate responses were received in total, all of which were from people 
involved with services in England. All responses were included within the preliminary results 
sent to participants, but the responses of three participants were excluded from the final 
analysis of data because two participants worked within services that were not classified as 
PMPs and one participant chose to withhold the name of the service within which they worked 
and so its PMP status could not be determined. Some participants chose to not respond to 
particular questions, but all proportions were calculated in relation to the overall maximum 
number of available responses, i.e. thirty-three.  
Whilst the survey was designed in consideration of an approved data extraction form, 
the various ways in which PMPs collect and publicise data means that an exact comparison 
between PMP and RCT data is not possible. Instead, a qualitative summary of the PMP data is 
provided in order to supplement the RCT data reported in Table 1 and the available 
comparisons in Table 2. As such, this was a descriptive study. 
Participant Characteristics 
More than two-thirds of participants (n=22) stated that they were responding as 
individuals, with the remaining eleven stating that their responses were on behalf of their 
team. Twenty-four participants (73%) were members of the British Pain Society, and the 
majority (67%; n=22) were physiotherapists (n=13) or clinical psychologists (n=9). The 
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remaining eleven participants (33%) classified themselves as belonging to the medical, nursing 
or occupational therapy professions.  
Team Characteristics 
Thirty-one of the participants (94%) classed themselves as belonging to an ‘inter-
disciplinary’ team where multi-disciplinary professionals worked together on a routine basis. 
The results indicated that these teams frequently comprised administrative staff, clinical 
psychologists, physiotherapists and members of the medical and nursing professions. Several 
respondents also stated that assistant psychologists and PICTs, CBT therapists, counselling and 
health psychologists, graduate patients, pharmacists and occupational therapists made 
contributions to the team. Such multi-disciplinary teams were also commonly reported within 
the RCT literature.  
In terms of professional development, 67% of participants (n=22) stated that an 
induction programme was routine for new staff and that systematic clinical supervision was 
routinely provided. Whilst only 36% (n=12) stated that therapeutic training was routinely 
provided for clinicians, 85% (n=28) agreed that staff were encouraged to allocate time for 
continuing professional development on a regular basis. Several participants suggested that 
the manner in which continuing professional development, clinical supervision, inter-
disciplinary working and induction periods were encouraged and provided was variable.  
Patient Characteristics 
Participants’ estimates of the number of patients seen per annum varied, reflecting the 
varied capacities and clinical foci of PMPs. Most estimated that fewer than 100 patients were 
treated per annum (52%; n=17), 36% (n=12) estimated between 100 and 200, and 12% (n=4) 
estimated more than 200. Similar data were not extractable from the RCTs, but all participants 
estimated that the average age of patients was between 40 and 50, and as Table 1 
demonstrates, this was not dissimilar to the average age amongst participants entered into the 
RCTs (mean 51.5; SD 11.7). Services did not appear to have imposed upper age limits, but only 
6% of respondents (n=2) implied that referrals of patients under the age of 18 would be 
accepted. Both PMP and RCT settings seemed to comprise a larger proportion of female than 
male patients, as 85% of participants (n=28) estimated that at least 60% of patients were 
female; similar to the 72% of RCTs shown in Table 1 (n=26) comprising samples where at least 
60% of patients were female.  
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Table 1: Included studies and preliminary sample and outcome data 
Study Mean age (SD) % female Primary 
diagnosis or 
site of pain 
Follow-up data 
collected 
Altmaier 1992 39.9 (8.9) 27 CLBP • 
Astin 2003 47.7 (10) 99 MSK (Fib) • 
Basler 1997 49.3 (9.7) 59 CLBP • 
Becker 2000 56.5 (15) 64 Mixed • 
Bliokas 2007 45.2 (9.6) 56 Mixed ◦ 
Carson 2005 51.1 (nk) 60 CLBP ◦ 
Cook 1998 77.6 (nk) 62 Mixed • 
Ersek 2003 82 (nk) 87 Mixed  ◦ 
 Ersek 2008 81.9 (nk) 85 Mixed  • 
Evers 2002 53.7 (nk) 71 RA • 
Flor 1993 42.4 (9.7) 64 Mixed • 
Greco 2004 47.3 (10.4) 93 SLE • 
Haldorsen 1998 43 (10.6) 64 Mixed  ◦ 
 Jensen 2001 43.3 (10.4) 56 Mixed • 
Johansson 1998 43.5 (7.6) 78 MSK • 
Keefe 1990 64 (11.5) 72 OA • 
Keefe 1996 62.6 (10.1) 61 OA • 
Kraaimaat 1995 57 (12.7) 68 RA • 
Linton 2008 47.5 (8.6) 55 Spi 
 
◦ 
Mishra 2000 35.7 (9.9) 82 TMD ◦ 
Moore 1985 49.3 (13.2) 98 Mixed • 
Morone 2008 74.9 (6.1) 57 CLBP ◦ 
 Newton-John 1995 45.4 (11.6) 61 CLBP • 
Nicassio 1997 53.1 (nk) 89 MSK (Fib) • 
Puder 1988 52.7 (14.4) 71 Mixed • 
Radojevic 1992 54.4 (nk) 76 RA • 
Thieme 2003 47.6 (nk) 100 MSK (Fib) • 
Turner 1988 46 (nk) 59 CLBP • 
Turner 1990 44 (nk) 48 CLBP • 
Turner 1993 42 (nk) 54 CLBP • 
Turner 2006 37.1 (11.3) 81 TMD • 
Vlaeyen 1995 42.2 (nk) 75 CLBP • 
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Study Mean age (SD) % female Primary 
diagnosis or 
site of pain 
Follow-up data 
collected 
Vlaeyen 1996 44 (9.4) 88 MSK (Fib) ◦ 
 Williams 1996 50 (nk) 56 Mixed • 
Woods 2008 46.5 (11.9) 66 CLBP • 
Zautra 2008 52.4 (nk) 68 RA ◦ 
 
Note • = measured, ◦ = not measured ; % female = percentage of patients in each sample who were female, calculated from 
published information therefore sometimes at start of treatment, sometimes at end; CLPB = Chronic Low Back Pain; Fib =  
Fibromyalgia; MSK = Musculoskeletal; nk = not known; OA = Osteoarthritis; RA = Rheumatoid Arthritis; SLE = Systemic Lupus 
Erythematosus; Spi = spinal; TMD = Temperomandibular.  
 
The preliminary RCT data extracted within study 2 also allowed for some specific 
diagnostic comparisons to be made. For example, 21% of participants (n=7) made specific 
reference to the fact that it was common for patients with multiple sites of pain and mixed 
diagnoses to be seen within their PMP (with service inclusion criteria exerting the main 
influence). The RCT literature also made reference to the multiple sites of pain experienced by 
many patients and the influence of service inclusion criteria, with 31% of studies (n=11) 
involving patients with mixed diagnoses.  
Twenty-one of the participants (64%) estimated that at least 61% of their patients 
commonly had chronic low back pain, and nearly a third of the included RCTs (28%; n=10) 
involved patients with this primary diagnosis. Sixteen participants (48%) estimated that at least 
70% of their patients had musculoskeletal pain, and 14% of the included RCTs (n=5) might 
therefore apply to them. Both the RCT and PMP data implied that osteoarthritis was a less 
common diagnosis amongst patients treated, as nearly half of all PMP respondents estimated 
that around 11% of their patients had this diagnosis, and only two of the included studies (6%) 
involved patients with this primary diagnosis. Amongst the remaining included RCTs, 
rheumatoid arthritis was the primary diagnosis within four studies (11%), temperomandibular 
joint syndrome the focus of two (6%) and systemic lupus erythematosus of one (3%). The 
remaining study involved patients with primary spinal pain.  
Participants suggested that fewer patients were likely to present with diagnoses such 
as complex regional pain syndrome, facial pain, headache, inflammatory arthropathy such as 
rheumatoid arthritis or lupus, temperomandibular joint syndrome, vascular, post-operative or 
visceral pain.  
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Treatment Characteristics 
Participants were asked to describe the components of the main psychological 
treatment offered within their PMP, and so for comparative purposes, data regarding a 
psychological treatment deemed to be primary was extracted from the RCTs included in study 
2. Table 2 demonstrates the proportion of characteristics within PMP treatments and primary 
psychological treatments characteristics from included RCTs.  
Table 2: Comparison of treatment and outcome characteristics between PMPs and RCTs 
Characteristic 
PMP data 
(%) 
RCT data 
(%) 
Primary Treatment  
 
  
Out-patient 88 86 
Total duration at least 10 hours 91 94 
CBT
 a
 
 
 39 61 
CBT plus other components 18 11 
Mixed/other/unknown primary treatment
 b
 43 28 
Group based 61 89 
Individual based 0 11 
Involvement of significant others 58 16 
Mixed methods of delivery c
 
 27 28 
Components of treatment   
Educational 97 100 
Relaxation 88 80 
Cognitive restructuring 85 72 
Behavioural management 73 72 
Goal-setting 97 69 
Coping-skills 97 69 
Exercise 94 47 
Problem-solving 88 50 
Mindfulness 67 8 
Biofeedback 30 8 
Outcome measures   
Administered pre-treatment 94 100 
Post-treatment 94 100 
Follow-up 85 75 
Note 
a CBT = Cognitive Behavioural Therapy. 
b
 Unknown treatment refers to the response of one participant within the PMP survey.  
c mixed methods of delivery refers to treatments that, for example, may involve the delivery of some components in a group, other 
components on an individual basis etc.  
 
PMPs and RCTs are clearly comparable with regard to the provision of treatments 
within out-patient settings using mixed methods of delivery of at least ten hours duration. The 
mean number of hours treatment was higher in PMPs (51) than RCTs (28.9), although the large 
standard deviation (SD) in RCTs (34.1) reflects the variability in treatment duration which 
ranged from six to 160 hours. As participants gave approximate estimates of treatment 
duration it was not possible to calculate the SD from the mean of PMP treatment duration, but 
26 
 
they estimated that the main psychological treatments provided were between three and over 
one-hundred hours in duration. This indicates that both research and clinical settings involve 
treatments of varying duration.  
A greater proportion of the primary psychological treatments in RCTs than PMPs were 
classified as CBT or CBT in addition to other components (72% and 57% respectively). Whilst 
the proportion of PMPs using such treatments was significant, several participants described a 
recent move to more ‘third wave’ cognitive behavioural treatments such as Acceptance and 
Commitment Therapy (ACT) and mindfulness based cognitive therapy, particularly when pain 
was not related to activity (n=1) or where many patients did not have English as a first 
language (n=1).  
Similar proportions of non-CBT primary treatments were reported within the PMP and 
RCT data, and a large proportion of all primary treatments in both settings were provided 
within groups, although 11% of the RCTs (n=4) described individual psychological treatments. 
PMPs were more likely than RCTs to involve significant others within the main psychological 
treatment, and seventeen of the nineteen participants who stated this implied the 
involvement of significant others within specific treatment sessions rather than as integral to 
the treatment as a whole.  
A large proportion of PMPs and RCTs cited education, relaxation, cognitive 
restructuring, behavioural management, goal setting and coping skills as components of the 
main psychological treatment, although the latter two were more common within PMPs. 
Additionally, exercise, problem solving, mindfulness and biofeedback were more commonly 
components of the main PMP treatments than the main RCT treatments.  
Within PMPs, 48% of participants (n=16) reported that manuals were used within the 
main psychological treatment, and 44% (n=7) implied that they guided all aspects of treatment. 
RCTs were more likely to refer to manuals (61%; n=22), although on closer inspection, 91% of 
these studies (n=20) had adapted treatments that were described within published papers 
rather than following a specified manualised protocol. Similarly, all manuals used within PMPs 
had been developed in-house and specifically tailored in line with the treatment aims.  
Whilst it was not possible to determine the proportion of RCTs who offered follow-up 
appointments to patients, 91% of PMP participants (n=30) stated that their programme offered 
follow-ups, with 39% (n=13) stating that they routinely followed up patients who dropped out 
of treatment; usually by telephone or in writing.  
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Outcome Characteristics 
Similar proportions of RCTs and PMPs administered outcome measures both before 
and after treatment (94% of PMPs and 100% of RCTs), with a slightly greater proportion of 
PMPs than RCTs administering follow-up measures (85% and 75% respectively).   
Participants reported that outcome measures within the domains of coping, mood, 
disability and health and social care use were most likely to be administered within PMPs, and 
all participant-reported measures of coping, mood, disability and pain experience were 
standardised. There was some consistency within the coping domain within which the Coping 
Strategies Questionnaire (CSQ) of Rosensteil and Keefe (1983) and the Pain Self-Efficacy 
Questionnaire (PSEQ) of Bandura (1997) were commonly used. The Hospital Anxiety and 
Depression Scale (HADS) designed by Zigmond and Snaith (1983) was the most commonly 
employed measure of mood. Within the domain of health and social care use, employment 
status, medication use and number of GP and other medical service visits were commonly 
recorded, and there was less consistency amongst measures of disability.  
DISCUSSION 
This study sought to determine the extent of the similarities between the published 
literature of psychological treatments of chronic pain and routine clinical practice in terms of 
team, patient, primary psychological treatment and outcome characteristics. Its ultimate aim 
was to ascertain whether routine clinical practice is evidence-based, and therefore if it would 
be meaningful for clinical settings to apply benchmarks developed from the efficacy literature.  
The results imply that, at least amongst the PMPs sampled, clinical practice is similar 
enough to the RCT literature to be considered ‘evidence-based’ for a number of reasons. 
Firstly, the multi-disciplinary nature of teams within both settings is promising, and reflects an 
initial comparability. Secondly, the range of estimated diagnoses amongst patients within 
PMPs was similar to those reported within RCTs. Even though the estimated representation of 
patients with particular diagnoses in PMPs was not equivalent to that reported in RCTs, 
anecdotal reports and research suggesting that diagnosis does not exert a major impact on 
outcome  (Van Tulder, et al., 1997) imply that this does not provide a cause for concern. 
Patient groups were also estimated to comprise people with a similar average age and have 
similar levels of female predominance. Thirdly, treatment characteristics were commonly 
comparable; particularly when the main psychological models employed, treatment settings 
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and ranges of duration were considered. Given that the primary psychological treatments in 
both PMPs and RCTs were seen to be CBT plus components of other treatments, the significant 
overlap of many treatment components is perhaps not surprising. Finally, the timing of the 
administration of outcome measures was similar in both settings. Whilst the outcome domains 
were considered further in studies two, three and four and so were not discussed within this 
study, all in all, the results of this study give credence to the argument that it would be 
meaningful to develop benchmarks from efficacy data that could be applied within routine 
clinical settings.  
Although it was not possible to compare the exact team and patient characteristics 
(e.g. the number of patients treated annually within services described in RCTs) and so the 
level of resources in both settings could not be determined, these results suggest that there is 
a ‘good enough’ level of similarities amongst PMPs and the published literature to ensure that 
any benchmarks produced would be meaningful. A number of factors require further 
consideration, however, including the discrepancies noted amongst treatment components. 
With this in mind, it is noteworthy that one of the consequences of benchmarking by 
aggregating data from many studies is that the external validity of the results may be 
compromised. However, unless, following the example of Wade et al. (1998), PMPs develop 
services based on treatments provided within the published literature, benchmarking will 
always be carried out within sufficiently comparable clinical and research contexts rather than 
exactly comparable contexts (Minami, et al., 2009). The methods of determining treatment 
components within the RCT data may also have contributed to such discrepancies and 
similarities, as data were only examined for psychological treatments that, for the purposes of 
this research, were deemed to be primary. The decision making process regarding the 
classification of primary treatments is described within study 2, and such a process was 
necessary to manage the volume of data generated by the included studies and ensure that it 
led to meaningful benchmarks. However, whilst it facilitated a straightforward comparison 
between the two sets of data, an unfortunate consequence of such a focus is a lack of 
understanding of all treatments offered within both settings. Another confounding factor may 
have been the RCT authors’ reporting of treatment components, as a lack of explicit mention of 
any component meant that it was deemed to be lacking, whether or not this was in fact the 
case. The scope of this research did not permit a more thorough comparative description of 
treatments in both settings, as it aimed to ascertain feasibility, but future research may benefit 
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from describing components of all treatments provided within both PMPs and RCTs in order to 
gain a more thorough appreciation of the similarities between treatments offered in both 
settings, and therefore the extent to which research findings have external validity.  
Another potential methodological limitation of this study was the fact that current 
PMP activity (i.e. at the time of data collection in 2009) was compared with historical RCT data, 
as studies had been published between 1985 and 2008. The description of treatment specific 
components may have overcome this to an extent, but until the volume of published data is 
sufficient enough to warrant only comparing recent PMP activity with recently published data, 
such a limitation is difficult to overcome.   
In further consideration of the methods employed, the potential for bias amongst the 
self-selected sample of participants within this descriptive study needs to be considered. For 
example, although anonymity was assured, the 33% of participants (n=11) who stated that 
they were responding on behalf of their team may have felt the need to portray their PMP in a 
particular manner, and as such the results should be considered as an indicator of PMP 
practice rather than conclusive evidence. The fact that 67% of respondents (n=22) considered 
themselves to be responding as individuals within their PMP also may have influenced the 
results and needs consideration. The decision to give participants the option to respond either 
as an individual or on behalf of their PMP was a deliberate attempt to encourage participation 
even if responders were unable to discuss the survey responses with colleagues, but a 
‘collective’ PMP response may also have been very different. Another potential source of bias 
may have been profession-related, as most participants were physiotherapists or clinical 
psychologists and may have provided significantly different responses to colleagues of other 
professions. In future, a larger sample from a wider range of professionals would provide a 
more representative set of results and hopefully reflect the multi-disciplinary teams described 
within PMPs and RCTs. This may involve seeking more precise data, using more than 
descriptive methods, within a service evaluation context however, and the potential impact on 
participant recruitment would require some forethought. In the meantime, this study should 
be considered to have provided an indication of PMP activity and how appropriate it is to apply 
RCT data to such contexts, based on estimates from a small sample of participants within 
approximately 41% of the 87 PMPs in England (Waring & Booth, 2006). 
Finally, whilst in so far as it was possible, every effort was taken to determine whether 
it would be meaningful to apply the efficacy literature to PMPs, without analysing the specific 
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aims and detailed content of the interventions provided within both settings the actual 
comparability can only ever be assumed. It is known that RCTs tended to adapt treatments 
described within published papers, and PMPs are more likely to develop in-house manuals, but 
the precise content of all treatments remains unknown. In future, a greater transparency of the 
components of interventions tested within efficacy trials would mean that they had greater 
clinical utility and facilitate more ‘fine-grained’ comparisons to be made, and perhaps the  
publication of accessible (e.g. internet based) manuals would facilitate comparisons in this 
manner (Thorn, Cross & Walker, 2007). In response to Green and Glasgow’s (2006) argument 
that ‘if we want more evidence-based practice, we need more practice based evidence’ (p. 
126) though, perhaps PMPs also need to be more transparent regarding their treatment aims 
and interventions; and this may also be more feasible within a service evaluation context, 
where the publication of data is considered. 
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STUDY 2: DOES THE PUBLISHED LITERATURE CONTAIN DATA WHICH FACILITATES THE 
DEVELOPMENT OF BENCHMARKS? 
AIMS  
Study 1 demonstrated that in principle, it would be meaningful to use the efficacy 
literature to develop benchmarks which can be applied to routine clinical settings. This study 
aimed to determine whether or not the aggregation of data from the published literature was 
likely to produce benchmarks.  
BACKGROUND LITERATURE  
In attempting to achieve this study’s aim, it was fundamental that high quality data 
were identified within the published literature. Several methods of review were therefore 
considered. The systematic review methods of the ‘Cochrane Review’ are considered to 
produce the highest standard of evidence-based research as they apply pre-defined and 
rigorous methods for searching the literature (The Cochrane Collaboration, 2010). Such 
systematic methods involve a thorough search of published primary literature and are 
considered scientific as they aim to identify as much of the relevant literature as possible. Such 
methods also control for bias and random error due to specified inclusion criteria and the 
statistical methods employed. Pre-defining literature search methods within Cochrane reviews 
also allows readers to make judgements about the quality of the review and ensure that 
methods are both open to criticism (DeCoster, 2004) and replicable (Centre for Reviews and 
Dissemination, 2001, 2009; Davies & Crombie, 2001; Glass, 1976; Lipsey & Wilson, 2001; 
Quintana & Minami, 2006; White, 1994).  
Alternatively, narrative reviews may be conducted. These tend to be as comprehensive 
as systematic reviews but subjective interpretation of the data are likely, whereas within 
systematic reviews, the reader should be able to draw the same conclusions as the author 
(Centre for Reviews and Dissemination, 2001, 2009). Although both types of review involve 
aggregating the literature and weighting the included studies in order that studies employing 
larger samples contribute a greater proportion to the overall results, systematic reviews rely on 
more sophisticated systematic procedures for doing so (Lipsey & Wilson, 2001). Narrative 
methods also tend to solely rely on statistical significance measures, despite the recognised 
unreliability of such measures within research (Quintana & Minami, 2006). They are also more 
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appropriate when research questions are broad rather than focused as they facilitate a 
qualitative description of study results (Centre for Reviews and Dissemination, 2001; D. Cook, 
Mulrow & Haynes, 1997; Quintana & Minami, 2006). In contrast, benchmarking necessitates 
the quantitative analyses of results using meta-analysis; and only a systematic literature review 
can facilitate such methods (Centre for Reviews and Dissemination, 2001, 2009). 
METHOD  
Design 
A consideration of the available methods of review and the chronic pain literature led 
to a decision to extract data from studies identified within the 2009 Cochrane review of 
Eccleston et al. 
Ethical Clearance 
As identifying and manipulating the literature to conduct benchmarks involved the use 
of secondary data within the public domain, this study did not require the approval of an ethics 
committee.  
Measures  
A modified version of the data extraction form used in the Eccleston et al. (2009) 
review was developed. This enabled data about study design, participants, diagnoses, 
treatments and outcome measures to be extracted (see Appendix 4). A data extraction code 
book was also developed so that data regarding treatment arms and outcome measures could 
be coded appropriately (Appendix 5). 
Procedure 
Selection Criteria 
The original selection criteria of Eccleston et al. (2009) had been designed to facilitate 
the statistical comparison of post-treatment change between active psychological treatments 
and other active treatments or controls from waiting list control (WLC) or treatment as usual 
(TAU) samples. This research, however, aimed to identify data which could be used to produce 
benchmarks of pre-post change. A priori selection criteria regarding participants, psychological 
treatments and outcomes were therefore modified slightly in order that studies providing 
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appropriate pre, post and, if applicable, follow-up data be included (the methods of meta-
analysis which this data facilitated, and their justification, are reported within study 4). In 
practice, this meant that studies were deemed appropriate for selection if they contained at 
least one treatment with a specified psychological component which was led, or supervised by, 
a professional with psychological training, and had also employed a suitable control group. In 
order to ensure that benchmarks were as meaningful to PMPs as possible, ‘control’ groups 
were classified as groups that would be viable within PMPs, and so were either from a WLC or 
specified TAU sample, or another sample deemed to be reasonable within PMPs. Only data 
from studies with more than ten independent participants within each treatment or control 
group were included.  
Data Collection 
All studies identified within the 2009 Cochrane review were examined for eligibility for 
inclusion. Following the initial selection, only those facilitating the extraction of appropriate 
data were included. The types of outcome measures typically employed within the chronic pain 
literature and associated suitable methods of meta-analysis had been considered, and 
outcome measures scored on continuous scales were deemed appropriate.   
The first stage of data collection involved identifying studies reporting raw mean pre 
and post-treatment scores for treatment and control groups, and pre-treatment and control 
SDs, or data enabling the calculation of pre-treatment SDs (e.g. pre-treatment standard errors 
of the mean). Raw scores are known to produce more conservative estimates of effect size 
than pre-post mean change scores (Morris & De Shon, 2002), but if such data were not 
available, studies were still deemed appropriate for inclusion if they reported pre-post mean 
change scores and pre-treatment SDs (as such data facilitated the calculation of effect sizes). 
Where suitable data were not published, primary authors were contacted. If they did not 
respond within a reasonable time frame, the study was excluded from the analysis; based on 
the approaches used in previous research (Eccleston et al., 2009; Morley et al., 1999).  
As the methods by which data identified from systematic literature reviews are stored, 
organised and analysed are considered to be the most important factors in meta-analytic data 
management (Cooper & Hedges, 1994), guidance recommends that data identified is managed 
within software which has the ability to code data (Centre for Reviews and Dissemination, 
2009). However, as the coding of data evolved as data were extracted and unfamiliar issues 
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became more overt, a less complex software package which facilitated the entry of data from 
more than two treatment arms and multiple outcome measures was necessary for initially 
storing data. Microsoft Excel was considered to provide the most appropriate storage medium, 
and data from each study was extracted into an individual Microsoft Excel file, and pooled if 
necessary. The evolving code book was used to develop ‘value labels’ within an SPSS (Statistical 
Package for the Social Sciences) version 15 file. To minimise the risk of data extraction errors, 
each Excel file was separately transferred to SPSS and visually scanned for errors and 
omissions. Examples of the Excel and SPSS files can be seen in Figures 1 and 2. In order to 
ensure reliability, SM checked a proportion of data for errors, and each SPSS file was then 
transferred into a single SPSS file where frequency analyses and other checks were run to 
identify missing data and that which had been entered erroneously.  
The classification of primary psychological treatments and control arms was also 
discussed at this stage, as preliminary data extraction demonstrated the potential volume of 
data that was available within studies given their frequent reporting of more than one 
treatment and control arm. The subsequent need to be selective for pragmatic reasons and to 
ensure that benchmarks could be as of much utility to PMPs as possible was therefore 
identified. All suitable data were extracted from the included studies, and then supervision was 
used to discuss how to classify primary psychological treatment and control arms in studies 
with more than one of each arm. The predominance of treatments based on CBT principles and 
with the involvement of significant others identified in study 1 meant that they were classed as 
primary if they were available; with CBT with no involvement of significant others otherwise 
classified as primary. A decision was also made to prioritise out-patient over in-patient 
treatments if necessary due to their predominance within PMPs. Amongst studies with more 
than one control arm, WLCs were selected as primary if available, as most PMPs have access to 
waiting lists and therefore could feasibly identify comparable data.  If studies had not 
employed a WLC, a decision was made as to whether a specified TAU or another active control 
(e.g. education only) would be feasible within PMPs, and if studies reported more than one 
active control then the least intensive one was classified as primary. 
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Figure 1: Screen shot of Microsoft Excel data extraction file 
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Figure 2: Screen shot of SPSS data extraction file   
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RESULTS 
The Eccleston et al. (2009) review had included 62 papers referring to 52 RCTs. This 
study additionally examined papers whose inclusion was yet to be confirmed when the review 
was published. In total, 72 publications reporting 62 RCTs were examined for inclusion, and 38 
publications reporting 36 separate studies were deemed eligible. Figure 3 displays the selection 
of studies for inclusion, and information about included and excluded studies is displayed in 
Tables 3 and 4 respectively.  
Figure 3: Flow chart demonstrating the selection of Randomised Controlled Trials (RCTs) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a of which 5 had not yet been classified within the 2009 Cochrane review 
b of which 6 had not yet been classified within the 2009 Cochrane review 
Publications meeting Eccleston et al. (2009) 
inclusion criteria (n=62) 
 
RCTs meetings Eccleston et al. (2009) inclusion 
criteria (n=52) 
Publications excluded from 
Study 2 (n=34) 
 
RCTs excluded from Study 2 
(n=26) 
 
Reasons for n=26 study 
exclusion: 
Data not appropriate n=19 
Did not meet inclusion criteria 
n=7 Publications included in study 2 
(n=38)
a 
 
 
Number of RCTs included in study 2 (n=36)
b 
 
 
Publications to check for inclusion since 
Eccleston et al. (2009) (n=10) 
 
RCTs to check for inclusion since Eccleston et al. 
(2009) (n=10) 
Total potential number of publications: (n=72) 
 
Total potential number of RCTs (n=62) 
38 
 
Included Studies 
Table 3: Characteristics of included studies  
  Psychological Treatment Control 
Primary author 
and year of 
publication 
N* Primary** Active 
treatment 
2 
Active 
treatment 
3 
Duration 
(hours) 
WLC Active 
Altmaier 1992 45 CBT
 a
 ◦ 
 
◦ nk ◦ TAU 
Astin 2003 128 Mind ◦ ◦ 20 ◦ Edu 
Basler 1997 94 CBT ◦ ◦ 30 ◦ TAU 
Becker 2000 166 CBT ◦ 
 
◦ nk • Med 
Bliokas 2007 143 CBT CBT-ex ◦ 66.5 • ◦ 
 Carson 2005 43 LKM ◦ ◦ 12 ◦ TAU 
Cook 1998 28 CBT ◦ ◦ 10/12
b
 ◦ Edu 
Ersek 2003 45 CBT ◦ ◦ 10.5 ◦ Edu 
Ersek 2008 256 CBT
 a
 ◦ ◦ 10.5 ◦ Edu 
Evers 2002 64 CBT ◦ ◦ 11 ◦ TAU 
Flor 1993 120 CBT BFB ◦ 8 ◦ TAU 
Greco 2004 92 CBT-ex ◦ ◦ nk ◦ Sym, TAU 
Haldorsen 1998 469 CBT ◦ ◦ 120 ◦ TAU 
Jensen 2001 214 CBT CBT-ex BT-ex 54, 80, 140
c
 ◦ TAU 
Johansson 1998 42 CBT
 a
 ◦ ◦ 160 • ◦ 
 
Keefe 1990 99 CBT ◦ ◦ 15 ◦ Edu, TAU 
Keefe 1996 88 CBT-ex  CBT ◦ 20 ◦ Edu 
Kraaimaat 1995 77 CBT ◦ ◦ 20 • TAU 
Linton 2008 34 BT ◦ ◦ nk  • ◦ 
 
Mishra 2000 94 CBT CBT-ex BFB 18, 24
d
 ◦ 
 
TAU 
Moore 1985 43 CBT-ex  CBT ◦ 32 • ◦ 
Morone 2008 37 Mind  ◦ 
 
◦ 12 • ◦ 
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  Psychological Treatment Control 
Primary author 
and year of 
publication 
N* Primary** Active 
treatment 
2 
Active 
treatment 
3 
Duration 
(hours) 
WLC Active 
Newton-John 
1995 
 
44 CBT BFB ◦ 16 • ◦ 
 
Nicassio 1997 86 BT ◦ ◦ 15 ◦ 
 
Edu 
Puder 1988 69 CBT ◦ ◦ 20 • ◦ 
 
Radojevic 1992 59 CBT-ex  CBT ◦ 6 ◦ Edu, TAU 
Thieme 2003 61 BT
 a
 ◦ 
 
◦ 75 ◦ TAU 
Turner 1988 81 CBT BT ◦ 16 • ◦ 
 Turner 1990 96 BT-ex BT ◦ 16 • PT 
Turner 1993 102 CT CTR ◦ 12 • R 
Turner 2006 158 CBT ◦ 
 
◦ nk ◦ 
 
Edu 
Vlaeyen 1995 71 CT BT BFB 16.5 • ◦ 
 
Vlaeyen 1996 125 CT ◦ 
 
◦ 18, 24
e
 • Edu 
Williams 1996 121 CBT CBT
 a
 ◦ 28, 144
f
 • ◦ 
Woods 2008 44 CBT BT ◦ 12 • ◦ 
Zautra 2008 143 CBT Mind ◦ 16 ◦ 
 
Edu 
Note. The primary authors are for the primary references describing these studies: the Keefe 1990 and Keefe 1996 studies were 
described in one additional paper each.  
 
*N is pre-intervention and does not necessarily match with the number of participants providing data for analysis.** the 
classification of treatment and control arms are for the purposes of analysis and do not necessarily reflect the primary authors’ 
classifications. 
 
a treatments provided within in-patient settings 
b the CBT treatment was of 10 hours duration, the education was of 12 hours duration 
c the CBT treatment was of 54 hours duration, the BT-ex was of 80 hours duration and the CBT-ex was of 140 hours duration 
d the CBT and BFB conditions were of 18 hours duration, the CBT-ex was of 24 hours duration.  
e the CT was of 18 hours duration, the Edu of 24 hours duration.  
f the CBT was of 28 hours duration, the in-patient CBT was of 144 hours duration 
 
 • = measured; ◦= not measured/not applicable; BFB = Biofeedback; BT = Behavioural Therapy; BT-ex = Behavioural Therapy plus 
extra components (Jensen 2001 and Turner 1990 = additional exercise components); CBT = Cognitive Behavioural Therapy; CBT-ex 
= CBT plus extra components (Bliokas 2007 = graded exposure; Greco 2004 and Mishra 2000 = Biofeedback; Jensen 2001 = 
behavioural and physical components; Keefe 1996, Moore 1985 & Radojevic 1992= CBT with the involvement of significant others) 
; CT = Cognitive Therapy; CTR = Cognitive Therapy and Relaxation; Edu: Education; LKM = Loving Kindness Meditation; Med = 
medical; Mind = Mindfulness; nk = not known; PT = Physical Therapy; R = Relaxation; Sym = Symptom Monitoring; WLC = Waiting 
List Control. 
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Patients 
As data regarding the patient diagnoses, ages and proportions of gender from the 
included studies was reported in Table 1 (study 1) it was not repeated within Table 3. It is 
worth remembering, however, that study 1 demonstrated the mean age of patients within 
included studies to have been 51.5 (SD 11.7) with a mean age range of between 35.7 and 81.9. 
It had also shown that all included studies reported the percentage of patients who were 
female, which ranged from 29 to 100% (mean 67.7; SD 16), and that the primary diagnostic 
labels reported within studies were: mixed (31%); chronic low back pain (28%); 
musculoskeletal (14%); rheumatoid arthritis (11%); osteoarthritis (5%), temperomandibular 
(5%) systemic lupus erythematosus (3%) and spinal (3%). 
Additionally, Table 3 demonstrates that a total of 3681 patients were entered into the 
thirty-six included studies, with a mean number of entered patients per study of 102.25 (SD 
81.13). At the end of treatments, 3160 patients completed outcome measures within these 
studies, giving a crude estimate of a drop-out rate of 14%.   
Treatments 
Sixteen of the included studies (44%) reported one active psychological treatment and 
one control arm, twenty-one (58%) had presented data from only one active psychological 
treatment, twelve (33%) from two active psychological treatments and three (8%) from three 
active psychological treatments. The classification of a psychological treatment as primary was 
necessary for the 42% of included studies (n=15) reporting more than one psychological 
treatment. This meant that 75% of included studies (n=27) were classed as having CBT as a 
primary psychological treatment, whether or not it had comprised an ‘extra’ component such 
as the involvement of a significant other. Twenty-eight studies (78%) had only one control arm 
and the remaining eight had two. Of those eight, five were then classified as having a primary 
WLC, two as a primary TAU control and one as a primary ‘symptom monitoring’ control.  
For the thirty-one studies for which data were available, the duration of the primary 
psychological treatments selected for analysis varied widely between 6 and 160 hours (mean 
28.9; SD 34.1); a variation which was not significantly reduced when in-patient treatments 
were excluded from the analysis (mean 22.79; SD 22.75).  
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Outcome Measures 
In terms of the measures reported within the included studies, on the assumption that 
sub-scales of measures would be analysed as a measure in their own right, a total of 278 
outcome measures employing continuous scales were deemed to provide data that would 
facilitate the development of benchmarks. 
Excluded Studies 
Table 4: Excluded studies and reasons for exclusion 
 Primary reason for not meeting inclusion criteria: 
Primary author and 
year of publication 
inappropriate data 
a no psychological 
treatment 
no appropriate 
control arm 
Babu 2007 ◦ • ◦ 
Bradley 1987   • ◦ ◦ 
Buckelew 1998 • ◦ ◦ 
Buhrman 2004   ◦ • ◦ 
Dworkin 1994  • ◦ ◦ 
Dworkin 2002   ◦ • ◦ 
Fairbank 2005 • ◦ ◦ 
Freeman 2002 • ◦ ◦ 
Geraets 2004  ◦ • ◦ 
Hammond 2001   ◦ • ◦ 
Jensen 1997 ◦ ◦ • 
Jensen 2005
b
 • ◦ ◦ 
Kaapa 2006 ◦ ◦ • 
Kole-Snijders 1999 • ◦ ◦ 
Leeuw 2008 ◦ ◦ • 
Lorig 2008 ◦ • ◦ 
Marhold 2001 • ◦ ◦ 
McCarberg 1999   • ◦ ◦ 
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 Primary reason for not meeting inclusion criteria: 
Primary author and 
year of publication 
inappropriate data 
a no psychological 
treatment 
no appropriate 
control arm 
O'Leary 1988  • ◦ ◦ 
Parker 1988 • ◦ ◦ 
Redondo 2004 ◦ ◦ • 
Smeets 2006 • ◦ ◦ 
Spence 1989   • ◦ ◦ 
Strauss 1986  • ◦ ◦ 
Strong 1998   • ◦ ◦ 
Turner-Stokes 2003 ◦ ◦ • 
 
Note. The primary authors are for the primary references describing these studies: the Fairbank 2005, Geraets 2004, Hammond 
2001, Kole-Snijders 1999, Smeets 2006 and Spence 1989 studies were all described in more than one publication. 
 a ‘Inappropriate data’ means that raw mean pre and post- treatment and control scores and pre treatment and control standard 
deviations, or data enabling the calculation of pre-treatment standard deviations or pre-post mean treatment and control change 
scores and pre-treatment standard deviations were not published or provided by the author, and therefore the data would not 
facilitate the calculation of effect sizes.  
b Jensen 2005 was a follow up paper, but the original study data were suitable for analysis and included (Jensen 2001).  
• = primary reason for exclusion; ◦= not applicable.  
 
Table 4 clearly demonstrates that the vast majority of studies (n=15; 58%) were 
excluded as they did not contain extractable data, i.e. the published data did not facilitate the 
calculation of pre-post treatment effect sizes. Fewer studies (n=6; 23%) were excluded as they 
did not contain a psychological treatment. The remaining five studies (19%) were excluded for 
not having a control arm which was explicitly specified as a TAU or that would be viable within 
PMPs (e.g. an education arm); but rather their self-certified ‘control’ arms were experimental. 
In contrast, Table 3 indicates that all included studies with more than one psychological 
treatment had specified at least one of those treatments as a TAU or had a control that was 
deemed to be viable within PMPs.   
DISCUSSION 
The results of this study, in addition to further demonstrating the comparability of RCT 
with PMP data in terms of treatments and patient groups, suggest that the published literature 
contains a significant enough volume of data to facilitate the production of benchmarks. The 
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potential external validity is great given not only this comparability but the fact that more than 
3000 patients were entered into the thirty-six included RCTs and that 86% also completed 
post-treatment measures deemed eligible for inclusion. In terms of the data itself, 
recommendations that data extracted within systematic reviews should be independently 
checked for accuracy and completeness (Centre for Reviews and Dissemination, 2009) had 
been followed within the Cochrane review. As this study involved the extraction of additional 
data, a proportion that had not previously been extracted was independently reviewed by SM. 
Whilst it is never possible to completely rule out data entry errors, such attempts to ensure the 
credibility of the results are considered to be a strength of this study.  
In order to try and ascertain the extent to which extracted data would be applicable to 
PMPs, several methodological matters require consideration. The thirty-six included studies, as 
originally identified within the 2009 Cochrane review, allowed a large volume of appropriate 
data to be collected and as such, more recently published literature was not sought. An 
updated literature search may have been advantageous, however, in allowing more recently 
published trials to be identified, and determining whether it reflected the PMP reports in study 
1 of a move towards third-wave treatments of chronic pain. More recent literature would have 
been unlikely to exert a great influence on the overall results, but may have overcome, to some 
extent, the limitation discussed in study 1 of comparing historical RCT data with recent PMP 
data. As mentioned previously, however, the comparison of treatment components rather 
than broad treatment types in study 1 may have overcome this to an extent, and pragmatically, 
the decision to not seek more recently published data was justified. However, the potential 
impact of not updating the literature search on the external validity of the benchmarks means 
that future research should aim to identify as much of the literature as possible.   
In further consideration of the literature searching methods employed in the 2009 
Cochrane review, whilst they were rigorous they did not seek to identify unpublished (‘grey’) 
literature. A decision was made to not seek the grey literature within this study given that the 
overall aim of this research was to determine whether the published literature is applicable to 
clinical settings, and such a focused research question did not necessitate an exploration of the 
grey literature. However, it is recognised that ignoring the unpublished literature introduces a 
publication bias and means that treatment effects are likely to be overestimated as non-
significant or negative results are less likely to be published. It is therefore generally agreed 
that systematic reviews should aim to minimise bias by either identifying unpublished 
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literature or using statistical methods to correct for the bias  (Hopewell, Loudon, Clarke, 
Oxman & Dickersin, 2009). In future, where relative to the research questions, the grey 
literature should be sought, but in the meantime, the fact that the benchmarks produced may 
overestimate treatment effects means that those generated should be interpreted with 
caution, and viewed as something to aim towards rather a minimum standard within PMPs.  
One additional factor with particular reference to the inclusion of data is the methods 
by which primary psychological treatment and control groups were classified. Preliminary data 
extraction suggested that the number of studies with multiple treatment and control arms 
warranted further consideration, and ultimately, the classification was pragmatic. This is 
because it was not feasible to consider benchmarks for every type of treatment and control 
group reported, but even without pragmatic restrictions, the total volume of data would not 
have permitted useful analyses. Classification also represented an attempt to ensure that the 
outcome data from particular treatments would be as meaningful to PMPs as possible, given 
the data generated by the sample of participants in study 1 concerning primary psychological 
treatments. However, it is recognised that the decision to prioritise a WLC or the least 
intensive control that was deemed to be feasible within PMPs may not produce the most 
meaningful benchmarks to PMPs. The decision to exclude studies based on the control groups 
they employed may also have been erroneous. As discussed in study 1, however, without an in-
depth knowledge of all treatments offered within PMPs it is only possible to produce 
benchmarks that may approximate to psychological treatments in clinical settings, and until a 
more comprehensive understanding of treatments for chronic pain in clinical and research 
settings is reached, such approximations will have to suffice.  
In spite of these methodological considerations, the results so far imply that there are 
enough similarities between clinical settings and the published literature to ensure that 
benchmarks can be meaningful, and that data within the published literature can facilitate 
their development. This study has only touched upon the volume of outcome measures 
reported within the published literature, but the manner in which they can be aggregated 
within domains in order to produce benchmarks requires further consideration; as explored 
within study 3.  
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STUDY 3: ARE THERE PARTICULAR OUTCOME DOMAINS WITHIN WHICH IT IS USEFUL TO 
PRODUCE BENCHMARKS FOR USE IN CLINICAL SETTINGS? 
AIMS 
The results of studies 1 and 2 demonstrated that the published literature contains data 
which would facilitate the development of benchmarks to be meaningfully applied within 
routine clinical settings. This study aimed to determine whether there are particular outcome 
domains of utility to clinicians within routine clinical practice, in order that the available data 
could be aggregated and analysed in a manner useful to PMPs.  
BACKGROUND LITERATURE 
Authors have utilised a wide variety of psychometrically validated measures within the 
benchmarking literature. Some have assessed ‘global’ constructs, such as the Clinical Outcomes 
in Routine Evaluation–Outcome Measure (CORE-OM) described in Barkham, Gilbert, Connell, 
Marshall and Twigg (2005) and employed by Barkham Rees et al. (2005) and Barkham et al. 
(2008). Others have examined specific constructs such as depression (Wade, et al., 1998) using 
the Beck Depression Inventory (BDI) which was designed by Beck et al. (1961). Client reported 
indices of positive outcome (Pugh, et al., 2007) and the selection of a primary measure to 
benchmark have also been described (Weersing & Weisz, 2002), and measures have been 
grouped by their specificity to the target problem or their reactivity in terms of who they were 
completed by, in an exploration of moderators of treatment outcome (Minami, et al., 2007).  
Within the chronic pain literature, a reduction in pain is often the primary outcome 
target of pharmacological treatment (Dworkin, et al., 2008). Psychological treatments, 
however, target a broader scope of constructs, including changes in emotional and physical 
functioning, coping and pain behaviours. Such outcomes are usually selected on the basis of 
clinician and researcher preference, and whilst such a selection procedure is important, it 
unfortunately increases bias as well as heterogeneity between studies (Turk, Dworkin, Revicki, 
et al., 2008). Bias and heterogeneity present obstacles to comparing efficacy and effectiveness 
research, but the introduction of common measures or domains aimed to overcome these 
(Dworkin, et al., 2005; Dworkin, et al., 2008; Thorn, et al., 2007). Accordingly, the core domains 
of pain intensity, physical functioning, emotional functioning, patient ratings of global 
improvement and treatment satisfaction, symptoms and adverse events, and participant 
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disposition have been recommended within clinical trials (Dworkin, et al., 2005; Dworkin, et al., 
2008; Turk, et al., 2006). The British Pain Society (2007) also recommend that PMPs measure 
changes to healthcare use and working status as well as the extent to which beliefs and modes 
of information processing have normalised; although they have not specified how the latter 
outcomes can be measured. Additionally, people with multiple chronic pain conditions have 
suggested the importance of measuring outcome on domains including relationships, sexual 
and social activities and home and family life (Turk, Dworkin, Revicki, et al., 2008).  
The chronic pain literature has demonstrated that in spite of recommendations, 
researchers, clinicians and people with chronic pain may differ in terms of the extent to which 
they value particular outcome domains. Such differing opinions are likely to explain why nearly 
300 continuous outcome measure scales with benchmarking potential were identified within 
study 2. However, variation in terms of the levels of importance given to a large number of 
outcome domains is both a reminder for clinicians and researchers to justify the use of 
measures within clinical and research settings (Dworkin, et al., 2005), and for this research to 
defend the production of benchmarks within particular domains.  
METHOD 
Design 
The chosen design of this study was that of the ‘Delphi method’. This method involves 
a structured process within which knowledge and opinion can be gained from participants in a 
given field in order to facilitate a group judgement (Adler & Ziglio, 1996). Delphi methods 
generate an expert consensus using an iterative approach within which honest responses can 
be considered as the researcher co-ordinates discussion but does not share verbatim 
responses amongst participants. The use of no more than two to three rounds is 
recommended as diminishing returns are common when more are used (Linstone & Turoff, 
2002).  
Ethical Clearance 
Determining meaningful outcomes to benchmark involved inviting participants of the 
survey described in study 1 to participate in an electronic study using the Delphi method, and 
confirmation that ethical approval was not required can be seen in Appendix 1.  
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Participants: Round One 
Typically, the Delphi method involves the selection of experts based on their level of 
expertise and knowledge. As academic expert opinions on domains to benchmark are already 
reflected, to an extent, within the published literature, and this thesis aimed to produce 
benchmarks of use in clinical settings, however, participants were sought amongst clinicians 
working within PMPs. In total, participants were thirteen members of staff working in PMPs in 
England; eleven of whom had participated in study 1. The remaining two volunteered to 
participate following discussions with colleagues who had taken part in study 1. All agreed to 
form part of an anonymous expert consensus group, which represented the disciplines of 
clinical psychology (n=3), physiotherapy (n=6) occupational therapy (n=1), nursing (n=2) and 
rheumatology (n=1).  
There was a 92% response rate to the first survey (n=12), of whom 58% were female 
(n=7) and half were physiotherapists (n=6, one of whom was a senior physiotherapist 
specialising in pain management and three of whom were clinical specialists). Other 
participants were clinical psychologists (n=2, 1 of whom was a consultant) and nurses (n=2, one 
consultant and one specialist in pain) in addition to one consultant rheumatologist and one 
occupational therapist. The length of time since participants had achieved primary professional 
qualifications varied between seven and twenty-nine years, with an average of 16.1 years (SD 
8.1). The average length of time for which participants had been employed within their current 
PMP was 5.2 years (range 1.5-10; SD 3.1).  
Measures: Round One 
In consideration of the recommendations of the British Pain Society (2007) and within 
the published literature (Dworkin, et al., 2005; Dworkin, et al., 2008; Eccleston, et al., 2009; 
Turk, et al., 2006), in addition to the results of study 1 and preliminary results of study 2, the 
first round asked participants to complete a survey which involved them rating the importance 
of measuring outcomes within particular domains, comment on a generated definition of each 
domain and suggest specific measures within domains considered to be at least ‘somewhat 
important’ within PMPs (see Appendix 6). The survey was developed and deployed using the 
‘Bristol Online Survey’ method (University of Bristol, 2009) as in study 1.  
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Procedure: Round One 
Participants had initially been invited to take part in this study during study 1. Several 
months later they were emailed an electronic link to the survey which made up this round. 
Following a reasonable time frame which gave participants an opportunity to respond to the 
survey, their responses were summarised using descriptive statistics and a qualitative summary 
of written responses, and used to develop the survey employed in round two.  
Participants: Round Two 
Of the thirteen original participants, there was a 69% response rate to the second 
round (n=9); 56% of whom (n=5) were female and 40% of whom (n=4) were physiotherapists (3 
clinical specialists). Three participants (30%) were clinical psychologists, in addition to one 
nurse and one consultant rheumatologist. Length of time since primary qualification varied 
between eight and thirty years, with an average of 15.6 years (SD 8.8). The average length of 
time for which participants had been employed within their current PMP was 6.1 years (range 
2-16 years; SD 4.8).   
Measures: Round Two 
A survey was designed based on participant responses to the first round, which 
comprised its quantitative and qualitative results (Appendix 7). The survey invited participants 
to reflect on the collective comments made regarding domain definitions and confirm whether 
or not they agreed that measures within particular domains should be recorded within PMPs. It 
should be noted that study 2 was being conducted concurrently to this study, and due to 
difficulties in assigning some measures in the published literature to a particular domain, 
participants were also invited to assign the measures that they had suggested in the first 
survey to an outcome domain.  
Procedure: Round Two 
The original thirteen participants were emailed an electronic link to the second round 
of the survey, and invited to respond within a reasonable time frame. Upon completion, all 
responses were summarised using descriptive statistics and a qualitative summary of written 
responses. A summary of responses was then sent to participants (Appendix 8) who were also 
asked for their permission to be acknowledged within this thesis and to indicate whether they 
would like a copy of the overall thesis results when available. 
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RESULTS  
The results of each round are detailed in Appendices 7 and 8 and so will not be 
described in detail here. It is important to recall the original aim of this study, however, which 
was to generate a list of outcome domains based on those reported within the RCT literature, 
that clinicians agreed were of importance within PMPs. Table 5 displays the level of agreement 
amongst participants within each round regarding the importance of measuring domains 
within PMPs.  
Table 5: Percentage agreement amongst PMP participants of the measurement of outcome 
domains 
Domain 
 
Round one (n=12)a 
 
 
Round two (n= 10)b 
 
Coping and Cognitive 
Appraisal 
92 
 
 
100 
Disability 66 
 
80 
Mood 66 
 
100 
Pain behaviour or activity 66 
 
50 
Pain experience 25 
 
40 
Physiology or fitness 25 
 
60 
Social Role Functioning 66 
 
70 
a Percentage agreement that the domain is very important to measure within PMPs 
b Percentage agreement that the domain should definitely be measured within PMPs 
 
Table 5 demonstrates that the agreed level of importance of each domain increased 
between rounds; with the exception of measures of pain behaviour or activity. Within the first 
round there had also been a lack of consensus regarding domain definitions and outcome 
domains to which particular measures could be assigned; reflective of the variation observed 
within the RCT literature and a recently published review of measures for people with chronic 
pain (Grimmer-Somers, Vipond, Kumar & Hall, 2009). The aim of the second round was 
therefore amended slightly in order to develop some clarification over domain definitions and 
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the assignment of measures to domains, with the intention that the results would inform the 
manner in which data were aggregated within the meta-analysis.  
In round two, the pre-specified criterion for consensus was set at 70%. It is common 
for researchers to set their own level of consensus (Hsu & Sandford, 2007), and so this was 
discussed within supervision with SM. Seventy percent was deemed significant enough to 
reflect consensus amongst the small number of participants, but not so high that it was 
unattainable. Table 5 demonstrates that a consensus was agreed that measures within the 
domains of coping and cognitive appraisal, mood, disability and social role functioning should 
definitely be measured within PMPs. Participants additionally suggested the careful 
consideration of measures within these domains, recommending that measures of anger and 
frustration be recorded within the mood domain, and that measures of disability would be of 
greatest utility if they were related to activities that were personally meaningful to patients. 
Participants also recommended that ‘social role functioning’ be renamed ‘role functioning’; 
predicting that patients may distinguish between ‘social’ i.e. work and non-familial 
relationships and more general ‘roles’ i.e. those carried out at home. Whilst the degree of 
overlap between many domains was observed by a number of participants, most were keen to 
state that overlap should not preclude measurement.  
However, the perceived overlap may have contributed to the lack of consensus that 
measures within the domains of physiology and fitness, pain behaviour or activity and pain 
experience should definitely be measured within PMPs. Participants had specifically 
commented on the difficulties in obtaining objective measures within the physiology and 
fitness domains, with a general view that whilst physical abilities were important to 
acknowledge, it would be more meaningful to measure client goals rather than physical 
abilities per se. Participants also made a distinction between pain behaviours and pain 
activities and recommended their separate classification, and referred to the differences 
between self-reported and observed behaviours and the need for a more specific definition. 
The lack of consensus that pain behaviours or activity should be recorded was therefore 
assumed to reflect the need for a more robust definition rather than the insignificance of 
measures that could potentially be included within this domain. Whilst the importance of 
acknowledging patients’ pain experience was implied, many participants stated that its 
measurement was not meaningful within PMPs given that they did not expect it to change, 
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with others suggesting a fear of measuring pain in case its lack of change or increase was seen 
to reflect badly upon the PMP.  
There was broad agreement between participants’ suggestions as to the allocation of 
outcome measures compared with my own. There were several discrepancies, however, which 
were discussed with SM in supervision where final decisions were made.  
Implications for Domains to Benchmark 
In order to overcome the lack of consensus regarding the inclusion of several outcome 
domains, the results of this study were considered alongside the published literature. This had 
recommended that RCTs consider the collection of outcomes of pain intensity, physical 
functioning, emotional functioning, patient ratings of improvement and satisfaction with 
treatment, symptoms and adverse events and participant disposition (Dworkin, et al., 2005; 
Turk & Burwinkle, 2005). The British Pain Society (2007) had additionally recommended 
healthcare use, working status, changes to beliefs and modes of information processing, and 
patients had suggested relationships, sexual and social activities and home and family life 
(Turk, Dworkin, Revicki, et al., 2008). Having considered these recommendations, the results of 
study 2 and the results of this study, the decision was made to classify measures within the 
domains of pain experience or behaviour, physical functioning, emotional functioning and 
coping and cognitive appraisal, and to therefore construct benchmarks within these domains. A 
brief rationale for these decisions follows.  
Pain Experience and Pain Behaviour 
The lack of participant consensus regarding the inclusion of measures within the ‘pain 
behaviour or activity’ domain was assumed to reflect the broad definition itself, and so the 
literature was consulted. Dworkin et al. (2005) recommend that a domain of ‘pain’ should 
incorporate measures of overt expressions of pain, the use of rescue analgesics and other 
medical treatments as well as the intensity, quality and experience of pain. Following 
discussions within supervision, overt expressions of pain, the use of rescue analgesics and 
other medical treatments were deemed to comprise a distinct category which was named ‘pain 
behaviours’, and other measures as suggested by Dworkin et al.(2005) were grouped into a 
‘pain experience’ domain. Though a consensus had not been reached in terms of the 
measurement of pain experience, this was overruled given suggestions that it should at least 
be acknowledged within PMPs, and research findings that it is the most consistently reported 
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outcome domain within RCTs (Eccleston, et al., 2009). In addition, anecdotal reports imply that 
most patients expect it to be measured within any treatment for chronic pain, and it seemed 
timely to challenge the assumption that pain experience cannot change as a result of 
psychological intervention, particularly given that the meta-analysis conducted by Morley et al. 
(1999) had demonstrated that psychological treatments were associated with a reduction in 
pain experience.  
Physical Functioning 
Participants had advocated the inclusion of measures within the domains of disability 
and role functioning, and Dworkin et al. (2005) suggest that a multifaceted domain named 
‘physical functioning’ can incorporate these domains alongside data regarding activities of daily 
living, sleep, quality of life and physical abilities; many of which had been recorded within the 
published literature and deemed of importance to patients within PMPs.  A ‘physical 
functioning’ domain was therefore agreed upon.  
Emotional Functioning 
Participants were keen to advocate the inclusion of measures of mood, but congruent 
with the recommendations of Dworkin et al. (2005), the decision was taken to rename this 
domain emotional functioning, which would also encapsulate measures of anger, frustration 
and other emotional states, as suggested by participants within round two.  
Coping and Cognitive Appraisal 
Researchers within the chronic pain field frequently include additional domains of 
relevance to the interventions under research (Hoffman, Papas, Chatkoff & Kerns, 2007). In 
consideration of this, the results of the 2009 Cochrane review of psychological treatments for 
chronic pain (Eccleston, et al.), consensus amongst participants and the recommendations of 
Breivik et al. (2008), the decision was made to also record appropriate measures within the 
domain of coping and cognitive appraisal. These constructs are often viewed as difficult to 
classify due to the recognition that they may inadvertently measure additional constructs such 
as adjustment (Jensen, Turner, Romano & Karoly, 1991). Also, their classification as helpful or 
maladaptive may vary depending on whether a person is seen as ‘assimilating’ or 
‘accommodating’ in response to chronic pain (Van Damme, Crombez, Goubert & Eccleston, 
2009). However, as participants suggested, difficulties in classification should not preclude 
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measurement, and so it was deemed acceptable to include this domain in order that such 
measures were captured. Final decisions regarding the classification of outcome measures 
within domains are displayed in the data extraction code book in Appendix 5. 
DISCUSSION  
In this study, the views of clinicians working within PMPs were considered alongside 
the preliminary results of study 2 and the published literature in order to determine whether 
there are particular outcome domains within which it is useful to produce benchmarks 
applicable to clinical settings.  
The methods employed within this study in order to decide upon these domains give 
credibility to the results. Minami et al. (2008), for example, recommended that outcomes used 
to construct benchmarks are determined after the literature has been reviewed and the 
studies and specific samples have been identified. This study followed these recommendations 
but also went one step further in seeking clinicians’ opinions on the literature and then turning 
to the literature for guidance to overcome the lack of consensus. Such a circular process 
demonstrates the ‘virtuous circle’ described by Barkham and Mellor-Clark (2003), and aimed to 
bridge one of the gaps between research and clinical practice in attempting to ensure that 
benchmarks could be developed within clinically meaningful domains.  
Additionally, the fact that the surveys were conducted electronically meant that they 
were widely accessible to a number of potential participants, and the phrasing of the questions 
in a neutral, non-profession specific or expert manner is likely to have ensured accessibility; 
regardless of professional background or level of PMP experience. Such accessibility was 
suggested in that participants represented core professions of varying levels of seniority and 
with variable levels of experience, and this increases the external validity of the results. 
Another advantage is that in conducting two rounds, participants were given the opportunity 
to re-evaluate their responses based on the emerging group consensus, without the issue of 
diminishing returns becoming pertinent.  
However, there are a number of factors which require further consideration, 
particularly with regard the participants, measures employed and methods of data analysis.  
Participants  
Whilst several PMP core professions were represented within this study, it could be 
argued that the small and self-selected sample and unfortunate lack of representation of other 
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professions limits the extent to which the views can be deemed representative of PMPs. 
Consequently, the external validity of participant views may be limited, and in future the 
selection of a sample from a wider range of professionals may be beneficial, although issues of 
confidentiality and researcher induced bias would require further consideration if individuals 
were invited to participate rather than volunteering. In the meantime, participants’ responses 
should be considered to provide an indication of the ways in which particular outcome 
domains are viewed by some professionals within PMPs. However, as responses were not used 
in isolation to determine domains but considered alongside the results of study 2 and 
recommendations within the published literature, the credibility of the results is increased.  
The decision to not seek input from people with chronic pain also requires some 
explanation. This was partially influenced by recent research suggesting that outcomes relating 
to relationships, sexual and social activities and home and family care are of importance (Turk, 
Dworkin, Revicki, et al., 2008), but also by time constraints; particularly given that this study 
comprises but one part of this overall thesis. However, the fact that these measures have been 
rated as important by people with chronic pain justifies their further consideration within both 
future clinical practice and research.  
Outcome Domains 
Unfortunately, the data analysis highlighted an oversight within the design of the 
survey; namely that participants had not been given the opportunity to comment on the 
inclusion or definition of a ‘health and social care domain’. Several measures within this 
domain had been identified within the preliminary results of study 2, and so possibilities for 
rectifying the situation were discussed in supervision. It was eventually agreed that the 
unfortunate lack of participant consultation, together with the fact that measures within this 
domain had not been reported frequently within the chronic pain literature meant that no 
further action should be taken to rectify the matter. Instead, the decision to exclude measures 
within this domain was made, and whilst clearly its inclusion in the first place would have been 
preferable, this was considered an acceptable solution.  
With regard to participants’ views about other outcome domains, the decision to not 
explore patient ratings of improvement and treatment satisfaction, as suggested by Dworkin et 
al. (2005), also requires some explanation; particularly as 40% of patients with chronic pain are 
thought to be dissatisfied with treatment effects (Breivik, et al., 2006). The preliminary results 
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of study 2 demonstrated that such data are rarely reported however, and so it would not have 
been meaningful to produce benchmarks within these domains. It is noteworthy that Dworkin 
et al. (2005) developed recommendations intended to cover a wide range of clinical trials 
which have a predominant focus on pharmacological treatments. The primary aim of these 
treatments is to produce analgesia; hence their additional suggestion that outcomes relating to 
symptoms and adverse events are considered. Such measures are rarely reported within trials 
of psychological treatments of chronic pain however, as demonstrated in study 2, and are 
unlikely to be recorded within PMPs. It was therefore considered inappropriate to ask 
participants to consider these domains.  
Finally, Dworkin et al. (2005) also recommend the recording of data of participant 
disposition, including how participants were selected for treatment, when and why they 
dropped out and reasons for exclusion. Such data is considered important in terms of ‘profiling’ 
and because these variables may exert an influence on the outcome of treatment. However, 
despite that fact that such information has been recorded within previous reviews (Eccleston, 
et al., 2009), it was not deemed relevant to this thesis given its focus on benchmarking. This is 
why participant disposition was neither recorded in study 2 nor referred to within this study, 
although future research may benefit from a consideration of such variables, regardless of its 
primary focus.  
Data Analysis  
The final limitations of this study concern the methods of data analysis, which could be 
viewed as a superficial analysis of participant data. Whilst the descriptive statistics were 
deemed an adequate method of summarising and describing the group consensus, the 
qualitative data may have benefitted from a more robust method of analysis than the broad 
summaries which were provided; particularly as they did not attempt to reduce bias. Linstone 
and Turoff (2002) recommend the use of a validated theoretical framework to assist with 
qualitative data analysis when an extensive number of open-ended questions are incorporated 
within the Delphi method, but as participant responses were summarised and described in a 
rudimentary manner, the results need to be interpreted with caution. Nevertheless, the 
intention of this study was to determine whether it would be useful to benchmark outcomes 
within particular domains, and use the views of several clinicians to inform this decision, rather 
than gain a consensus opinion from the majority of PMP staff. As such, the rounds may be 
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considered as comprising a pilot study which has reflected a number of opinions regarding 
some aspects of outcome measurement. The study has also, however, highlighted the need for 
further consideration of these issues within clinical settings and more extensive and 
scientifically stringent research. Such issues would require more time, and within this study, 
this would also have permitted the follow-up of participants to determine whether their 
participation in the study and its results impacted on the measures used within their PMPs. The 
wider impact of the discussion of outcome measure domains in comparison with the published 
literature’s recommendations may also therefore benefit from consideration in the future.  
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STUDY 4: WHAT DO THE BENCHMARKS SUGGEST ABOUT THE IMPACT OF PSYCHOLOGICAL 
TREATMENTS OF CHRONIC PAIN WITHIN PARTICULAR OUTCOME DOMAINS? 
AIMS  
The results of study 1 implied that benchmarks of outcomes for psychological 
treatments of chronic pain, developed from the published literature, could be meaningfully 
applied to PMPs in routine clinical settings, and study 2 that the published literature contained 
data which would facilitate their development. Study 3 identified a number of clinically 
meaningful outcome domains within which benchmarks could be produced. Together, these 
results suggest that it would be both feasible and meaningful to produce benchmarks for 
psychological treatments of chronic pain.  
The aim of this study was therefore to develop benchmarks which would reflect the 
impact of psychological treatments of chronic pain within research settings and could 
therefore give some indication of the relative outcome of psychological treatments within 
clinical settings.  
BACKGROUND LITERATURE 
Quintana and Minami (2006) acknowledged that ‘the basis of scientific knowledge is 
the accumulation of research’ and that ’to make sense of a body of research, some form of 
synthesis is needed’ (p. 839). Whether narrative or systematic methods should form such 
synthesis were discussed within study 2, and the decision was made to use studies identified 
within the systematic Cochrane review conducted by Eccleston et al. (2009) in order to reduce 
the subjectivity with which the results could be interpreted. Reducing subjectivity is facilitated 
by the application of statistical procedures to extracted data, as within meta-analysis, which 
has been defined as ‘the statistical analysis of a large collection of results from individual 
studies for the purpose of integrating the findings’ (p. 3, Glass, 1976).  
Meta-analysis is undoubtedly a pragmatic way in which large volumes of primary data 
can be analysed for the purposes of benchmarking, allowing multiple overall effects of 
treatment to be estimated (Glass, 1976; Lipsey & Wilson, 2001; Quintana & Minami, 2006). The 
considerable statistical power that meta-analyses have in comparison to individual primary 
studies is also a strength of its design (Centre for Reviews and Dissemination, 2001; Lipsey & 
Wilson, 2001; Quintana & Minami, 2006). 
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 To date, whilst a large volume of primary literature describing the outcomes of 
psychological treatments of chronic pain and control groups has been meta-analysed 
(Eccleston et al., 2009; Morley et al., 1999), the methods have not yet attempted to bridge the 
gap between research and clinical settings. In attempting to bridge this gap, properties 
inherent to the psychological treatment of chronic pain literature require consideration; as 
briefly discussed in the introduction to this thesis. One matter for consideration relates to the 
heterogeneity of psychological treatments, for although CBT’s predominance within research 
and clinical settings was identified in studies 1 and 2, there is emerging evidence into the 
application of other psychological treatments in both settings. This raises the question of 
whether the aggregation of data from different psychological treatments would be meaningful 
and produce more representative benchmarks. These methods were recommended by Minami 
et al. (2008), and have been followed by a number of authors (Barkham, Rees, et al., 2005; 
Barkham, et al., 2008; Minami, et al., 2007). They also seem plausible within the chronic pain 
literature, given the meta-analytic findings of equivalent effects of psychological therapies 
(Wampold, 2001; Wampold, et al., 1997). Similarly, the findings within study 1 that PMPs do 
not select patients on the basis of diagnostic group or site of pain, congruent with the 
literature’s tendency to categorise by presentation to services than diagnosis (Morley, 2008; 
Morley & Eccleston, 2008) means that the aggregation of data from studies with different 
diagnostic samples is defensible as an initial enquiry into the feasibility of benchmarking in this 
literature.  
In ensuring that benchmarks are of utility within clinical settings, the manner in which 
outcome data is meta-analysed also needs to be considered. The extant benchmarking 
literature described the relative efficacy of treatments to control groups (Weersing & Weisz, 
2002) in order that factors such as spontaneous remission be ruled out. Such methods are also 
recommended to reduce the likelihood that benchmarks overestimate treatment effects 
(Minami, et al., 2007). Other methods of benchmarking were varied, and determined by the 
types of data available from related outcome measures. The results of study 2 demonstrated 
that data from 278 outcome measures on continuous scales was extracted from the included 
studies; with the potential to facilitate the development of benchmarks using effect sizes and 
their CIs, as employed in the Scheeres et al. (2008) study. Such methods are highly 
recommended by several meta-analytic researchers (Becker, 1988; Hedges & Olkin, 1985) due 
to the growing consensus that effect sizes, as standardised scores, provide the most 
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meaningful conclusions about aggregated research findings (Henson, 2006; Quintana & 
Minami, 2006). Effect sizes and their CIs are also suitable when the treatment effects of studies 
with heterogeneous outcome measures and sample sizes are employed (Centre for Reviews 
and Dissemination, 2001, 2009; Hedges & Olkin, 1985). Effect sizes suggest the magnitude of a 
treatment effect within a population sample by comparing pre and post-treatment scores 
(Dunlap, Cortina, Vaslow & Burke, 1996) and therefore indicate the impact of that treatment 
on a specified outcome domain within a wider population (Henson, 2006; Quintana & Minami, 
2006). CIs indicate the relative precision of an effect size in providing an estimate of the range 
within which the true population effect size is expected to lie (Lipsey & Wilson, 2001); and so a 
95% CI demonstrates, with 95% confidence, that the true population effect size lies within the 
given range (Dunlap, et al., 1996; Quintana & Minami, 2006).  
METHOD 
Design 
A meta-analytic design was used to address the research question within this study, to 
enable data from the included studies to be analysed collectively for the purposes of 
benchmarking.  
Ethical Clearance 
This study involved the aggregation of data obtained in study 2 within the domains 
identified in study 3 and therefore did not require the approval of an ethics committee.  
Procedure 
The meta-analytic literature does not offer consistent guidance on the methods and 
statistical procedures most appropriate for studies of particular designs, but acknowledges that 
when studies employing independent-groups pretest-posttest designs are used, then effect 
sizes can be computed using the metric for independent groups or repeated measure designs 
(Morris & De Shon, 2002). As the primary concern of this research was pre-post change within 
treatment groups, the metrics employed were based on those for repeated measure designs; 
although those for independent group designs would have also been appropriate. The 
extraction and classification of data from included studies was outlined in the methods section 
of study 2, which also described the means by which a single SPSS file containing appropriate 
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data from primary psychological and control arms had evolved. Following the production of 
this file, the meta-analysis was conducted. The methods were based on those described by 
Minami et al. (2008) and Lipsey and Wilson (2001) but were adapted for the chronic pain 
literature, and comprised the following steps: 
1. Each included measure was coded by domain (coping and cognitive appraisal, 
emotional functioning, pain behaviour, pain experience or physical functioning) as 
decided within study 3.  
2. Table 3 (study 2) was examined and used to inform the decision making process about 
which data to meta-analyse, given the potential for a large number of effect sizes to be 
generated. Sixteen of the included studies (44%) had reported one psychological 
treatment and control arm, twenty-one (58%) had only one psychological treatment 
arm, and twenty-eight (78%) only one control arm. The number of studies reporting 
data from more than one treatment or control arm meant that a decision had to be 
made about how to conduct the analysis within the remit of this thesis, whilst also 
ensuring that the benchmarks were as meaningful to PMPs as possible. The decision 
was made to select the psychological treatment and control arms that had been 
classified as ‘primary’ within study 2, and as only ten of the primary psychological 
treatments were non-CBT, to conduct meta-analyses of data within two broad 
categories: all psychological treatments (N=36), and all CBT treatments (n=26). This led 
to four pairs of comparisons; all psychological treatments with an active (n=20) or WLC 
(n=16), and all studies with CBT as the primary psychological treatment and an active 
(n=16) or WLC (n=10).  
3. Several studies required corrections to be made prior to effect size computations. In one 
study, the raw pre and post-treatment scores had not been provided, so the effect size 
was calculated indirectly using the reported post-treatment minus pre-treatment change 
score (Bliokas, Cartmill & Nagy, 2007). Data from two studies had to be pooled before 
the calculations could be applied, either as data had been grouped by gender (Jensen, 
Bergström, Ljungquist, Bodin & Nygren, 2001) or by history of depression (Zautra et al., 
2008), and this was carried out using the equation:  
(1) 
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where Pooled M is the pooled pre or post treatment score (e.g. for both genders 
combined), M is the original pre or post treatment score per group to be pooled (e.g.   
= male,    = female) and n is the sample size within each group. The pooled SD was 
then calculated using the equation: 
(2) 
               
    
                
           
 
              
 
 
As the pre-treatment SD was not provided in the Zautra et al. (2008) study, it was 
estimated using the equation: 
(3) 
          
 
where SE is the standard error of the mean and N is the pre-treatment sample size. In 
the absence of the actual pre-treatment SD, this formula was considered to provide a 
‘good enough’ estimate.  
4. For each of the 278 outcome measure scales, a biased pre-post effect size (Cohen’s d) 
was then calculated, as is considered an appropriate measure when comparisons are to 
be made between groups (Centre for Reviews and Dissemination, 2001, 2009; Morris & 
De Shon, 2002; Quintana & Minami, 2006). This was calculated using the equation: 
(4) 
    
           
     
 
 
where Mpost is the post-treatment mean of the measure, Mpre is the pre-treatment 
mean of the measure and SDpre is the pre-treatment SD of the measure. The pre-
treatment SD is recommended when effect sizes are being calculated from studies 
employing independent groups pretest-posttest designs (Becker, 1988).  Whilst some 
authors recommend that the denominator in an equation used to calculate an effect size 
is the post-test or pooled pre-post SD (Dunlap, et al., 1996), pre-test SDs are more likely 
to be homogeneous across studies as they have not been influenced by repeated testing 
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and experimental manipulations, and so are more likely to produce a conservative 
estimate of effect size.  
5. An unbiased pre-post effect size      was then computed for each outcome measure 
scale so that a positive    indicated pre-post improvement and a negative    indicated 
pre-post deterioration. The equation used was: 
(5) 
      
 
     
 
          
     
 
 
where    is the sample size. This equation corrects for small sample sizes in repeated 
measures studies (Minami, et al., 2008).  
6. In order to determine whether there were any outliers that might impact on aggregated 
effect size results, box and whisker plots were then produced per outcome measure 
within each of the five specified outcome domains. This is a recommended graphing 
technique for determining outliers in an effect size distribution (Hedges & Olkin, 1985; 
Lipsey & Wilson, 2001), and identified twenty-nine outlying effect sizes. Further 
examination revealed that twenty-eight of these were unlikely to have a 
disproportionate impact on the overall results. The remaining outlier had been 
generated from the CBT arm of a study with a WLC within the coping and cognitive 
appraisal domain (Woods & Asmundson, 2008). The unbiased    for this measure was 
4.23, compared with a mean unbiased    for all measures within this domain amongst all 
treatments with WLCs of 0.36 (SD 0.84). As this reported unbiased    was more than 
three SDs from the mean, its inclusion was discussed in supervision with SM where the 
decision was made to monitor its impact on aggregated effect sizes and to then decide 
whether or not its inclusion, exclusion or correction would be most appropriate.  
7. It was common for studies to report multiple measures within a single outcome domain. 
This poses problems for the assumption of independence fundamental to most forms of 
statistical analysis, as entering all generated effect sizes into an analysis would 
overestimate treatment effects by suggesting that the results came from a larger 
sample. For example, generating effect sizes from a sample of twenty participants who 
completed five measures each within the emotional functioning domain would 
erroneously suggest an overall sample of one-hundred independent participants rather 
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than twenty participants who had completed five dependent measures. In order to 
reduce the potential bias that this method would have, a composite effect size was 
generated using the ‘aggregate’ methods described by Lipsey and Wilson (2001). This 
ensured that each study contributed a single effect size per treatment group per 
outcome domain and allowed for the calculation of a mean post-treatment sample size 
per outcome domain, as required within later computations. Such methods were 
congruent with those employed by previous meta-analytic researchers (Dworkin, et al., 
2005; Dworkin, et al., 2008; Turk, et al., 2006). 
8. As per standard meta-analytic procedures, the variance of each    value per domain was 
then computed using the equation:  
(6) 
   
     
          
 
  
    
  
 
   
 
 
where    is an estimated value of the correlation between the pre-treatment and post-
treatment scores of the outcome measure (Becker, 1988; Minami, et al., 2008). It has 
been recognised that pre-post treatment effect sizes may be over-inflated if the inherent 
larger correlations between the pre-post outcomes (when compared with independent 
group design correlations) are ignored. Taking a pre-post correlation estimate into 
account means that the final effect size produced is less likely to be a biased 
overestimate (Dunlap, et al., 1996). As 278 measures had been employed within the 
included studies, the calculation of individual pre-post correlation estimates was not 
possible, and thus a reasonable estimate was sought; as recommended by Minami et al. 
(2008). The recent evaluation of a CBT informed PMP had allowed pre-post correlations 
for nine outcome measures to be computed; all of which had been completed by 
between 720 and 833 participants (Morley, et al., 2008). Each of these measures had 
been reported by several of the included studies (average pain intensity, distress and 
interference as measured on numerical scales; the BDI; the HADS anxiety and depression 
subscales; the CSQ catastrophising subscale; the PSEQ (Bandura, 1997) and a five-minute 
walk test). The average pre-post correlation on these nine measures was 0.53 and hence 
an    value of 0.53 was considered to be a reasonable estimate for application within 
equation 6. However, as larger estimates of the correlation are known to produce more 
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conservative estimates of effect size benchmarks (Minami, et al., 2008), estimated 
   values of 0.3 and 0.7 were also used within the following calculations to determine 
their impact on the overall effect sizes generated. 
9. The ‘MEANES.SPS’ macro, as described by Lipsey and Wilson (2001) was then applied to 
the four pairs of comparisons (all psychological treatments with an active or WLC and all 
studies with CBT as the primary psychological treatment and an active or WLC). This 
generated a standardised mean effect size per domain per comparison, with associated 
CIs demonstrating the precision of the estimate. The macro ensured that a number of 
fundamental components of meta-analysis were conducted. For example, the inverse of 
the variance per domain per study was ‘weighted’ so that more precise estimates of 
effect size (usually from larger samples) would have a greater influence on the 
aggregated standardised mean effect size; which is therefore less biased and more 
reliable with less sampling error (Becker, 1988; Hedges & Olkin, 1985; Lipsey & Wilson, 
2001). It is good practice to report the magnitude of an effect alongside its statistical 
significance, i.e. the likelihood that it occurred by chance (Feise, 2002), and the macro 
also allowed statistical significance to be computed in terms of a p value. The level of 
homogeneity amongst the effect sizes contributing to the overall mean effect size was 
also determined using the Q statistic. Homogeneous effect sizes indicate that 
contributing effect size estimates are similar, and assume that the only variability 
between studies is at the participant level and is no more than would be expected by 
chance. Heterogeneous effect sizes indicate variability over and above that at the 
participant level and this requires consideration within meta-analysis. The preliminary 
analysis of the data within study 2 had demonstrated the variability amongst included 
studies in terms of size, specified treatment components, patient groups, and outcome 
measures employed, and so heterogeneity in terms of outcome was expected. Such 
heterogeneity indicates random variability at the study and individual participant level, 
and in these cases, the ‘random effects model’ of meta-analysis is required in order that 
each effect size is weighted according to sample size variability, in addition to variation 
between participants and studies (Centre for Reviews and Dissemination, 2001, 2009; 
Hedges & Olkin, 1985; Lipsey & Wilson, 2001; Minami, et al., 2008). In practice, this 
meant that aggregated effect sizes were generated using the ‘fixed-effects’ model when 
contributing effect sizes were considered to be statistically homogeneous, and the 
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‘random-effects’ model when heterogeneity was observed amongst contributing effect 
sizes.  
RESULTS 
Summary of Available Data 
As stated in study 2, a total of thirty-eight papers covering thirty-six separate studies 
met inclusion criteria and contained data which were suitable for analysis. All studies had been 
published between 1985 and 2008, and a total of 3681 participants had been entered into the 
studies with a mean number of entered participants per study of 102.25 (SD 81.13)  
Participants 
Once decisions had been made regarding the primary psychological treatment and 
control group, it was possible to calculate the number of participants within each treatment or 
control arm that had been included in the analyses. This demonstrated that a total of 2605 
participants within primary psychological treatment or control arms completed pre-treatment 
measures, with an average of 72.4 participants per study (range 21-469; SD 77.3) and 36.2 per 
primary psychological treatment or control arm (range 10-312; SD 40.6). It is of note that the 
average number of participants post-treatment per study was 68.1 (SD 66); and per primary 
psychological treatment or control arm was 34.1 (SD 36.9), reflecting a crude pre-post drop-out 
rate of 6%.  
 Measures 
 Study 2 demonstrated that each measure reported by individual studies, and, if 
applicable, its sub-scales, was classed separately and the thirty-six studies reported a total of 
278 outcome measures for which effect sizes were computable. In terms of outcome domains, 
approximately one-third of all outcomes measured physical functioning (35%; n=97), a slightly 
smaller proportion measured coping and cognitive appraisal (30%; n=84), approximately 15% 
measured constructs within the domains of pain and emotional functioning (n= 43 and 41 
respectively) and 5% (n=13) measured pain behaviour. Studies contributed between one and 
sixteen individual measures each, with a mean of 9.1 (SD 4.0) per study. Thirty-four of the 
included studies (94%) reported that at least half of the outcome measures employed had 
been patient self-ratings, with only two studies administering all measures by a blinded-
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researcher (Haldorsen, Kronholm, Skouen & Ursin, 1998; Morone, Greco & Weiner, 2008). Nine 
studies (25%) had administered at least some measures by a blinded-researcher, 16% (n=6) by 
a non-blinded researcher, and three studies (8%) reported at least some measures completed 
by a spouse or family member.  
Table 6 demonstrates that 92% of studies reported outcomes within the physical 
functioning domain (n=33), 86% the pain experience domain (n=31), 81% the emotional 
functioning domain (n=29), 73% the coping and cognitive appraisal domain (n=26), and 36% 
the pain behaviour domain (n=13). 
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Table 6: Primary treatment, control and outcome domain characteristics of included studies 
  Primary treatment and control characteristics 
 
Outcome domain 
 
Primary author and 
year of publication 
N* Duration 
(hours) 
Treatment  
 
Control Coping and 
cognitive 
appraisal 
Emotional 
functioning 
Physical 
functioning 
Pain 
experience 
Pain 
behaviour 
Altmaier 1992 45 nk CBT
 a
 TAU • • • • ◦ 
Astin 2003 128 20 Mind Edu ◦ • • • ◦ 
Basler 1997 94 30 CBT TAU • ◦ • • • 
Becker 2000 166 nk CBT WLC ◦ • • • ◦ 
Bliokas 2007 143 66.5 CBT WLC • • • • ◦ 
Carson 2005 43 12 LKM TAU ◦ • ◦ • ◦ 
Cook 1998 28 10 CBT Edu ◦ • • • • 
Ersek 2003 45 10.5 CBT Edu • • • • ◦ 
Ersek 2008 256 10.5 CBT
 a
 Edu • • • ◦ ◦ 
Evers 2002 64 11 CBT TAU • • • • ◦ 
Flor 1993 120 8 CBT TAU • • • • • 
Greco 2004 92 nk CBT-ex TAU • • • ◦ • 
Haldorsen 1998 469 120 CBT TAU ◦ • • • ◦ 
Jensen 2001 214 54 CBT TAU ◦ • • • ◦ 
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  Primary treatment and control characteristics 
 
Outcome domain 
 
Primary author and 
year of publication 
N* Duration 
(hours) 
Treatment  
 
Control Coping and 
cognitive 
appraisal 
Emotional 
functioning 
Physical 
functioning 
Pain 
experience 
Pain 
behaviour 
Johansson 1998 42 160 CBT
 a
 WLC • ◦ • • ◦ 
Keefe 1990 99 15 CBT TAU ◦ • • ◦ • 
Keefe 1996 88 20 CBT-ex  Edu • • • ◦ • 
Kraaimaat 1995 77 20 CBT WLC • • • • ◦ 
Linton 2008 34 nk  BT WLC • ◦ • • ◦ 
Mishra 2000 94 18 CBT TAU ◦ ◦ ◦ • ◦ 
Moore 1985 43 32 CBT-ex  WLC ◦ • • • • 
Morone 2008 37 12 Mind  WLC • • • • ◦ 
Newton-John 1995 44 16 CBT WLC • • • • ◦ 
Nicassio 1997 86 15 BT Edu • • • • • 
Puder 1988 69 20 CBT WLC • ◦ • • ◦ 
Radojevic 1992 59 6 CBT-ex  TAU • • • ◦ • 
Thieme 2003 61 75 BT
 a
 TAU • • • • • 
Turner 1988 81 16 CBT WLC • ◦ • • • 
Turner 1990 96 16 BT-ex WLC ◦ • • • • 
Turner 1993 102 12 CT WLC • • • • • 
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  Primary treatment and control characteristics 
 
Outcome domain 
 
Primary author and 
year of publication 
N* Duration 
(hours) 
Treatment  
 
Control Coping and 
cognitive 
appraisal 
Emotional 
functioning 
Physical 
functioning 
Pain 
experience 
Pain 
behaviour 
Turner 2006 158 nk CBT Edu • • • • ◦ 
Vlaeyen 1995 71 16.5 CT WLC • • • • ◦ 
Vlaeyen 1996 125 18 CT WLC • ◦ ◦ • ◦ 
Williams 1996 121 28 CBT WLC • • • • ◦ 
Woods 2008 44 12 CBT WLC • • • • ◦ 
Zautra 2008 143 16 CBT Edu • • • • ◦ 
 
Note: *N is pre-intervention and does not necessarily match with the number of participants providing data for analysis; a treatments provided within in-patient settings; • = measured; ◦ = not 
measured; BT = Behavioural Therapy; BT-ex = Behavioural Therapy plus extra components (Turner 1990 = additional exercise components); CBT = Cognitive Behavioural Therapy; CBT-ex = CBT plus 
extra components (Greco 2004 = Biofeedback; Keefe 1996, Moore 1985 and Radojevic 1992= CBT with the involvement of significant others); CT = Cognitive Therapy; Edu: Education; LKM = Loving 
Kindness Meditation; Mind = Mindfulness; nk = not known; TAU = Treatment As Usual; WLC = Waiting List Control. 
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Treatments 
The proportion of studies reporting data from more than one treatment and control 
arm was described in study 2 and so will not be repeated here.  
Table 6 demonstrates that 72% (n=26) of the primary psychological treatment arms 
were classed as some form of CBT, 11% (n=4) as behaviour therapy, 8% (n=3) as cognitive 
therapy, 6% (n=2) as mindfulness and 3% (n=1) as loving kindness meditation. The small 
number of non-CBT treatments had influenced the decision to not construct benchmarks from 
these studies alone, given their reduced collective power and therefore consequent predicted 
utility to PMPs.   
Nearly half of all included studies (44%; n = 16) contributed data from WLCs to the 
analyses, with the remaining twenty contributing data from active controls comprising either 
specified TAU (n=12; 33%) or education components (n=8, 22%).  
Aggregated Effect Sizes 
Table 7 provides aggregated pre-post treatment and control group effect sizes for all 
primary psychological treatment groups with active or WLCs, and CBT alone with active or 
WLCs, and Figure 4 is a graphical representation of each effect size and its associated 
confidence interval. A total of forty aggregated standardised mean effect sizes were generated; 
twenty for primary psychological treatment groups and twenty for control groups. The twenty 
studies with active controls contributed a total of 144 effect sizes (which had been aggregated 
by domains) to the analysis; thus contributing an average of 7.2 treatment and control effect 
sizes per study. The sixteen studies with WLCs contributed an average of 7.5 effect sizes each; 
120 in total. 
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Table 7: Pre-post treatment and control group effect sizes by outcome domain 
 
 
Domain 
 All treatments with 
waiting list control 
All treatments with 
active control 
CBT with waiting list 
control 
CBT with active 
control 
  T C T C T C T C 
C & CA k 12 12 13 13 7 7 11 11 
 n 276 270 518 483 168 160 442 427 
 d 0.19* 0.08 0.37* 0.06 0.17* 0.05 0.37* 0.08 
95% CI  -.002, 
.39 
-.08, .23 .23, .51 -.05, .17 -.13, .46 -.10, .21 .2, .54 -.01, .18 
          
EF k 12 12 18 18 7 7 14 14 
 n 292 266 917 681 179 158 792 567 
 d 0.30* 0.05* 0.33* 0.06 0.23* -0.12 0.30* 0.06 
95% CI  .095, 
.513 
-.11, .22 .22, .43 -.03, .13 -.01, .47 -.28, .03 .19, .41 -.02, .14 
          
P k 16 16 15 15 10 10 11 11 
 n 378 363 743 543 252 234 620 431 
 d 0.46* 0.11 0.50* 0.24* 0.41 0.03 0.55* 0.32* 
95% CI  .31, .61 -.004, 
.22 
.33, .66 .05, .43 .27, .55 -.10, .15 .37, .75 .12, .51 
          
PB k 4 4 9 9 2 2 7 7 
 n 69 70 242 230 35 33 166 174 
 d 0.37 0.10 0.29 0.14 0.32 0.06 0.29 0.09 
95% CI  .06, .67 -.13, .32 .13, .46 .02, .27 -.01, .65 -.27, .40 .07, .50 -.05, .24 
          
PF k 16 16 17 17 10 10 14 14 
 n 378 363 876 649 252 234 772 563 
 d 0.37* 0.08 0.25 0.15 0.29 0.002 0.25* 0.16 
95% CI  .22, .52 -.02, .18 .16, .34 .07, .22 .17, .42 -.12, .13 .14, .36 .07, .24 
Note* = computed using the random effects model due to heterogeneous contributing effect sizes. 
Effect sizes in bold and italics were significant at the 0.001 significance level. Effect sizes in bold, but not italicised, were significant 
at the 0.05 significance level. C = control group results; C&CA Coping and cognitive appraisal; CI = confidence interval; EF = 
Emotional functioning; d= standardised mean effect size, computed using the Lipsey & Wilson (2001) macro; k = number of 
included studies entered into the analysis; n= average number of participants contributing post-treatment data to each domain; P 
= Pain experience; PB = Pain behaviour; PF = Physical functioning; T = Treatment group results.
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In terms of outcome domains across all treatment and control groups, Table 7 
demonstrates that the greatest number of studies and participants contributed data to the 
meta-analyses within the domain of physical functioning (average 14.25 studies and 510.88 
participants respectively). Emotional functioning and pain experience had approximately 
equivalent contributions in terms of the average number of studies and patients contributing 
data (12.75 and 13 studies, and 481.5 and 445.5 patients respectively). Fewer studies 
contributed data within the coping and cognitive appraisal domain (10.75 studies and 343 
patients) and studies were least likely to report data within the pain behaviour domain, as 
indicated by the average 5.5 studies and 127.38 participants contributing data.  
As Minami et al. (2008) had suggested, increasing the value of     to 0.7 generated a 
slightly more conservative effect size than when the value of 0.53 was input, However, there 
was no significant impact upon the mean effect sizes when they were reported to two decimal 
places and so the estimated     value of 0.53 was used to generate the final effect sizes. 
Analyses had also demonstrated that the outlier of Woods and Asmundson (2008) did in fact 
impact on the mean effect sizes produced within the coping and cognitive appraisal domain for 
treatments with WLCs and so it was excluded from the final analyses; as is conventional when 
outliers are not believed to represent overall study findings (Lipsey & Wilson, 2001).  
All effect sizes contributing to those in Table 7 were aggregated under the fixed-effects 
model unless they were statistically heterogeneous, in which case they were aggregated under 
the random-effects model. Those generated using the random-effects model have been 
marked with an asterisk.  
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Figure 4: Error-bar chart with effect sizes and 95% Confidence Intervals (CIs) of pre-post change within treatment and control groups 
 
Note: C&CA Coping and cognitive appraisal; EF = Emotional functioning; P = Pain experience; PB = Pain behaviour; PF = Physical functioning. Dotted horizontal reference lines represent no change 
(effect size = 0) and dashed lines represent small (0.2) and medium (0.5) effect sizes. 
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Effects of all Psychological Treatments Combined 
Table 7 demonstrates that when all primary psychological treatment groups with 
active or WLCs were combined, statistically significant pre-post improvements were observed 
on measures within all outcome domains. The greatest improvements indicated were within 
the pain experience domain whether or not the psychological treatment had been conducted 
alongside a WLC (p<0.001, d =0.46, CI 0.31-0.61,) or active control (p<0.001, d =0.5, CI 0.33-
0.66), and following Cohen’s descriptors of magnitude that effect sizes of 0.2, 0.5 and 0.8 or 
above are considered small, medium and large respectively, such effects can be classified as 
medium (Cohen, 1988, 1992). The significance levels indicate that there was less than a 1% 
likelihood that these effects were a result of chance, and so the null hypothesis that the 
primary psychological treatments were not associated with an improvement on these domains 
is rejected.  
Overall, all psychological treatments were associated with a small to medium pre-post 
improvement. Figure 4 additionally indicates that all psychological treatments combined were 
superior to WLCs within the pain experience and physical functioning domains as treatment 
and control CIs did not overlap. Within the domains of coping and cognitive appraisal and 
emotional functioning, Figure 4 also demonstrates that combined psychological treatments 
were superior to active controls, and Table 7 that these effects were between small and 
medium and statistically significant (p<0.001, d =0.37, CI 0.23-0.51 and p<0.001, d =0.33, CI 
0.22-0.43 respectively). 
Effects of CBT 
Figure 4 indicate CBT’s superiority to WLCs on the domains of pain experience and 
physical functioning; which were statistically significant improvements with small to medium 
effect sizes (p<0.001, d =0.41, CI 0.27-0.55; p<0.001, d =0.29, CI 0.17-0.42 respectively). CBT 
was also superior to active controls in the domains of coping and cognitive appraisal and 
emotional functioning (p<0.001, d =0.37, CI 0.2-0.54; p<0.001, d =0.30, CI 0.19-0.41).    
Precision of Estimates 
The precision of estimates of effect are indicated by the width of CIs, with narrower 
ranges indicating more precise estimates and wider CIs reflecting a wider range within which 
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the true estimate of effect size may fall. Additionally, when CIs do not include zero, as 
demonstrated in most of the treatment CIs in Figure 4, the null hypothesis can be rejected and 
so it can be concluded that the pre-post change was not zero. There were several exceptions to 
this, as seen in combined treatment groups with a WLC on the coping and cognitive appraisal 
domain (p<0.05, d = 0.19, CI -0.002 – 0.39), and all CBT with WLC groups on the coping and 
cognitive appraisal (p =n.s., d = 0.17, CI -0.13 – 0.46), emotional functioning (p =n.s., d = 0.23, CI 
-0.11 – 0.47) and pain behaviour (p =n.s., d = 0.32, CI -0.01 – 0.65) domains. As only one of 
these effect sizes was statistically significant, these results may have been due to chance. It is 
generally accepted that when a confidence interval includes zero, the estimated effect size 
should be discarded given the chance that the true effect may reflect no change; and the lack 
of statistical significance of these effect sizes also implies that this would be advisable. This 
means that the effect sizes generated on these domains are not meaningful, but suggest that 
zero pre-post change occurred. 
Control Group Effects 
Table 7 demonstrates a number of statistically significant effects within active control 
groups. These were observed within the domains of pain experience and physical functioning 
amongst all treatments with an active control (p<0.05, d =0.24, CI 0.04-0.43; p<0.05, d =0.15, CI 
0.07-0.22 respectively) and the same domains amongst CBT with an active control (p<0.05, d 
=0.32, CI 0.12-0.51 and p<0.05, d =0.16, CI 0.07-0.24 respectively). It is of note that the CIs of 
these estimates did not include zero, unlike those of all other control group estimates with the 
exception of combined treatments with an active control on the pain behaviour domain, where 
the effect, although statistically significant, was less than small (p<0.05, d =0.14, CI 0.02-0.27). 
Overall, this indicates that these control groups demonstrated true pre-post change.    
Homogeneity of Contributing Effect Sizes 
Sixteen of the forty effect sizes (40%) were generated using the random-effects model 
due to the heterogeneity amongst contributing effect sizes. The pain and emotional 
functioning domains contained particularly heterogeneous effect sizes (five out of eight in each 
domain were computed using this model), with half of the aggregated coping and cognitive 
appraisal and two of the aggregated physical functioning effect sizes comprising 
heterogeneous estimates. 
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DISCUSSION 
This study aimed to develop a number of benchmarks which would indicate the 
association between psychological treatments of chronic pain reported in the published 
literature and pre-post outcomes within specified domains. The intention was to be able to 
apply these benchmarks to routine clinical settings, thus building a bridge between research 
and practice. The results demonstrate that within the included clinical trials and following 
Cohen’s descriptors of magnitude (1988, 1992) all psychological treatments combined are 
associated with a small to medium, and statistically significant, effect on outcome within all 
specified domains. They also demonstrate that in many cases, the pre-post difference was 
superior to the outcomes within control groups. The results indicate that measures of pain 
experience and physical functioning are particularly subject to post-treatment improvement 
when compared with WLCs, that measures within the coping and cognitive appraisal and 
emotional functioning domains are subject to post-treatment improvement compared to 
active controls and that the results of CBT alone are comparable to those when all 
psychological treatments are combined. The results are broadly congruent with previous 
literature describing the impact of psychological treatments of chronic pain, which have 
demonstrated pre-post improvements on measures classed within the pain experience and 
behaviour (Eccleston, et al., 2009; McCracken, et al., 2007; Morley, et al., 1999), emotional and 
physical functioning (Eccleston, et al., 2009; McCracken, et al., 2007; McCracken, et al., 2005; 
Morley, et al., 1999) and coping and cognitive appraisal domains (McCracken, et al., 2007; 
Morley, et al., 1999).  
The similarity between effect sizes and their associated CIs, whether of psychological 
treatments combined or CBT alone, is a likely reflection of the predominance of CBT within the 
included studies. Psychological treatments combined or CBT alone demonstrated superiority to 
WLCs on measures of pain experience (p<0.001, d =0.46, CI 0.31-0.61 and p<0.001, d =0.41, CI 
0.27-0.55 respectively) and physical functioning (p<0.001, d =0.37, CI 0.22-0.52 and p<0.001, d 
=0.29, CI 0.17-0.42 respectively). Similarly, all treatments combined or CBT alone 
demonstrated superiority to active controls within the coping and cognitive appraisal (p<0.001, 
d =0.37, CI 0.23-0.51 and p<0.001, d =0.37, CI 0.2-0.54 respectively) and emotional functioning 
domains (p<0.001, d =0.33, CI 0.22-0.43 and p<0.001, d =0.30, CI 0.19-0.41 respectively).  
Whilst effect sizes and their associated CIs were employed in order to produce 
benchmarks, meaningful benchmarks are those generated when there is no chance that the 
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pre-post treatment change would be zero or is similar to that demonstrated within control 
groups. This means that technically, benchmarks have been produced for psychological 
treatments of chronic pain compared to WLCs within the domains of pain experience and 
physical functioning, and compared to active controls within the domains of coping and 
cognitive appraisal and emotional functioning. Intuitively, superiority of psychological 
treatments to WLCs is more understandable than superiority to active controls, and the 
suggestion that psychological treatments demonstrate superiority to active controls, but not 
WLCs, in the domains of coping and cognitive appraisal and emotional functioning, is 
surprising. Rather than discuss the possible explanations for this here, however, ways in which 
both the data reported within the included studies and methodological components of this 
study may have had an impact upon the generated effect sizes have been given further 
consideration.  
The external validity of the results of any study are influenced by power, and the fact 
that 2605 participants completed pre-treatment measures that were included in the meta-
analyses demonstrates the overall power of the results; notwithstanding the estimated crude 
drop-out rate of 6%. This crude rate did not significantly reduce the number of participants 
providing data for analysis, but it does reflect the fact that the vast majority of studies only 
reported data for patients who completed outcome measures at post-treatment and therefore 
had completed the treatment programme. Data from such samples is known to lead to 
overestimated results of any study, and so authors such as Minami et al. (2008) suggest that 
when the results of meta-analyses are intended to produce benchmarks that clinical settings 
can strive towards, only trials reporting intention to treat (ITT) samples are included. Some 
authors have followed these recommendations and hence have increased the external validity 
of their results (Minami, et al., 2007; Scheeres, et al., 2008; Wade, et al., 1998). However, 
within this study, such methods would have led to the exclusion of more than 80% of data 
from otherwise included studies and so they were not followed. Rather than diminishing the 
utility of the resulting effect sizes as benchmarks, however, they ought to simply be 
interpreted with caution and considered by PMPs as guidelines to strive towards. In the future, 
both research and practice would benefit from the reporting of ITT samples, however, in order 
that PMPs had more realistic expectations of outcome, and could perhaps also generate 
completion rate benchmarks, as within the study of Curtis, Ronan, Heiblum and Crellin (2009).  
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Pain behaviour was the only domain within which no benchmarks were generated, and 
only 5% of all measures extracted were classed within this domain. Table 7 indicates that all 
treatment generated effect sizes within this domain were between small and medium, but 
Figure 4 demonstrates a lack of precision of estimates. Had measures within this domain been 
reported more frequently, the results may have been different but clearly, in spite of 
recommendations that overt expressions of pain, the use of rescue analgesics and other 
medical treatments are recorded within clinical trials (Dworkin, et al., 2005), this is yet to 
become routine. Future researchers and clinicians therefore need to give greater consideration 
to the use of outcomes within this domain.  
Another data extraction consideration was the observation that SDs of the raw scores 
used to compute effect sizes were frequently almost as large as the actual mean raw scores. 
This indicates heterogeneity in terms of participant scores, and is another factor which means 
that the benchmarks should be interpreted with caution, although given the heterogeneity 
reported by PMPs in terms of treatments, patients and outcome measures (study 1), variability 
in outcome scores may also be common within PMPs; and so this heterogeneity may in fact 
increase the external validity of the benchmarks. With additional regard to data extraction, it is 
unfortunate that in spite of the collection of follow-up data, time constraints meant that it was 
not possible to generate pre to follow-up effect size benchmarks. In future, the early 
classification of primary psychological and control treatment arms would limit the extraction of 
data and so allow time for such analyses to take place, but regardless of classification, research 
should strive to make use of any follow-up data reported.  
The validity of the results of any mode of research synthesis are limited by the quality 
of the included studies as well as the methods of synthesis. Whilst meta-analysis was deemed 
an appropriate method for the synthesis of the chronic pain literature, it has been argued that 
it is a crude way in which to group individual clients’ data (Kazdin, 2008). Slavin (1986) also 
argues that combining studies of varying methodological quality is an inherent flaw within 
meta-analyses which can limit their external validity. With this in mind, the potential exclusion 
of studies that did not meet pre-defined quality standards was considered. The final decision to 
not use quality as an exclusion criterion, however, was influenced by a number of factors, 
including an inability to decide whether it would be more useful to exclude on the basis of 
inadequate study design quality, treatment quality or overall quality; all of which had been 
described in an objective measure for rating the quality of trials reporting psychological 
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treatments of chronic pain (Yates, Morley, Eccleston & Williams, 2005). Eccleston et al. (2009) 
had reported a weak association between study design and treatment quality and a 
consequent lack of consistency within studies regarding their quality scores. In terms of overall 
treatment quality, at least 25% of the included studies (n=9) were not considered to have 
achieved what the authors of the quality scale deemed to be an ‘adequate’ score, and as such 
would have been excluded from the analyses within this study. More significant than the 
reduced power that would have resulted from such exclusion, however, was the recognition 
that including studies with varying levels of quality would be more likely to produce 
benchmarks with greater external validity, as treatments provided within PMPs are unlikely to 
be of equivalent quality; in whatever way it is judged. Additionally, the included studies had 
met a number of other pre-defined criteria of direct relevance to the research questions, and 
so to an extent, the suitability of their inclusion had been considered by other means. Future 
researchers, however, may wish to consider quality and whether it should determine inclusion, 
as some authors have recommended (Lipsey & Wilson, 2001). 
The procedure conducted within this study comprised a complex collection of 
elements of methods reported within the published literature; none of which were completely 
appropriate for the chronic pain literature given its many idiosyncrasies. For example, 
preliminary analyses of the included studies demonstrated the potential for a single study to 
contribute myriad effect sizes to the meta-analyses, which would have overestimated 
treatment effects due to a violation of the assumption of statistical independence (Lipsey & 
Wilson, 2001). A conservative response to this is to ensure that each study only contributes a 
single effect size (Quintana & Minami, 2006); wherein a great deal of potentially useful data is 
discarded.  A less conservative response is to follow the methods of aggregation across 
domains and studies, as recommended within the chronic pain literature and employed within 
the depression literature (Dworkin, et al., 2005; Dworkin, et al., 2008; Minami, et al., 2008; 
Minami, et al., 2007; Turk, et al., 2006). Aggregation ensured that most of the data that would 
be of utility to PMPs was used to generate the effect sizes, and data were also weighted to 
ensure that studies made a fair contribution to the overall results (Lipsey & Wilson, 2001; 
Minami, et al., 2008; Quintana & Minami, 2006). However, the decision making process leading 
to the aggregation of particular data may have influenced the results. For instance, study 2 
described in detail how primary psychological and control groups were classified in an attempt 
to ensure that aggregated data would be of as much utility to PMPs as possible. In spite of this, 
80 
 
Figure 4 demonstrates a lack of superiority of psychological treatments to active controls on 
the domains of pain experience and behaviour and physical functioning. It also displays a more 
surprising finding that psychological treatments were only associated with superior pre-post 
change on measures of coping and cognitive appraisal and emotional functioning when 
compared with an active control. The similarity in treatment and control results may be a 
consequence of flaws within the process by which active controls were classified, for even 
though efforts were made to ensure that the ‘active’ control was the least intensive treatment 
offered, collectively, they may have been more similar in content to psychological treatments 
than intended. This has implications for PMPs in terms of the data that they use as 
benchmarks, and implies that future research may benefit from a more in-depth consideration 
of the classification of primary psychological treatment and control arms.  
With further reference to the potential impact of data aggregation on the results, the 
use of the random-effects model meant that, in spite of heterogeneity between and within 
studies, a meaningful and fair aggregation of the data reported could be conducted. One 
assumption of this model, however, is that the literature contributing to a meta-analysis is 
randomly selected; an assumption that is usually violated due to publication bias and the 
necessary focus of any research question (Quintana & Minami, 2006). Unfortunately, weighting 
studies further enhances this publication bias as smaller studies are given less credence (Centre 
for Reviews and Dissemination, 2001, 2009). Additionally, without correcting for publication 
bias, it is likely that effects will be an overestimate (Hopewell, et al., 2009). In spite of these 
unfortunate consequences, the random-effects model is recognised to be of benefit in 
producing conservative estimates of aggregated effect size when contributing effect sizes are 
heterogeneous and when researchers aim to generalise the results of the meta-analysis to 
other settings (Centre for Reviews and Dissemination, 2001, 2009; Quintana & Minami, 2006). 
This model was used to compute 40% of the aggregated effect sizes (n=16) within the pain 
(n=5), emotional functioning (n=5), coping and cognitive appraisal (n=4) and physical 
functioning (n=2) domains. Whilst it is a strength that the use of this model led to more 
conservative effect size estimates within these domains, the variability in contributors implies 
that moderating variables may have influenced the results. Moderators may include factors 
such as initial severity of chronic pain, treatment modality, length of treatment, whether the 
sample was ITT and its size, therapist factors, allegiance to the mode of therapy and treatment 
integrity. The professional backgrounds and levels of training amongst therapists delivering 
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psychological treatments of chronic pain are known to be heterogeneous (Eccleston, et al., 
2009; Morley, et al., 1999) and also may exert a moderating influence on outcome. Factors 
such as the specificity to the target problem and reactivity of the outcome measures are also 
potential moderators (Minami, et al., 2007), but specificity is difficult to ascertain within the 
chronic pain literature given the lack of explicit treatment aims. Only 3% of outcome measures 
in the included studies were non-patient rated, and as such reactivity would also have been 
difficult to determine. However, future research may benefit from exploring the impact of 
potential moderators on effect sizes using weighted multiple regression analyses for 
continuous variables (Hedges & Pigott, 2004; Minami, et al., 2007; Quintana & Minami, 2006). 
This is of particular importance, for whilst previous research suggests that therapist factors are 
unlikely to impact on outcome (Wampold, et al., 1997), factors such as allegiance are known to 
overestimate effect sizes (Roth & Fonagy, 1996), and until moderators are considered, the 
impact of the psychological treatments themselves on the generated benchmarks can only be 
implied.  
Until the influence of moderators is ascertained, PMPs should strive towards the 
benchmarks that were generated within the domains of pain experience, physical functioning, 
coping and cognitive appraisal and emotional functioning rather than considering them as an 
absolute minimum which should be achieved; as recommended within the depression 
literature (Minami, et al., 2007). Though conclusions as to the impact of the psychological 
treatments themselves on the generated benchmarks cannot be drawn, the results of this 
study suggest an association between psychological treatments of chronic pain and outcomes 
within the domains of coping and cognitive appraisal and emotional functioning when 
compared with active controls, and pain experience and physical functioning when compared 
with WLCs. The impact of these benchmarks in the context of all four research questions and 
their potential influence on future research and clinical practice will now be considered.  
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OVERALL DISCUSSION  
It has already been acknowledged that the most meaningful benchmarks are those 
developed when treatments and outcomes are homogeneous across trials and the clinical 
settings within which their application is intended, and patient groups are also similar 
enough to warrant a useful comparison. It was recognised from the beginning that these 
conditions would not be met within the chronic pain literature or PMPs in general clinical 
settings, and therefore this thesis sought to ascertain the feasibility of benchmarking whilst 
addressing the heterogeneity inherent within the chronic pain literature. In doing so, a 
number of necessary and considered compromises were made within four separate 
studies. 
Study 1 sought to determine the extent of the similarities between the published 
literature and PMPs with specific regard to team, patient, treatment and outcome 
characteristics, and therefore whether it would be meaningful to use the efficacy literature 
to develop benchmarks for use in clinical settings. Some issues with discrepancies in 
treatment components, the manner in which primary psychological treatments were 
classified, bias within the PMP sample and a lack of complete understanding of the specific 
aims and contents of treatments in both settings were identified. Ultimately, however, 
responses were received from participants within a significant proportion of PMPs in 
England (41%), and the results implied that there were enough similarities between PMPs 
and RCTs to warrant the meaningful comparison of benchmarks from the published 
literature to PMPs.  
The specific aim of study 2 was to determine whether the published literature 
contained data which would facilitate the development of benchmarks. The decision to use 
literature identified within a rigorous and methodologically sound Cochrane review 
(Eccleston, et al., 2009) was expected to increase the credibility of the results. Publication 
bias and its potential association with overestimates of treatment effect, given that it was 
not corrected for, was recognised, and though the most recent published literature was not 
sought, the examination of specific treatment components regardless of publication date 
was thought to overcome this to an extent. Within this study, whether the manner in which 
the primary psychological treatment and control groups had been classified would or 
would not influence the external validity of the results was raised once again. However, the 
results implied that the published literature could facilitate the development of 278 
separate benchmarks from the outcome measure scales reported by included studies. In 
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order to use this data in a manner which would be meaningful to PMPs, the categorisation 
of these scales by outcome domain was then explored within study 3.  
In effect, study 3 was a pilot study which aimed to gain a preliminary indication of 
views of clinicians working in PMPs as to outcome domains to benchmark. The surveys 
used to obtain their views were widely accessible, although responses did not represent 
the views of a wide range of professions or of patients themselves. The study raised 
questions with regard patient ratings of improvement and satisfaction, alongside 
considerations about the methods used to analyse responses. However, the results were 
considered alongside highly credible recommendations within the published literature, 
subsequently leading to the decision to classify measures within the five outcome domains 
of coping and cognitive appraisal, emotional functioning, physical functioning, pain 
experience and pain behaviour.   
Study 4 then aimed to use the published literature to generate a number of 
benchmarks within these outcome domains. The methods by which benchmarks were 
constructed were complex, given that the extant benchmarking literature had not faced 
issues inherent to the chronic pain literature, therefore could not provide an exact 
methodological model. However, the methods employed were carefully considered and 
the power of the results was indicated by the number of patients contributing outcome 
measure scores to the generated effect sizes. Once again, questions as to the methods of 
classifying primary psychological treatment and control groups were raised in terms of 
their potential influence on the benchmarks and ways in which they could be utilised within 
PMPs. Possibilities that the effect sizes were overestimated due to studies not accounting 
for attrition or publication bias, or underestimated due to the conservative methods 
applied to heterogeneous contributing effect sizes were considered, alongside the 
potential impact of the quality of the trials and the consistency within which outcome 
measures in specific domains were employed. The decision to aggregate outcome 
measures within domains was justified given known characteristics of the chronic pain 
literature, but it was acknowledged that the heterogeneity of the contributing effect sizes 
may reflect unknown moderator variables; which also may have exerted an impact on the 
generated effect sizes. In spite of these considerations, the results of study 4 demonstrated 
the significant contribution that CBT made to the effect sizes generated when psychological 
treatments were combined, and produced benchmarks for pain experience and physical 
functioning when compared with WLCs, and coping and cognitive appraisal and emotional 
functioning when compared with active controls. Figure 5 demonstrates that when 
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compared to active controls and applying Cohen’s descriptors of magnitude (1988, 1992), 
pre-post improvements within the coping and cognitive appraisal and emotional 
functioning domains achieved small to medium effects, and when compared to WLCs, pre-
post improvements within the pain experience and physical functioning domains are of a 
similar size. Given the similarity of the generated effect sizes whether psychological 
treatments were combined or CBT was considered alone, but that combined psychological 
treatments are likely to be applicable to a greater number of PMPs, the results of combined 
psychological treatments have been reported.  
Figure 5: Benchmarks generated in study 4, with 95% Confidence Intervals (CIs) 
 
Note: C&CA Coping and cognitive appraisal; EF = Emotional functioning; P = Pain experience; PF = Physical functioning. 
Horizontal lines represent small (0.2) and medium (0.5) effect sizes. C&CA and EF benchmarks were generated from 
treatments compared with active controls, and P and PF benchmarks from treatments compared with waiting list controls.  
 
Determining the Meaning of the Results  
It is of some concern that in spite of these benchmarks, the potential for 
unexamined variables to have exerted an influence means that it is impossible to conclude 
whether these results are representative of true effect size estimates, have been 
overestimated or underestimated. Additionally, in order to fulfil the definition of a 
benchmark, these evidence-based practice results must be considered in relation to 
practice-based evidence. In comparing these benchmarks with evidence generated as a 
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informed PMP (Morley, et al., 2008), several discrepancies were observed. The adapted 
ACT treatment reported medium to large effects on measures of pain experience, and large 
effects within the coping and cognitive appraisal, emotional functioning, physical 
functioning and pain behaviour domains, and the CBT informed PMP demonstrated 
medium pre-post effects within the domains of emotional functioning, physical functioning 
and pain behaviour, and medium to large effects of measures within the coping and 
cognitive appraisal domains. Although this comparison is deliberately crude and for 
illustrative purposes, the incongruence may indicate that these particular practice-based 
psychological treatments are more powerful, or of differing levels of intensity and quality 
to the aggregated data and therefore that the comparison is not a meaningful one. 
Alternatively, the differences may indicate that the generated benchmarks do not provide a 
true estimate due to issues previously discussed, or that a combination of both these 
factors makes the comparison unfair. The reasons for the discrepancies are of less concern, 
however, than the question of how the benchmarks produced from aggregated RCT data 
may be of utility within PMPs whilst questions as to their validity remain unanswered. One 
answer may be that they cannot, for in spite of the suggested similarities between the 
published literature and routine clinical settings, essentially the chronic pain literature does 
not lend itself to the production of meaningful benchmarks from meta-analysis; whether or 
not potentially confounding factors such as the classification of treatments and controls, 
study quality and moderators are considered. This suggestion is supported by the fact that 
although, on a practical basis, it has been possible to generate effect sizes and some 
benchmarks, it is difficult to interpret the results and their magnitude compared with 
practice-based evidence. This potential answer is of some concern, however, given the 
intention of this research to bridge a gap between research and practice, and allow PMPs 
to determine realistic expectations of outcome and the relative effectiveness of their 
psychological treatments in a clinical governance context (Department of Health, 1999).  
The Application of Benchmarks within PMPs 
A number of other factors require consideration in relation to the difficulties in 
determining the meaning of the results, and so how, if at all, they might be applied within 
PMPs. The aggregation of myriad outcome measures within domains is one such factor, as 
although it was justified given the heterogeneity of outcomes reported within trials, 
aggregation makes it difficult to determine the specific meaning of a pre-post change of a 
given magnitude; whether or not it was in line with practice-based evidence. Rather than 
aggregating outcome measures, other benchmarking studies have overcome the limitations 
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of heterogeneous measures by focusing upon particular measures and transforming the 
scores so that those used in clinical and research settings are comparable (Barkham, Rees, 
et al., 2005; Barkham, et al., 2008). The focus on particular measures, but not the 
transformation of scores, would be feasible within the chronic pain literature, and indeed 
recommendations that clinical pain trials focus on a single measure (Turk, Dworkin, 
McDermott, et al., 2008) would facilitate this. Whilst such a focus in RCTs would ensure a 
more straightforward transfer of benchmarks to clinical settings, however, it is unlikely to 
be seen in the near future, and heterogeneity amongst outcome measures is likely to 
continue to prevail.  
Rather than using a meta-analysis of the relevant literature, other benchmarking 
studies have avoided the limitations of aggregation by generating benchmarks from several 
trials providing similar treatments to those in specified clinical settings (Curtis, et al., 2009; 
Scheeres, et al., 2008; Wade, et al., 1998). This is one option for PMPs, but as it would lead 
to the development of benchmarks which were meaningful to specific services, it would 
require a great deal of effort by many PMPs and reduce both the power of the benchmarks 
and their wider external validity. This thesis deliberately focused on the meta-analysis of 
data reported within RCTs as such methods are considered to provide the highest quality 
evidence (Greenhalgh, 2006), not least due to the power of generated results, as the 
intention was to generate benchmarks of utility to many PMPs. However, that PMPs would 
benefit more from specific benchmarks generated from several pertinent trials cannot be 
ruled out. In the meantime, though the ‘virtuous circle’ described by Barkham et al. (2006) 
cannot be drawn as a number of unanswered questions prevent the straightforward 
transfer of benchmarks to PMPs, there are several ways in which they can be applied; 
alongside the caveats referred to previously.  
The transparency of the decision making process around the classification of 
primary psychological treatment and control arms and the detail provided about each 
included study means that PMPs might look to the included RCTs and ascertain their 
comparability to a primary psychological treatment, and therefore how applicable the 
benchmarks might be. One question that this raises is whether treatments compared with 
an active control or a WLC would be more applicable to PMPs; a question that is difficult to 
answer without a comprehensive understanding of all treatments offered within PMPs. 
However, it is reasonable to conclude that it would be appropriate for PMPs to strive 
towards the benchmarks produced from combined psychological treatments with a WLC. 
This option would be viable given that PMPs are more likely to have a WLC group than 
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another active treatment of any level of intensity, and meaningful given previous findings 
of equivalent effects of psychological treatments conducted by qualified therapists 
(Wampold, et al., 1997). Such a decision would mean that only the benchmarks within the 
domains of pain experience and physical functioning were of use within PMPs, but that 
WLC benchmarks were also available for comparison, as Table 7 and Figure 4 (study 4) 
demonstrated that all WLCs had CIs overlapping zero and so imply that no change would be 
expected within these groups. Study 3 demonstrated that PMP participants reached a 
consensus that measures within the domains of disability (which were included within the 
physical functioning domain) should definitely be recorded within clinical settings, but only 
40% agreed that outcomes within the domains of pain experience should be measured. It is 
of note that many participants based their decisions on the assumption that pain 
experience would not change, yet study 4 demonstrated that change of the greatest 
magnitude was observed within this domain. The lack of consensus cannot be assumed to 
reflect actual practices within PMPs though, particularly as study 1 suggested the use of 
measures within most domains as common practice and the sample of PMPs was small, 
and so in the meantime, it is reasonable to assume that benchmarks within these domains 
would be of utility within PMPs.  
That the benchmarks, particularly those within the pain experience and physical 
functioning domains, should be striven towards rather than considered as minimum 
standards to be achieved has been discussed, and is of particular importance given the 
inability to conclude whether they have been under or overestimated or the potential 
impact of moderating variables on outcome. The incongruence between the crude 
practice-based evidence and evidence-based practice comparisons also suggests that 
striving would be more appropriate. However, the methods that PMPs may employ to 
generate effect sizes that can be compared with the benchmarks ought to be addressed.  
One suggestion is that clinical settings collect pre-post outcome data within the 
outcome domain, record the sample size and generate collective means and SDs. Where 
multiple outcome measures within a domain were recorded, the decision could be made as 
to whether data from a single measure should be used, or whether an aggregated mean 
score would be more useful. PMPs would then need to apply the equation described in 
step 5 of the procedure in study 4, namely: 
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Congruent with the suggestion that PMPs strive towards these benchmarks, a 
simple comparison of effects and their magnitude may suffice. In the event that the 
methodological constraints preventing conclusions from being drawn are rectified, 
however, PMPs may choose to employ more precise methods of comparison such as those 
described by Curtis et al. (2009) and Minami et al. (2009). Both publications detail how this 
data could be used to calculate a critical value that the clinical effect size must exceed to be 
classified as clinically equivalent to the benchmark, and essentially this means that a 
difference of less than 0.2 or 10% would suggest equivalence.  
PMPs could also generate CIs and determine the statistical significance of pre-post 
treatment improvements to compare with benchmarks. This would be possible using the 
equation reported in step 8 of the procedure of study 4 to estimate the variance of   , 
using the    value of 0.53 or their own estimates of pre-post correlation of the outcome 
measure, namely: 
   
     
          
 
  
    
  
 
   
 
Clinical settings have previously used such methods in benchmarking psychological 
treatments of CFS (Scheeres, et al., 2008) and the precise calculations have been described 
by Lipsey and Wilson (2001).  
Future Considerations 
Regardless of the how the generated benchmarks are interpreted and applied 
within PMPs, this thesis has highlighted a number of factors that require consideration 
within research and clinical settings to ensure that, in the future, meaningful benchmarks 
are generated from the chronic pain literature; not least to meet clinical governance 
requirements (Department of Health, 1999). Following consideration of these factors, such 
research might achieve some of the aims that were not fully realised within this thesis; 
including bridging the gap between research and clinical settings, understanding what the 
benchmarks suggest about the impact of psychological treatments of chronic pain and 
determining realistic outcomes.  
Trials reporting psychological treatments of chronic pain must consider the clinical 
utility of reported outcome measures. These would influence both the available methods 
of benchmarking and how clinically meaningful the results were. Similarly, rather than 
conducting a meta-analysis of many trials, the use of data from several trials of relevance 
to PMPs may produce more clinically meaningful benchmarks. Homogeneity of 
standardised outcome measures in particular would mean that the proportion of patients 
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achieving statistically reliable change (Jacobson & Truax, 1991; Vowles & McCracken, 
2008), normative ranges on outcome measures (Barkham, et al., 2008; Scheeres, et al., 
2008; Wade, et al., 1998), clinically important change (Dworkin, et al., 2008) or sample size 
dependent critical cut-off values (Minami, et al., 2008) could be determined. However, 
whether or not future benchmarking methods involve meta-analyses or comparison with 
several pertinent trials, the potential impact of moderators needs to be explored in order 
that the extent of the impact of psychological treatments of chronic pain can be 
determined. Follow-up data should also be analysed whenever possible to ensure that the 
stability of any treatment effects over time can be ascertained. Until such time, the impact 
of psychological treatments of chronic pain on outcomes within specified domains can only 
be assumed.  
To conclude, the issues precluding the straightforward comparison of clinical and 
research data, including determining whether PMP and efficacy data is comparable, the 
likely over or underestimation of these benchmarks and the potential impact of moderator 
variables are unlikely to be resolved in the near future. The overall aim of this thesis was to 
assess the feasibility of generating benchmarks which would reflect the impact of 
psychological treatments of chronic pain and be meaningful to routine clinical settings, 
however, and absence of evidence does not imply evidence of absence. Until the issues 
discussed are resolved, recommendations that the generated benchmarks be seen as a 
general standard to strive towards, alongside a consideration of their limitations, is viable. 
This would ensure their transfer to clinical settings as intended; although that benchmarks 
developed from several RCTs would be more meaningful to PMPs than those generated 
from a meta-analysis cannot be ruled out.  
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APPENDICES  
Appendix 1: Correspondence Relating to Ethical Approval 
  
Date:  Mon, 16 Feb 2009 13:47:15 +0000 [16/02/2009 13:47:15 GMT] 
From:  Amy Beckitt <Amy.Beckitt@leedsth.nhs.uk> 
To:  Grania Fenton <ugm6g2f@leeds.ac.uk> 
Subject: Re: ethics confirmation for PMP survey 
 
Hi Grania,  
 
Further to our telephone conversation and email correspondence, please note that the 
below proposal has been reviewed by a Chair of an NHS Research Ethics Committee and 
resultantly, the proposal does not require NHS REC approval.  
 
Should you require any further information, please do not hesitate to ask.  
 
Kind Regards, 
 
Amy Beckitt 
Committee Assistant Coordinator 
Leeds (East) Research Ethics Committee 
Room 5.2 
Clinical Sciences Building 
St James's University Hospital 
Leeds 
LS9 7TF 
 
Tel: 0113 206 5637 
Fax: 0113 206 6772 
Email: amy.beckitt@leedsth.nhs.uk  
 
Streamline your research application process with IRAS (Integrated 
Research Application System). To view IRAS and for further information 
visitwww.myresearchproject.org.uk (http://www.myresearchproject.org.uk/) 
 
>>> Grania Fenton <ugm6g2f@leeds.ac.uk> 16/02/2009 13:28 >>> 
Hi Amy, 
 
the proposal is as follows: 
 
To ask lead NHS staff from UK Pain Management Programmes (PMPs) to   
complete a brief online survey about broad characteristics of their   
client group and the services offered to them. This is to ascertain   
how comparable routine clinical activity is to descriptions of   
treatments and participants within published RCTs, and therefore   
ultimately how applicable RCT data is to clinical settings. 
 
Participation will be entirely voluntary, and the survey will be   
advertised at the Pain Society conference, in a newsletter and   
possibly through an email sent to all PMP leads. At the end of the  
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survey participants may be asked to email me if they would like to  
participate in a further brief electronic study to gain a consensus on  
outcome measures that are useful within PMPs. The aim of this brief  
study is to ensure that the ways in which I interrogate the published  
RCT data with regards outcome measures is as useful to PMPs as possible. 
Let me know if you've any further questions, 
 
Kind regards, 
 
Grania Fenton 
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Appendix 2: Survey Questions (study 1) 
 
This PMP survey has four sections regarding team, patient, treatment and outcome 
characteristics. 
 
If you would prefer not to answer a particular question please select don't know/prefer not 
to say rather than leaving it blank. 
 
Once you have completed all four sections, please click on the continue button at the 
bottom of the page. Please note that once you have done this, your responses will be 
automatically submitted and you will not be able to return to review or amend them. 
  
Team characteristics   
1.  Please state the PMP that you work for in the below space (n.b. this information will be 
treated with the strictest confidence and simply help to ensure a representative sample).   
a.  Please state whether you are responding to this survey on behalf of your team or as an 
individual  
How long have you worked here? 
< 6 months, 6 months to a year,  1 - 3 years, 3 - 5 years, > 5 years, Don't 
know/prefer not to say   
b.  Are you a member of the British Pain Society? 
Yes, No, Don't know/prefer not to say   
c.  Please select your core profession from the list below 
Administrative staff, Assistant psychologist, CBT therapist, Clinical psychologist, Counselling 
psychologist, Graduate patient, Health psychologist, Medical, Nurse   
Occupational therapist, Pharmacist, Physiotherapist, Psychologist in Clinical Training, Don't 
know/prefer not to say, Other (please specify): 
 d. Please select all of the professions who work within your PMP 
(select all that apply) 
Administrative staff, Assistant psychologist, CBT therapist, Clinical psychologist, Counselling 
psychologist, Graduate patient, Health psychologist, Medical, Nurse   
Occupational therapist, Pharmacist, Physiotherapist, Psychologist in Clinical Training, Don't 
know/prefer not to say, Other (please specify): 
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2.  Does your PMP routinely provide an induction period for new staff?    
Yes, No, Don't know / prefer not to say   
 
3.  Does your PMP routinely provide systematic clinical supervision for clinical staff? 
Yes, No, Don't know / prefer not to say   
 
4.  Does your PMP routinely provide therapeutic training for clinicians (specifically 
regarding patients with chronic pain) before they start working with patients?    
Yes, No, Don't know / prefer not to say   
 
5.  Would you describe your PMP team as 'inter-disciplinary' (i.e. one in which diverse 
professionals work together on a routine basis)?    
Yes, No, Don't know / prefer not to say   
 
6.  Would you agree that staff members are encouraged to allocate time for continuing 
professional development on a regular basis?    
Yes, No, Don't know / prefer not to say   
 
7.  If you have any further comments about these team characteristics questions, please 
write them in the space provided below    
 
Patient characteristics   
I appreciate that some Pain Management Programmes may not collect some types of 
patient data routinely or that it may not be easily accessible, so please simply provide your 
best estimate to questions in this section. 
 
 
8.  Approximately how many patients are seen within your PMP in a given year?   and 
approximately what percentage of these patients are female? 
 
9.  What would you estimate the average age of patients to be?    
 and what would you estimate the approximate age range of patients to be? (E.g. 
18-60 etc.) 
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10.  What percentage of patients would you estimate to be currently employed (either 
part-time or full time)?    
 
11.  Please estimate the approximate percentage of patients that may fall into each 
diagnostic category. (I appreciate that this is an estimate and so the percentage may not 
add up to 100 
 Don't know/prefer not to say     
0%, <5%,  5-10%,  11-20%,  21-30%,  31-40%,  41-50%,  51-60%,  61-70%,  71-80%, 81-90%, 
91-100%  
 a. Chronic low back pain  b. Complex regional pain syndrome  c. Facial  
 d. Fibromyalgia  e. Headache  f. Multiple sites of pain g. Musculoskeletal  
 h. Neuralgia  i. Osteo-arthritis  j. Rheumatoid arthritis  k. Temporomandibular joint 
syndrome l. Upper limb  m. Visceral  n. Other   
 
12.  If you have selected 'other' in the diagnostic category question above, please specify 
the diagnosis/diagnoses and approximate percentage of patients in the space below.   
 
13.  If you have any further comments about these patient characteristics questions, please 
write them in the space provided below. 
     
Treatment characteristics   
14.  What would you consider to be the main treatment orientation of this PMP?   
Acceptance and Commitment Therapy (i.e. a psychological intervention which incorporates 
acceptance, mindfulness and value oriented behavioural strategies).   
 
Behaviour Therapy (i.e. a psychological intervention based on principles of operant 
conditioning and social reinforcement, involving techniques such as identifying and 
reducing unhelpful patterns of behaviour and building upon helpful patterns of behaviour 
in order to facilitate change).   
 
Biofeedback (i.e. techniques which use external feedback to raise levels of conscious 
control over body functions such as muscle tension, with the aim of improving control over 
such functions. May also include relaxation components but NOT as the main focus of 
therapy).   
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Cognitive Behaviour Therapy (i.e. a goal oriented psychological therapy involving 
examination of the links between cognitions, emotions, physiology and behaviour. Involves 
the use of Socratic questioning and collaborative empiricism e.g. testing beliefs and 
assumptions through behavioural experiments, in addition to techniques such as activity 
scheduling, in order to influence change).   
 
Mindfulness (i.e. teaching skills in paying attention in the present moment, on purpose and 
non-judgementally using specific 'mindfulness meditations').   
 
Mixed (i.e. a combination of several of the treatments mentioned in this section. If you 
select this option, please specify the treatments in the space below).   
 
Relaxation (i.e. the use of a specific training strategy designed to induce physical or mental 
relaxation).   
 
Don't know/prefer not to say   
 
Other (please specify) 
 
a.  Please indicate the average length of this treatment in number of weeks (excluding any 
follow-up/booster sessions) 
 
b.  Please indicate the average number of hours per week of this treatment (excluding any 
follow-up/booster sessions) 
 
c.  Do you routinely offer follow-up/booster sessions? 
Yes, No, Don't know / prefer not to say  
 
d.  If yes, please state the average length of time in weeks between the start of treatment 
and the first follow-up/booster session(s) 
 
e.  Do you routinely follow-up patients who drop out of treatment? 
Yes, No, Don't know / prefer not to say   
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f.  If yes, please use the below space to detail how you follow-up patients who drop out and 
what you do with the information 
 
15.  In consideration of the main treatment orientation as specified above, please indicate 
the individual components of treatment   
a.  Is there a specific education component within the main treatment specified above? 
Yes, No, Don't know / prefer not to say  
 
b.  Is there a specific exercise component within the main treatment specified above? 
Yes -- managed by non-psychological principles (e.g. physiotherapy)   
Yes -- managed by psychological principles (e.g. graded exposure)   
No, Don't know / prefer not to say 
 
c.  Is there a specific goal setting component within the main treatment specified above? 
Yes, No, Don't know / prefer not to say   
 
d.  Is there a specific problem solving component within the main treatment specified 
above? 
Yes -- it is the main focus of treatment   
Yes -- but it is not the main focus of the treatment   
No, Don't know / prefer not to say 
 
e.  Is there a specific relaxation component within the main treatment specified above? 
(i.e. the use of a specific training strategy designed to induce physical or mental relaxation, 
e.g. progressive muscle relaxation, relaxation with imagery. Please record biofeedback or 
mindfulness/meditation below). 
Yes -- some strategies are taught within the main treatment   
Yes -- it is the main focus of the treatment   
No, Don't know/prefer not to say  
 
f.  If yes, please state the type of relaxation that is a component of treatment in the space 
below 
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g.  Is there a specific biofeedback component within the main treatment specified above? 
(i.e. a component which raises patients' awareness and levels of conscious control over 
body functions such as muscle tension). 
Yes -- some strategies are taught within the main treatment   
Yes -- it is the main focus of the treatment   
No, Don't know / prefer not to say   
 
h.  Is there a specific behavioural management component within the main treatment 
specified above? (i.e. using concepts of operant conditioning etc. as described in behaviour 
therapy above, but not as the main focus of treatment). 
Yes -- some strategies are taught within the main treatment   
Yes -- it is the main focus of the treatment   
No, Don't know / prefer not to say   
 
i.  Is there a specific attention management component within the main treatment 
specified above? (i.e. teaching attention management skills with the aim of limiting the 
impact of pain and enhancing the sense of control over it, either by switching attention to 
another stimulus complex (internal or external) or by 'retuning' to the pain stimulus with 
the aim of altering the appraisal of it. Includes attention-diversion training, distraction, and 
sensory reinterpretation. Please record mindfulness/meditation below). 
Yes - some strategies are taught within the main treatment   
Yes - it is the main focus of the treatment   
No, Don't know / prefer not to say   
 
j.  Is there a specific mindfulness/meditation component within the main treatment 
specified above? (i.e. teaching skills in paying attention in the present moment, on purpose 
and non-judgementally using specific 'mindfulness meditations'. Please record attention-
diversion training, distraction, and sensory reinterpretation above). 
Yes - some strategies are taught within the main treatment   
Yes - it is the main focus of the treatment   
No, Don't know / prefer not to say   
 
k.  Is there a specific coping skills component within the main treatment specified above? 
(i.e. teaching a range of methods to help patients to manage specific pain episodes) 
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Yes - some strategies are taught within the main treatment   
Yes - it is the main focus of the treatment   
No, Don't know / prefer not to say   
 
l.  Is there a specific cognitive restructuring component within the main treatment specified 
above? (i.e. aiming to move patients beyond the specifics of coping with a particular pain 
episode by encouraging them to restructure their appraisals and attributions about their 
pain, thus changing their relationship towards it). 
Yes - some strategies are taught within the main treatment   
Yes - it is the main focus of the treatment   
No, Don't know / prefer not to say   
 
m.  In consideration of the main treatment orientation as specified above, please use the 
below space to record any other components of treatment 
 
16.  Please indicate the setting in which the majority of your PMP's treatments are 
provided    
In-patient   
Out-patient community   
Out-patient hospital   
Don't know/prefer not to say   
Other (please specify): 
   
17.  Please select the predominant mode of treatment delivery in your PMP (n.b significant 
others are defined as spouse, partners, family members etc.).    
Group   
Individual   
Mixed group and individual   
Mixed group and significant others   
Mixed individual and significant others   
Mixed group and individual and significant others   
Don't know/prefer not to say   
Other (please specify): 
If significant others are involved in treatment, please select their level of involvement 
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Significant others are considered to be a part of the treatment (i.e. they attend for one or 
two specific sessions)   
Significant others are considered to be integral to the treatment (i.e. they are involved in a 
significant proportion of the treatment)   
Don't know/prefer not to say   
  
18.  Do you use manuals for any of the treatments that you offer within this Pain 
Management Programme?    
Yes -- for some treatments/components of treatments   
Yes -- for all treatments/components of treatments   
No, Don't know/prefer not to say   
If you have indicated yes to the above question, please record the names of the manuals 
that you use for specific components in the below space 
  
19.  If you have any further comments about these treatment characteristics questions, 
please write them in the space provided below    
 
Outcome characteristics   
20.  With the main treatment orientation as specified above in mind, please indicate when, 
if at all, you use outcome measures    
      Yes    No    Don't know / prefer not to say  
 a. before treatment     
 b. after treatment     
 c. at follow-up     
 
21.  You will be aware that there a number of domains on which outcomes of treatments 
provided within PMPs can be measured. In consideration of the following domains, please 
indicate those outcomes that are routinely measured within your PMP.    
a.  Coping 
(select all that apply) 
Coping Strategies Questionnaire   
Don't know / prefer not to say   
Not applicable - don't measure   
Other (please specify):  
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b.  Mood 
(select all that apply) 
Arthritis Impact Measurement Scale (AIMS) Mental Disability   
Arthritis Impact Measurement Scale (AIMS) Psychological Disability   
Hospital Anxiety and Depression Scale (HADS)   
Beck Anxiety Inventory (BAI)   
Beck Depression Inventory (BDI)   
Brief Symptom Inventory (BSI) Distress   
Centre for Epidemiologic Studies Depression Scale (CES-DS)   
Clinical Outcomes in Routine Evaluation (CORE)   
Depression Adjective Checklist (DACL)   
Depression Scale (DEPS)   
Geriatric Depression Scale (GDS)   
Hopkins Symptom Checklist Distress (HSCD)   
Impact of Rheumatic diseases on General health and Lifestyle (IRGL) Depression subscale   
Minnesota Multiphasic Personality Inventory (MMPI) Depression subscale   
State-Trait Anxiety Inventory State (STAI-S) Subscale   
State-Trait Anxiety Inventory Trait (STAI-T) Subscale   
(West Haven) Multidimensional Pain Inventory (WHYMPI) Distress subscale Don't know / 
prefer not to say   
Not applicable - don't measure   
Other (please specify): 
 
c.  Disability 
(select all that apply) 
Arthritis Impact Measurement Scale (AIMS) Activities of Daily Living   
Arthritis Impact Measurement Scale (AIMS) Physical Disability   
Disability Rating Index   
Dusseldorf Disability Scale   
Fibromyalgia Impact Questionnaire   
Impact of Rheumatic diseases on General health and Lifestyle (IRGL) Functional Disability   
Oswestry Disability Index   
Pain Disability Inventory   
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Roland and Morris Disability Questionnaire   
Sickness Impact Profile (SIP; other)   
Sickness Impact Profile (SIP; self)   
SF-36 Physical Function   
(West Haven) Multidimensional Pain Inventory (WHYMPI) Activity subscale   
(West Haven) Multidimensional Pain Inventory (WHYMPI) Pain Interference subscale   
Don't know / prefer not to say   
Not applicable - don't measure   
Other (please specify): 
 
d.  Pain behaviour 
Direct observation   
Exercise tests (e.g. five minute walk, sit to stand)   
Medication count   
Self-report schedule (please specify which one below if so)   
Don't know / prefer not to say   
Not applicable - don't measure   
Other (please specify): 
 
 e.  Pain experience 
(select all that apply) 
Arthritis Impact Measurement Scale (AIMS)   
Arthritis Self-Efficacy Scale   
Brief Pain Inventory (BPI)   
Characteristic Pain Intensity   
Graded Chronic Pain Scale   
Impact of Rheumatic diseases on General health and Lifestyle (IRGL)   
McGill Pain Questionnaire Pain Rating Index   
Memorial Pain Questionnaire   
Multi-dimensional Pain Inventory (MPI) Pain Severity Rating   
Numerical Rating Scale   
SF-36 Bodily Pain Scale   
Verbal Rating Scale   
Visual Analogue Scale   
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Don't know / prefer not to say   
Not applicable - don't measure   
Other (please specify): 
 
f.  Social role functioning (i.e. how much pain interferes with social roles) 
(select all that apply) 
Pain Disability Inventory   
Sickness Impact Profile (SIP; other)   
Sickness Impact Profile (SIP; self)   
Visual Analogue Scale of Interference to social role functioning   
(West Haven) Multi-dimensional Pain Inventory (MPI) Pain Interference subscale   
Don't know / prefer not to say   
Not applicable - don't measure   
Other (please specify): 
 
g.  Health and social care use by the patient 
(select all that apply) 
Employment status   
Number of visits to GP   
Number of visits to other medical settings   
Medication Use   
Don't know / prefer not to say   
Not applicable - don't measure   
 
22.  Have the outcomes of treatments within this PMP ever been written up for clinical 
audit, research or service evaluation purposes?    
Yes, No, Don't know / prefer not to say   
 If yes, please detail any publications 
 
23.  If you have any further comments about these outcome characteristics questions or 
would like to record any other outcome measures that your PMP administers, please use 
the below space.  
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Appendix 3: Preliminary Survey Results (study 1) 
   
All seventy-six members of the British Pain Society’s Pain Management Programme Special 
Interest Group1  (PMP SIG) and attendees of the most recent PMP conference were invited 
to participate in this survey between May and August 2009.  
 
Thirty-six separate responses were received in total, all of which were from respondents 
involved with services in England. Thirty-three responses appeared to be from people 
within different NHS based PMPs, several from within the same Trust. One respondent was 
from an Expert Patient Programme and one was from an independent healthcare provider 
working with the NHS. Additionally, one respondent chose not to state the PMP in which 
they worked, but I have chosen to summarise data from all respondents at this stage of the 
analysis.  
 
One third of responses (n=12) were on behalf of PMP teams, with the remaining two-thirds 
classified as individuals’ responses.  
 
The main results were as follows2: 
 
Team Characteristics 
 
 74% of respondents (n=26) were members of the British Pain Society. 
 The majority of respondents (61%; n=22) were physiotherapists or clinical 
psychologists. The remaining classified themselves as belonging to the medical, 
nursing, occupational therapy or clinical and health psychology professions, with one 
respondent describing themselves as a trainer.  
 92% of respondents (n=33) classed themselves as belonging to an ‘inter-disciplinary’ 
team where multiple professions worked together on a routine basis. Teams were 
frequently made up of administrative staff, clinical psychologists, physiotherapists and 
members of the medical and nursing professions, although several respondents also 
stated that assistant and trainee clinical psychologists, CBT therapists, counselling and 
                                                     
1 British Pain Society (2009) Pain Management Programme Society SIG. Retrieved 24th August 2009, from 
http://www.britishpainsociety.org/members_sigs_pmp.htm  
 
2 Please note that questions completion rates were not 100% and so the total n used to calculate overall percentages is 
varied. Percentages reported are approximate and so totals may not add up to 100.  
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health psychologists, graduate patients, pharmacists and occupational therapists made 
contributions to the team.  
 With regards professional development, two-thirds of respondents (n=24) stated that 
an induction programme was routine for new staff and 61% (n=22) stated that 
systematic clinical supervision was routinely provided. Whilst only 36% (n=13) stated 
that therapeutic training was routinely provided for clinicians, 86% (n=31) agreed that 
staff were encouraged to allocate time for continuing professional development on a 
regular basis.  
 Several respondents suggested that the manner in which continuing professional 
development, clinical supervision, inter-disciplinary working and induction periods 
were encouraged and provided was variable.  
 
Patient Characteristics 
 
 Estimates of the number of patients seen per annum varied widely between 20 and 
3000, reflecting the varied capacities and clinical foci of the services described by 
respondents.  However, the vast majority (61%; n=22) estimated that fewer than 100 
patients were treated within PMPs per annum, 25% (n=9) estimated between 100 and 
200, and 8% (n=3) between 200 and 400. Only 4% (n=2) of respondents, both of whom 
worked within NHS PMPs, estimated that more than 1500 patients were treated 
annually.   
 86% of respondents (n=30) estimated that at least 60% of patients treated were 
female. 
 Although all respondents estimated that the average age of patients was between 40 
and 50, services did not appear to have imposed upper age limits. However, only 5% of 
respondents (n=2) implied that adolescent referrals would be accepted within their 
service.  
 The vast majority of respondents (81%; n=29) estimated that fewer than one third of 
patients treated were in any form of employment, and only one respondent suggested 
that this was due to many patients being outside the usual working age range.  
 It was recognised that many patients have multiple sites of pain, and many 
respondents reported that service inclusion criteria influenced the likely range of 
presenting diagnoses and sites of pain reported by their patients. However, 
respondents estimated the following: 46% (n=16) that at least 70% of patients had 
125 
 
musculoskeletal pain; 58% (n=21) that at least 61% had chronic low back pain; 69% 
(n=25) that at least 11% had fibromyalgia; 47% (n=17) that at least 11% had 
osteoarthritis and 40% (n=14) that at least 11% had upper limb pain. Fewer patients 
were estimated to be likely to present with complex regional pain syndrome, facial 
pain, headache, inflammatory arthropathy such as rheumatoid arthritis or lupus, 
temporomandibular joint syndrome, vascular, post-operative or visceral pain.  
 
Treatment Characteristics 
 
 Only one respondent chose not to report the main treatment orientation of their 
programme. The vast majority cited Cognitive Behavioural Therapy (CBT) as the main 
orientation (42%; n=15), with a further 17% (n=6) citing CBT in addition to components 
of other treatments. 
 5% of respondents (n=2) described Acceptance and Commitment Therapy (ACT) as the 
main theoretical orientation of their programme, with the same proportion stating that 
ACT was a component of the main treatment. One respondent described a recent 
service move to ACT from CBT, and mindfulness methods were described as being 
employed where pain was not related to activity (n=1) or where many patients did not 
have English as a first language (n=1).  
 73% of respondents (n=24) reported that their programme ran for at least twenty-five 
hours, and although the average number of treatment hours was forty-nine, this 
ranged from three hours to over one hundred.  
 53% of respondents (n=18) reported a treatment duration of at least eight weeks, and 
although the average duration was 6.8 weeks, this ranged from three to thirteen weeks 
in total. One respondent specifically described a two-week long residential programme, 
although 18% of respondents (n=6) implied that their programme comprised similarly 
intensive non-residential programmes. 
 86% (n=30) of respondents stated that treatments were conducted in out-patient 
settings; two-thirds of which were in hospital and one-third of which were in 
community locations.  
 89% of respondents (n=31) stated that their programme offered follow-ups to patients, 
and 40% (n=14) that they routinely followed-up patients who dropped out of 
treatment; usually by telephone or in writing.  
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 The vast majority of respondents (more than 90%) described treatments as containing 
an educational component, an exercise programme, teaching goal-setting and coping 
skills or some methods of relaxation. Relaxation components frequently comprised 
autogenic, progressive muscular, imagery or mindfulness exercises.  More than 70% of 
respondents described problem-solving, specific mindfulness or cognitive restructuring 
components of treatment and 68% (n=23) described behavioural management 
components. Biofeedback was reported as a component of treatment by 35% of 
respondents (n=12).  
 58% of respondents (n=21) reported that treatments were delivered in groups, 28% 
(n=10) described mixed methods of delivery, and only 6% (n=2) reported any level of 
individual treatment.  
 Of the twenty respondents who answered a question about the involvement of 
significant others in the programme, 85% (n=17) implied their involvement in several 
specific treatment sessions but only one respondent described them as being integral 
to the whole treatment package.  
 51% of respondents (n=18) reported that manuals were used within the treatments 
offered, and half of these respondents implied that manuals guided all aspects of 
treatment. Many respondents also reported that handouts were an integral part of the 
treatment, and all manuals described by respondents had been developed in-house.  
 
Outcome Characteristics 
 
 The vast majority of respondents (97%; n=34) described administering outcome 
measures before treatment, with slightly fewer using them post-treatment (89%; n=31) 
and at follow-up (86%; n=30).   
 All respondent reported measures of coping, mood, disability and pain experience were 
standardised.  
 Outcome measures within the domains of coping, mood, disability and health and 
social care use were most likely to be administered within PMPs. There was some 
consistency within the domains of coping (the Coping Strategies Questionnaire or Pain 
Self-Efficacy Questionnaire were commonly used), mood (the Hospital Anxiety and 
Depression Scale was the most commonly employed measure), and health and social 
care use (employment status, medication use and number of GP and other medical 
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service visits were commonly recorded). However, there was less consistency with 
regards the measures of disability that were administered.  
 Several respondents stated that their PMP did not routinely administer measures 
within the following domains: social role functioning (40%; n=14); coping (25%; n=9); 
pain behaviour (20%; n=7); mood (8%; n=3) or disability (8%; n=3).  
 63% of respondents (n=22) stated that treatment outcomes had been written up, 
typically for internal auditing purposes. However, several respondents reported that 
outcome data had comprised post-graduate research, conference posters or been 
published.  
 
A more formal comparison of the data collected within this survey and the published 
clinical trial data is currently in progress and will be completed by the end of 2010, but in 
the meantime if you have any queries about these findings, please contact:  
 
Grania Fenton (contact details supplied) 
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Appendix 4: Modified Data Extraction Form 
General Information  
 
Date of data extraction: ______________________  
Study Identifiers  
 
Study/Article Number: ___________ 
 
Author(s): __________________________________________________________ 
Title: __________________________________________________________ 
Journal: _________________________Year: _______Vol/Pages: _______ 
Type of Report: 
 
1.   Full report  2. Follow-up data only   If 2 give study Number of original 
_____ 
  
Location of study:  
 
1.   Europe     2.   North America     3.  Australia & NZ    4.  Other 
(state)__________________ 
 
Participants 
 
Source of sample:    Sampling strategy: 
Pain or rehab clinic   1.   Random from specified pop.   
Community referral   2.   Convenience from specified pop.  
Volunteer     3.   Consecutive referrals   
Other __________    4.   Not reported     
 
Total sample size before selection or attrition:  ___    _____   
Number entered into trial, after selection / refusal:  __    ______ 
Number of participants at end of treatment:   ____    ____ 
Number of participants at end of final follow-up: ___    _____ 
Number of males at start of trial:   ____      ___  
Number of females at start of trial:   ___       ____ 
Mean age of total sample (to 2 d.p)**   _____: ____ 
SD of sample age:      _____: ____ 
Lowest age:       ________   _  
Highest age:       ____   _____  
***   If age not reported: note means, SD and N for each group page 2. 
Averaged years in education   ____________   If not reported note the page where details 
of education given 
Work status of sample – give as much detail as possible:  
 1. % employed       __________ 
2. % not employed because of pain   __________ 
3 % not employed for any other reason   __________   
  
Mean years of pain of sample: ____:____  or  Median if reported   ______ 
  
Number of previous non-surgical treatments: ___:___ 
Number of previous surgeries: ____:___Percent of sample with previous surgery:  
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Diagnostic label for sample:   Primary site of pain: 
    
Chronic low back pain   1.   Low back   
Rheumatoid arthritis   2.   Limb   
Osteo-arthritis    3.   Mixed   
Upper limb    4.   Generalised pain  
Fibromyalgia    5.   Other – description of sample 
TempMandibJoint         ___________________________ 
Facial     
Visceral _________  
CRPS     
Multiple sites of pain     
Mixed      
Other – specify  _______________________ 
 
Notes of on any other aspect of Sample that may need to be discussed 
 
Treatments  *** Use separate sheet for each treatment in the trial including control 
group(s)*** 
Type and delivery details 
 
Name of treatment as given by author: __________________________________________ 
Treatment Type:       
CBT – multiple components      
Behaviour therapy       
Cognitive therapy     
Unimodal treatment e.g. biofeedback    name here 
_______________________ 
Combined e.g. Biofeedback + relaxation    name here 
_______________________ 
Waiting list control – no treatment    i.e. no treatment given by health care 
Waiting list -Treatment as usual available   i.e. assigned as WL but TAU available 
Treatment as usual control     i.e. assigned to TAU  
Education/bibliotherapy control       
Other  _____________________ 
 
Treatment setting: 
In-patient    2.   Out-patient Community   
3.    Outpatient: Hospital  4.  Mixed    
________________ 
 
Format of delivery – patients: 
Group     5.   Group & spouse   
Individual    6.   Group & individual & spouse  
Group & individual   7.   Unclear – give comment  
Individual & spouse        __________________________ 
 
Personnel involved: 
Psychological expertise 
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Lay counsellor or trained patient  4.   Clin. Psych qualified +5yrs    
Clin. Psych. in training    5.   Qualified non-psychologist  
 (nurse/CBT therapist) 
Recently qualified Clin. Psych  6.   Not given    
 
Health care team 
1.  No details given    
2.    Multi-professional group of staff involved  i.e. no ‘team work’  
3.    Multidisciplinary team    i.e. definite mention of team 
 
Duration of intervention in weeks: _____Total hours for this treatment: ________ 
Length of time to follow-up from start of treatment to longest follow up (in weeks):   
_________ 
 
Treatment components 
 
Note  If not details are given rate as 0 – not present or if you think that it is present rate it 
at the lowest level you think appropriate 
 
Education:       Comments here 
No education mentioned as part of treatment   
Education mentioned      
Comprehensive education – manualised program  
 
 
Exercise:       Comments here 
No exercise programme      
Specific programme of exercise mentioned     
Exercise managed by psychological principles    
 
Goal setting:        
Not explicitly mentioned     Comments here  
General statement that used      
  
 
Problem Solving:      Comments here 
No training given      
Strategies taught in therapy     
PS is the main focus of treatment     
 
 
Relaxation:       Comments here 
No relaxation       
Relaxation included in treatment    
Relaxation is main focus of treatment    
 
 
Biofeedback:       Comments here 
No biofeedback       
Biofeedback included in treatment    
Biofeedback is main focus of treatment    
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Behavioural management:      Comments here 
Not present        
Behavioural management included in Tx  
Behavioural management is main focus     
  
 
 
Attention management:     Comments here       
  
Not present       
Attention management included    
Attention management is main focus   
 
 
Mindfulness / Meditation     Comments here 
Not present      
M/M is part of treatment     
M/M is main treatment focus    
 
 
Coping skills training      Comments  here 
Not present      
CS is part of treatment      
CS is main treatment focus    
 
 
Cognitive restructuring:      Comments  here 
Not present      
Cog restruct is part of treatment    
Cog restruct is treatment focus    
 
 
Spouse/Family involvement:      Comments here 
No spouse or family involvement     
Spouse or family member present for some part      
Spouse or family member involved as integral part of therapy   
 
Notes of on any other aspect of Treatment that may need to be discussed 
 
Outcomes   *** Use separate sheet for each measure*** 
Name of measure as used by author: __________________________________________ 
Domain of measurement 
1.  Coping/Cognitive appraisal      
2.  Mood / affect      
3.  Disability      
4. Pain behaviour      
5.     Pain experience     
6.     Social role functioning   
7.     Health and social care use   
8.     Physiology / fitness     
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9.     Other ____________________ 
 
Source of measurement: 
Patient self-rating      
Spouse or family member     
Researcher / therapist, not blind to treatment   
Researcher, blind      
not stated        
Page number where data obtained: ________ 
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Treatment/control name.............................. Treatment/control  name.................... 
 
Mean pre-treatment:  __________  Mean pre-treatment:  __________ 
SD pre-treatment:  __________  SD pre-treatment: __________ 
N pre-treatment:  __________  N pre-treatment: __________ 
Mean post treatment: __________  Mean post treatment: __________ 
SD post treatment:  __________  SD post treatment:  __________ 
N post treatment:  __________  N post treatment: __________ 
Mean f-up 1:  __________  Mean f-up 1:   __________ 
SD f-up 1:   __________  SD f-up 1:   __________ 
N f-up 1:  __________  N f-up 1:  __________ 
Mean f-up 2:   __________  Mean f-up 2:  __________ 
SD f-up 2:  __________  SD f-up 2:   __________ 
N f-up 2:  __________  N f-up 2:   __________ 
 
Treatment/control name.............................. Treatment/control  name.................... 
Mean pre-treatment:  __________  Mean pre-treatment: __________ 
SD pre-treatment:  __________  SD pre-treatment:__________ 
N pre-treatment:  __________  N pre-treatment:__________ 
Mean post treatment: __________  Mean post treatment:_________ 
SD post treatment:  __________  SD post treatment: __________ 
N post treatment:  __________  N post treatment:________ 
Mean f-up 1:  __________  Mean f-up 1:  __________ 
SD f-up 1:   __________  SD f-up 1:  __________ 
N f-up 1:  __________  N f-up 1: __________ 
Mean f-up 2:   __________  Mean f-up 2: __________ 
SD f-up 2:  __________  SD f-up 2:  __________ 
N f-up 2:  __________  N f-up 2:  __________ 
Please give the times of the f-up data e.g. 6 months.  __________________ 
If the data is not in the form above is there a t or F test available if so what page is this on?  
_______________________________________________________ 
 
Do the authors report either of the following? 
t of pre-post change   Yes  No  on page no.  _____ 
correlation of pre-post change Yes  No  on page no.  _____ 
Reliable change index  Yes  No  on page no.  _____ 
Clinically significant change Yes  No  on page no.  _____ 
 
Notes of on any other aspect of the Outcome extraction that may need to be discussed 
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Appendix 5: Data Extraction Code Book 
Value Label   
arm_code 1 ACT as experiment   
  2 ACT as TAU   
  3 Behaviour therapy as experiment   
  4 Behaviour therapy as TAU   
  5 Biofeedback as experiment   
  6 Biofeedback as TAU   
  7 CBT as experiment (group) OUTPATIENT   
  8 CBT as TAU   
  9 Mindfulness as experiment   
  10 Mindfulness as TAU   
  11 Mixed as experiment   
  12 Mixed as TAU   
  13 Relaxation as experiment   
  14 Relaxation as TAU   
  15 education/bibliotherapy as experiment   
  16 education/bibliotherapy as control   
  17 arthritis education as experiment   
  18 arthritis education as TAU   
  19 specified standard care/TAU   
 20 Waiting list control   
 21 CBT as experiment (individual)   
 22 Exercise as experiment   
 23 Behavioural/Exercise as experiment   
 24 Cognitive therapy as experiment   
 25 cognitive & relaxation as experiment   
 26 CBT as experiment (GROUP) INPATIENT   
 27 Social support as experiment    
 28 Group CBT with family support 
(outpatient) 
  
 29 Education with family support   
 30 Spouse assisted group outpatient CBT   
 31 CBT plus biofeedback as experiment   
 32 Symptom monitoring and support as   
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Value Label   
experiment 
 33 Individual physiotherapy (outpatient)    
 34 Group outpatient loving kindness 
meditation  
  
 35 Education and behavioural as experiment 
group outpatient  
  
 36 Behavioural plus physical plus CBT group 
outpatient  
  
 37 GP medical review plus education   
 38 Education/attention/support in group 
outpatient as control  
  
 39 Mixed individual and group CBT as 
intensive outpatient experiment 
  
 40 CBT as experiment (individual) plus 
psychoeducation and TAU 
  
 41 Individual TAU plus psychoeducation    
 42 Behaviour therapy as experiment 
(inpatient) 
  
 43 CBT as experiment (group inpatient) plus 
gender specific components 
  
 44 CBT group outpatient plus graded 
exposure 
  
  (note: C&CA = coping and cognitive appraisal, EF = 
emotional functioning, PF = physical functioning, 
Pain = pain experience, PB = pain behaviour) 
OUTCOM
E 
DOMAIN 
 
measurement_code 1 coping strategies questionnaire (coping 
domain) 
C&CA 0 
  2 AIMS overall psychological dysfunction 
(mood domain) 
EF 0 
 
  3 AIMS anxiety (mood domain) EF 0 
  4 AIMS depression (mood domain) EF 0 
  5 HADS total (mood domain) EF 0 
  6 HADS anxiety (mood domain) EF 0 
  7 HADS depression (mood domain) EF 0 
  8 BAI (mood domain) EF 0 
  9 BDI (mood domain) EF 0 
   10 Brief symptom inventory (BSI) distress 
(mood domain) 
EF 0 
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Value Label   
  11 Centre for Epidemiologic Studies 
Depression Scale (CES-DS) (mood domain) 
EF 0 
  12 Clinical Outcomes in Routine Evaluation 
(CORE) total (mood domain) 
EF 0 
  13 CORE 34 W (mood domain) EF 0 
  14 CORE 34 P (mood domain) EF 0 
  15 CORE 34 F (mood domain) EF 0 
  16 CORE 34 R (mood domain) EF 0 
  17 Depression Adjective Checklist (DACL) 
(mood domain) 
EF 0 
  18 Depression Scale (DEPS) (mood domain) EF 0 
  19 Geriatric Depression Scale (GDS):  (mood 
domain) 
EF 0 
  20 Hopkins Symptom Checklist Distress 
(HSCD): (mood domain) 
EF 0 
  21 Impact of Rheumatic diseases on General 
health and Lifestyle (IRGL) Depression 
subscale (mood domain) 
EF 0 
  22 Minnesota Multiphasic Personality 
Inventory (MMPI) Depression subscale 
(mood domain) 
EF 0 
  23 State-Trait Anxiety Inventory State (STAI-
S) Subscale (mood domain) 
EF 0 
  24 State-Trait Anxiety Inventory Trait (STAI-
T) Subscale (mood domain) 
EF 0 
  25 (West Haven) Multidimensional Pain 
Inventory (WHYMPI) affective Distress 
(negative mood) subscale (mood domain) 
EF 0 
  26 Arthritis Impact Measurement Scale 
(AIMS) Activities of Daily Living (disability 
domain) 
PF 0 
  27 AIMS Physical Disability(disability domain) PF 0 
  28 AIMS mobility (disability domain) PF 0 
  29 AIMS dexterity (disability domain) PF 0 
  30 AIMS household activity (disability PF 0 
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domain) 
  31 AIMS physical activity(disability domain) PF 0 
  32 Disability Rating Index (disability domain) PF 0 
 EXCLUDE 33 Dusseldorf Disability Scale  (disability 
domain) 
 
6.4 DECIDED TO EXCLUDE AS NO 
DIRECTION POSSIBLE 
 
PF D
K 
  34 Fibromyalgia Impact Questionnaire total 
(disability domain) 
PF 0 
  35 Impact of Rheumatic diseases on General 
health and Lifestyle (IRGL) 
mobility/Functional Disability (disability 
domain) 
PF 0 
  36 Oswestry Disability Index   (disability 
domain) 
PF 0 
  37 Pain Disability Inventory   (disability 
domain) 
PF 0 
  38 Roland and Morris Disability 
Questionnaire   (disability domain) 
PF 0 
  39 Sickness Impact Profile (SIP; other) 
(disability domain) 
PF 0 
  40 Sickness Impact Profile (SIP; self)  
(disability domain) 
PF 0 
  41 SF-36 Physical Function/PHYSICAL HEALTH   
(disability domain) 
PF 1 
  42  (West Haven) Multidimensional Pain 
Inventory (WHYMPI) Activity subscale   
(disability domain) 
PF 1 
  43 (West Haven) Multidimensional Pain 
Inventory (WHYMPI) Pain Interference 
subscale  (disability domain) 
PF 0 
  44 Pain Behaviour Direct observation (pain 
behaviour domain) 
PB 0 
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  45 Pain Behaviour Exercise tests (e.g. five or 
ten minute walk, sit to stand, stairs 
climbed in x minutes etc)    (pain 
behaviour domain) 
PF 1 
  46 Pain behaviour Medication count    
(health and social care use) 
PB 0 
 EXCLUDE 47 Pain behaviour Self-report schedule  (pain 
behaviour domain) 
 
6.4 DECIDED TO EXCLUDE AS NO 
DIRECTION POSSIBLE – MUST HAVE ONLY 
BEEN USED IN BOS ANYWAY AS NOT IN 
SPSS 
PB D
K 
  48 Arthritis Impact Measurement Scale 
(AIMS) pain subscale (pain experience 
domain) 
Pain 0 
  49 Arthritis Self-Efficacy Scale  (pain 
experience domain) 
C&CA 1 
  50 Brief Pain Inventory (BPI)   (pain 
experience domain) 
Pain 0 
  51 Characteristic Pain Intensity   (pain 
experience domain) 
pain 0 
 
  52 Graded Chronic Pain Scale (pain 
experience domain) 
Pain 0 
  53 Impact of Rheumatic diseases on General 
health and Lifestyle (IRGL)  pain subscale 
(pain experience domain) 
pain 0 
  54 McGill Pain Questionnaire Pain Rating 
Index  (pain experience domain) 
Pain 0 
  55 
Memorial Pain Questionnaire   (pain 
experience domain) 
Pain 0 
  56 (West Haven) Multi-dimensional Pain 
Inventory (MPI) Pain Severity/Intensity 
Rating (pain experience domain) 
Pain 0 
  57 Numerical Rating Scale   (pain experience 
domain) 
pain 0 
  58 SF-36 Bodily Pain Scale  (pain experience 
domain) 
pain 1 
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  59 Verbal rating pain scale (pain experience 
domain) 
pain 0 
  60 Visual Analogue Scale  pain rating (pain 
experience domain) 
pain 0 
  61 Spielberger State Trait Anxiety Inventory 
(state subscale) (mood domain)  
EF 0 
  62 Sickness Impact Profile (SIP; other)   
(disability domain) 
PF 0 
 
  63 Sickness Impact Profile (SIP; self)  
(disability domain) 
PF 0 
  64 Visual Analogue Scale of Interference to 
social role functioning  (social role fn 
domain) 
PF 0 
  65 (West Haven) Multi-dimensional Pain 
Inventory (MPI) Life Control Subscale 
coping/cognitive appraisal domain) 
C&CA 1 
  66 AIMS social activity subscale (social role fn 
domain) 
PF 0 
 EXCLUDE 67 employment status (health and social 
care use domain) 
TBC E
X 
  68 Number of visits to GP   (health and social 
care use domain) 
PB 0 
  69 Number of visits to other medical settings 
(health and social care use domain) 
PB 0 
  70 Medication Use  (health and social care 
use domain) 
PB 0 
  71 Direct observation of motor pain 
behaviour (pain behaviour domain) 
PB 0 
  72 PSEQ (pain self-efficacy questionnaire; 
coping/cog appraisal domain) 
C&CA 1 
  73 Pain Catastrophising Scale (PCS; 
coping/cog appraisal domain) 
C&CA 0 
  74 chronic pain acceptance questionnaire 
(coping/cog appraisal domain) 
C&CA 1 
  75 DAPOS depression subscale (depression, 
anxiety and positive outlook scale; mood 
domain) 
EF 0 
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  76 DAPOS anxiety subscale (depression, 
anxiety and positive outlook scale; mood 
domain) 
EF 0 
  77 DAPOS positive outlook subscale 
(depression, anxiety and positive outlook 
scale; mood domain) 
EF 1 
  78 PASS - cognitive (Pain Anxiety Symptoms 
Scale, cognitive subscale, mood domain) 
C&CA 0 
  79 PASS - fear (Pain Anxiety Symptoms Scale, 
fear subscale, mood domain) 
C&CA 0 
  80 PASS - escape avoidance (Pain Anxiety 
Symptoms Scale, escape avoidance 
subscale, pain behaviour domain) 
C&CA 0 
  81 PASS - physiological (Pain Anxiety 
Symptoms Scale, physiological subscale, 
mood domain) 
C&CA 0 
  82 PASS total OR total short-form (Pain 
Anxiety Symptoms Scale, total, mood 
domain) 
EF 0 
  83 Brief Pain Inventory (BPI) interference 
subscale  (disability domain) 
PF 0 
  84 non veterans Pain Outcome 
Questionnaire total (disability domain) 
PF 0 
  85 non veterans Pain Outcome 
Questionnaire ADL subscale (disability 
domain) 
PF 0 
  86 non veterans Pain Outcome 
Questionnaire mobility subscale (disability 
domain) 
PF 0 
  87 non veterans Pain Outcome 
Questionnaire vitality subscale (disability 
domain) 
PF 0 
EXCLUDE 88 non veterans Pain Outcome 
Questionnaire fear subscale (mood 
domain) 
EF 0 
EXCLUDE 89 non veterans Pain Outcome 
Questionnaire negative affect subscale 
(mood domain) 
EF 0 
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EXCLUDE 90 SF-8 health related QoL (total:Disability 
domain) 
PF 1 
EXCLUDE 91 
WHO-QoL (total:disability domain) 
 d
k 
  92 Self-designed Physical Activity Profile 
(DIASBILITY domain) 
PF 0 
EXCLUDE 93 Self-designed Medication Review 
Questionnaire (health and social care use) 
 d
k 
EXCLUDE 94 British Pain Society Pain Rating Scale (pain 
experience domain) 
Pain 0 
  95 McGill Pain Questionnaire Short Form 
Pain Rating Index  (pain experience 
domain) 
Pain 0 
  96 Tampa Scale for Kinesophobia total 
(coping/cognitive appraisal) 
C&CA 0 
EXCLUDE 97 Patient generated index of social role fn 
(social role fn domain) 
 d
k 
EXCLUDE 98 Satisfaction with support scale (social role 
fn domain) 
 d
k 
EXCLUDE 99 
Euro-QoL (total: disability domain) 
 d
k 
EXCLUDE 100 Chronic pain coalition 5th vital sign scale 
(VAS; 1st 4 questions: pain experience 
domain) 
 d
k 
EXCLUDE 101 Chronic pain coalition 5th vital sign scale 
(VAS; last question: disability domain) 
 d
k 
EXCLUDE 102 Jenkins Sleep Scale (disability domain) PF 0 
 103 Fear Avoidance Beliefs Questionnaire 
(FABQ; coping/cognitive appraisal 
domain) 
C&CA 0 
EXCLUDE 104 Readiness to change questionnaire 
(coping/cog appraisal domain) 
 d
k 
EXCLUDE 105 Locus of control (coping/cog appraisal 
domain) 
 d
k 
EXCLUDE 106 Pain perception VAS (pain experience 
domain) 
 d
k 
EXCLUDE 107 
Pain anger domain VAS (mood domain) 
 d
k 
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 108 Patient-Related Self-Statements (PRSS) 
catastrophising scale (coping/cognitive 
appraisal domain) 
C&CA 0 
 109 Patient-Related Self-Statements (PRSS) 
active coping scale (coping/cognitive 
appraisal domain)  
C&CA 1 
EXCLUDE 110 Pain Coping Inventory (coping/cognitive 
appraisal domain)  
6.4 DECIDED TO EXCLUDE AS NO 
DIRECTION POSSIBLE – MUST HAVE ONLY 
BEEN USED IN BOS ANYWAY AS NOT IN 
SPSS 
C&CA d
k 
 111 Pain Coping Inventory, distraction by 
pleasant activities subscale 
(coping/cognitive appraisal domain) 
C&CA 1 
 112 Impact of Rheumatic diseases on General 
health and Lifestyle (IRGL) self-care 
domain ( disability domain)  
PF 1 
 113 Impact of Rheumatic diseases on General 
health and Lifestyle (IRGL) anxiety 
subscale (mood domain) 
EF 0 
 114 Impact of Rheumatic diseases on General 
health and Lifestyle (IRGL) potential 
emotional support subscale (social role 
functioning domain) 
PF 1 
 115 Impact of Rheumatic diseases on General 
health and Lifestyle (IRGL) actual 
emotional support subscale (social role 
functioning domain) 
PF 1 
 116 Impact of Rheumatic diseases on General 
health and Lifestyle (IRGL) mutual visits 
subscale (social role functioning domain) 
PF 1 
 117 Pain Behavior Checklist (pain behaviour 
domain) 
PB 0 
 118 Pain Behavior Checklist – modified 
(Spouse) (pain behaviour domain) 
PB 0 
N/B IN FINAL MEASURE 
COUNT JUST COUNT 
THESE WITH NORMAL 
SIP FOLLOWING 
119 
Sickness Impact Profile modified (SIP; self) 
(disability domain) 
PF 0 
143 
 
Value Label   
15.1.2010 DISCUSSION 
WITH SM 
N/B IN FINAL MEASURE 
COUNT JUST COUNT 
THESE WITH NORMAL 
SIP FOLLOWING 
15.1.2010 DISCUSSION 
WITH SM 
120 
Sickness Impact Profile modified (SIP; 
other) (disability domain) 
PF 0 
 121 Cognitive Errors Questionnaire 
(coping/cognitive appraisal domain)  
C&CA 1 
 122 Pain Disability Index total score (disability 
domain)  
PF 0 
 123 Pain Beliefs Questionnaire 
(coping/cognitive appraisal domain)  
 
C&CA 0 
 124 Pain diary pain experience (pain 
experience domain) 
Pain 0 
 125 Tubingen Pain Behavior Scale (PBS; pain 
behaviour domain)  
PB 0 
EXCLUDE 126 Electromyographic (EMG) baseline 
(microvolts) (physiology/fitness domain) 
 E
X 
EXCLUDE 127 Electromyographic EMG change from 
baseline (microvolts) (physiology/fitness 
domain) 
 E
X 
 128  Likert scale pain interference (disability 
domain) 
PF 0 
 129 Likert scale  pain distress (pain 
experience) 
pain 0 
 130 Likert  pain rating (pain experience 
domain) 
pain 0 
 131 Visual analogue scale pain experience 
SPOUSE (pain experience domain) 
Pain 0 
 132 Pain Cognitions Questionnaire – 
HOPELESSNESS SUBSCALE (PCQ; 
coping/cognitive appraisal domain) 
C&CA  0 
 133 State-Trait Anxiety Inventory TOTAL (STAI) 
(mood domain) 
EF 0 
 134 Pain Cognitions Questionnaire – ACTIVE 
COPING (PCQ; coping domain) 
C&CA 1 
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 135 Non-specified self-efficacy scale 
(coping/cognitive appraisal domain)  
C&CA 1 
 136 Lehmann low back physical scale (physical 
subscale (disability domain) 
PF  1 
 137 Lehmann low back pain rating scale 
(patient reported disability; disability 
domain) 
PF 1 
 138 Lehmann low back pain rating scale 
(physician reported disability; disability 
domain) 
PF 1 
 139 Lehmann low back pain rating scale (total; 
disability domain)  
PF 1 
 140 Check list for inter-personal pain 
behaviour: distorted mobility scale (CHIP 
distorted mobility; pain behaviour 
domain)  
PF 0 
 141 Check list for inter-personal pain 
behaviour: nervousness scale (CHIP 
nervousness; mood domain)  
EF 0 
 142 Check list for inter-personal pain 
behaviour: depression scale (CHIP 
depression; mood domain) 
EF 0 
 143 Pain Cognitions List: impact (PCL impact; 
coping/cognitive appraisal domain) 
C&CA 0 
 144 Pain Cognitions List: catastrophising (PCL 
catastrophising; coping/cognitive 
appraisal domain) 
C&CA 0 
 145 Behavioural Approach Test walking 
distance (BAT walking distance; pain 
behaviour domain) 
PF 1 
 146 Behavioural Approach Test walking time 
(BAT walking time; pain behaviour 
domain) 
PF 1 
 147 Pain Cognitions List: outcome efficacy 
(PCL outcome efficacy; coping/cognitive 
appraisal domain) 
C&CA 0 
 148 Likert coping (coping/cognitive appraisal 
domain) 
C&CA 1 
 149 Pain Management Inventory: active 
coping (PMI active; coping/cognitive 
C&CA 0 
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appraisal domain) 
 150 Pain Management Inventory: passive 
coping (PMI passive; coping/cognitive 
appraisal domain) 
C&CA 0 
 151 Combined measures of pain control 
(coping/cognitive appraisal)  
C&CA 1 
 152 Coping strategies questionnaire; 
relaxation (coping/cognitive appraisal 
domain)  
C&CA 1 
 153 Combined measures of catastrophising 
(coping/cognitive appraisal) 
C&CA 0 
 154 Combined measures of pain intensity 
(pain experience domain) 
Pain 0 
 155 Combined measures of pain 
behaviour(pain behaviour domain)  
Pain 0 
 156 Combined measures of activity (walking 
distances etc (disability domain) 
PF 1 
 157 Maudsley Obsessive Compulsive 
Inventory (unclear domain) 
EF 0 
 158 Fear Survey Schedule  EF 0 
EXCLUDE 159 Dutch Hyperventilation Questionnaire 
(DHQ; PAIN BEHAVIOUR DOMAIN)  
 e
x 
 160 Coping strategies coping scale 
(coping/cognitive appraisal domain)  
C&CA 1 
 161 Coping strategies pain control scale 
(coping/cognitive appraisal domain) 
C&CA 1 
 162 Health assessment questionnaire 
(disability domain)  
PF 0 
 163 Arthritis self-efficacy scale function 
(coping/cognitive appraisal) 
C&CA 1 
 164 Arthritis self-efficacy scale – arthritis 
(coping/cognitive appraisal) 
C&CA 1 
 165 Zung depression scale (mood)  EF 0 
 166 Perceived stress scale (coping/cognitive 
appraisal) 
C&CA 0 
 167 Perceived stress scale – coping scale 
(coping/cognitive appraisal)  
C&CA 1 
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 168 UCLA loneliness scale (coping/cognitive 
appraisal domain) 
C&CA 0 
 169 SF-36 Physical Role Function   (disability 
domain) 
PF 1 
 170 Impact of Rheumatic diseases on General 
health and Lifestyle (IRGL) social network 
(social role functioning domain) 
PF 1 
 171 Checklist individual strength fatigue scale 
(physiology/fitness)  
PF 0 
 172 Pain Coping Inventory ACTIVE COPING 
(coping/cognitive appraisal domain) 
C&CA 1 
 173 Pain Coping Inventory PASSIVE COPING 
(coping/cognitive appraisal domain) 
C&CA 0 
 174 Illness cognition questionnaire 
helplessness(coping/cognitive appraisal domain) 
 
C&CA 0 
 175 Illness cognition questionnaire acceptance 
(coping/cognitive appraisal domain) 
 
C&CA 1 
 176 Utrechtse Coping Lijst stress active coping 
(coping/cognitive appraisal domain) 
C&CA 1 
 177 Utrechtse Coping Lijst stress passive 
coping (coping/cognitive appraisal 
domain) 
C&CA 0 
 178 Impact of Rheumatic diseases on General 
health and Lifestyle (IRGL) mobility and 
self-care composite score (disability 
domain) 
PF  0 
 179 Perceived stress scale 4 item version 
(coping/cognitive appraisal) 
C&CA 0 
 180 
SF-36 fatigue severity (disability domain) 
PF 1 
 
 181 SF-36 global self-assessment  (disability 
domain) 
PF 1 
 182 likert subjective working capacity 
 (coping/cognitive appraisal) 
 
C&CA 1 
 183 likert benefits of working after 2 
years(coping/cognitive appraisal) 
C&CA 1 
 184 likert general wellbeing (disability 
domain)  
PF 0 
 185 Fibromyalgia Impact Questionnaire Physical PF 0 
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function (disability) 
 
 
 186 Fibromyalgia Impact Questionnaire feel 
good (mood) 
EF 0 
 187 Fibromyalgia Impact Questionnaire VAS 
pain (pain experience) 
Pain 0 
 188 Fibromyalgia Impact Questionnaire VAS 
fatigue (disability) 
PF 0 
 189 Fibromyalgia Impact Questionnaire VAS 
sleep (disability) 
PF 0 
 190 Fibromyalgia Impact Questionnaire VAS 
stiffness (disability) 
PF 0 
 191 Fibromyalgia Impact Questionnaire VAS 
anxiety (mood) 
EF 0 
 192 Fibromyalgia Impact Questionnaire VAS 
depression (mood) 
EF 0 
 193 McGill pain rating index intensity subscale 
(pain experience domain)  
pain 0 
 194 SF-36 general health (disability domain) 
 
PF 1 
 195 SF-36 vitality (disability) PF 1 
 196 SF-36 social functioning (social role 
functioning) 
PF 1 
 197 SF-36 emotional role (disability) PF 1 
 198 SF-36 mental health (mood/affect) EF 1 
 199 Chronic Pain Self-Efficacy Scale pain 
management (coping/cognitive appraisal) 
 
C&CA 1 
 200 SF-36 health change (coping/cognitive 
appraisal) 
 
C&CA 1 
 201 Chronic Pain Self-Efficacy Scale physical 
function (coping/cognitive appraisal)  
C&CA 1 
 202 Chronic Pain Self-Efficacy Scale symptoms 
(coping/cognitive appraisal) 
C&CA 1 
 203 
 
Chronic Pain Coping Inventory asking for 
assistance (coping/cognitive appraisal) 
C&CA 0 
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 204 Chronic Pain Coping Inventory guarding 
(coping/cognitive appraisal) 
C&CA 0 
 205 Chronic Pain Coping Inventory resting 
(coping/cognitive appraisal) 
C&CA 0 
 206 Chronic Pain Coping Inventory relaxation 
(coping/cognitive appraisal) 
C&CA 1 
 207 Chronic Pain Coping Inventory task 
persistence (coping/cognitive appraisal) 
C&CA 1 
 208 Chronic Pain Coping Inventory exercise 
(coping/cognitive appraisal) 
C&CA 1 
 209 Chronic Pain Coping Inventory social 
support (coping/cognitive appraisal) 
C&CA 1 
 210 Chronic Pain Coping Inventory self-
statements (coping/cognitive appraisal) 
C&CA 1 
 211 McGill pain rating index sensory subscale 
(pain experience domain) 
Pain 0 
 212 McGill pain rating index affective subscale 
(pain experience domain) 
Pain 0 
 213 McGill pain rating index evaluative 
subscale (pain experience domain) 
Pain 0 
 214 Brief pain inventory usual pain (pain 
experience domain) 
Pain 0 
 215 Brief pain inventory worst pain (pain 
experience domain) 
Pain 0 
 216 State trait anger expression STAXI-II anger 
expression in(Mood domain) 
 
EF 0 
 217 State trait anger expression STAXI-II anger 
expression out (Mood domain) 
EF 0 
 218 State trait anger expression  STAXI-II 
control in (Mood domain) 
EF 0 
 219 State trait anger expression STAXI-II 
control out (Mood domain) 
EF 0 
 220 AIMS2 upper limb (disability) PF 0 
 221 AIMS2 lower limb (disability) PF 0 
 222 Arthritis Self-Efficacy Scale OTHER 
symptoms (self-efficacy domain) 
C&CA 1 
 223 Rheumatoid Attitudes Index Helplessness 
(coping/cognitive appraisal) 
C&CA 0 
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 224 Rheumatoid Attitudes Index 
Internality(coping/cognitive appraisal) 
C&CA 0 
 225 AIMS2 health status (ie AIMS total) 
(disability domain)  
PF 0 
 226 AIMS2 satisfaction with health (domain 
TBC) 
PF 0 
 227 Joint Protection Behaviour Assessment 
(JPBA) (pain behaviour)  
PB 1 
 228 Hand pain visual analogue scale (pain 
experience) 
Pain 0 
 229 Graded Chronic Pain Scale   activity 
interference (disability domain) 
PF 0 
 230 Graded Chronic Pain Scale  pain intensity 
(pain experience domain) 
Pain  0 
 231 Survey of Pain Beliefs (SOPA) disability 
(disability domain) 
C&CA 0 
 232 Survey of Pain Beliefs (SOPA) harm 
(Coping/cognitive appraisal) 
C&CA 0 
 233 Survey of Pain Beliefs (SOPA) control 
(coping/cognitive appraisal) 
C&CA 1 
 234 TMD Self-Efficacy Scale  
(COPING/COGNITIVE APPRAISAL) 
C&CA 1 
 235 Coping strategies questionnaire 
catastrophising domain (coping/cognitive 
appraisal)  
C&CA 0 
 236 Pain Catastrophising Scale rumination 
(PCS; coping/cog appraisal domain) 
C&CA 0 
 237 Days without pain per week (pain 
experience) 
Pain 1 
 238 Likert control over pain (coping/cognitive 
appraisal)  
C&CA 1 
 239 Days with medication per week (health 
and social care use) 
PB 0 
 240 Heidelberg Coping Scale Cognitive 
Strategies (coping/cognitive appraisal)  
C&CA 1 
 241 Heidelberg Coping Scale avoidance 
behaviour (Coping/cognitive appraisal) 
C&CA 0 
 242 Heidelberg Coping Scale pleasant 
activities (Coping/cognitive appraisal)  
C&CA 1 
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 243 Heidelberg Coping Scale social support 
(Coping/cognitive appraisal) 
C&CA 1 
 244 Heidelberg Coping Scale philosophical 
beliefs (coping/cognitive appraisal)  
C&CA 0 
 245 Dusseldorf Disability Scale  disability to 
social relations (social role functioning) 
PF 0 
 246 Dusseldorf Disability Scale  disability to 
social roles (social role functioning) 
PF 0 
 247 Dusseldorf Disability Scale  disability to 
physical functions (disability)  
PF 0 
 248 Dusseldorf Disability Scale  disability to 
mental performance (disability) 
PF 0 
 249 Dusseldorf Disability Scale  disability to 
physical performance (disability)  
PF 0 
 250 Psychological General Well Being scale 
(disability domain) 
PF 1 
 251 Shortened version (16 item) Roland and 
Morris Disability Questionnaire   
(disability domain) 
PF 0 
 252 Physician related concerns re pain meds 
intake (health and social care use domain) 
PB 0 
 253 Brief Norwegian version of Hopkins 
Symptom Checklist : (mood domain) 
EF 0 
 254 Ursin’s health inventory subjective health 
total (disability domain) 
PF 0 
 255 Visual Analogue Scale of Interference 
(disability domain) 
PF 0 
 256 (West Haven) Multidimensional Pain 
Inventory (WHYMPI) household chores 
(disability domain) 
PF 1 
 257 (West Haven) Multidimensional Pain 
Inventory (WHYMPI) outdoor work 
(disability domain) 
PF 1 
 258 (West Haven) Multidimensional Pain 
Inventory (WHYMPI) activities away from 
home (disability domain) 
PF 1 
 259 (West Haven) Multidimensional Pain 
Inventory (WHYMPI) social 
activities(disability domain) 
PF 1 
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 260 Coping strategies questionnaire; diverting 
attention (coping/cognitive appraisal 
domain) 
C&CA  1 
 261 Coping strategies questionnaire; 
reinterpret pain sensations 
(coping/cognitive appraisal domain) 
C&CA  1 
 262 Coping strategies questionnaire; coping 
self-statement (coping/cognitive appraisal 
domain) 
C&CA  1 
 263 Coping strategies questionnaire; ignore 
pain sensations (coping/cognitive 
appraisal domain) 
C&CA  1 
 264 Coping strategies questionnaire; praying 
and hoping (coping/cognitive appraisal 
domain) 
C&CA  0 
 265 Coping strategies questionnaire; increase 
activity level (coping/cognitive appraisal) 
C&CA  1 
 266 Coping strategies questionnaire; increase 
pain behaviours (pain behaviour domain) 
C&CA  0 
 267 (West Haven) Multidimensional Pain 
Inventory (WHYMPI) support (social role 
functioning domain) 
PF 1 
 268 (West Haven) Multidimensional Pain 
Inventory (WHYMPI) punishing responses 
(negative responses) (social role 
functioning)  
PF 0 
 269 (West Haven) Multidimensional Pain 
Inventory (WHYMPI) solicitous responses 
(social role functioning)  
PF 0 
 270 (West Haven) Multidimensional Pain 
Inventory (WHYMPI) distracting responses 
(social role functioning) 
PF 0 
EXCLUDE 271 Pain Discomfort Scale (pain domain)  0 
EXCLUDE 272 11-Point Box Scale (likert) (pain 
experience domain) 
 0 
 273 Quality of Well Being Scale (QWB) 
(disability domain) 
PF 1 
 274 Myalgia score (pain experience domain) pain 0 
 275 Quality of social support scale (social role PF 1 
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functioning) 
 276 Combined measures of depressed and 
negative cognitions (mood domain) 
EF 0 
EXCLUDE 277 Combined measures of using acute pain 
strategies (coping/cognitive appraisal) 
6.4 DECIDED TO EXCLUDE AS NO 
DIRECTION POSSIBLE – MUST HAVE ONLY 
BEEN USED IN BOS ANYWAY AS NOT IN 
SPSS 
C&CA  
 278 (West Haven) Multidimensional Pain 
Inventory (WHYMPI) self-efficacy scale – 
item added to German version  
(coping/cognitive appraisal) 
C&CA 1 
 279 No. Of hours sleep (disability domain) PF 1 
 280 Visual analogue scale anxiety (mood 
domain) 
EF 0 
 281 Global self rating index of health 
perception (GSI; disability) 
PF 0 
 282 Arm endurance test (physical functioning 
domain) 
PF  1 
 283 Sleep quality (physical functioning) PF  1 
 284 Survey of Pain Beliefs (SOPA) medical cure 
(coping/cognitive appraisal) 
C&CA 0 
 285 Upper limb activity (physical functioning) PF  1 
 286 Lower limb activity (Physical functioning 
domain) 
PF  1 
 287 
Vertebral column activity (Physical 
functioning domain 
PF  1 
 288 
Mandibular function impairment 
questionnaire masticatory(MFIQ; physical 
function) 
PF  0 
 289 
Mandibular function impairment 
questionnaire non-masticatory(MFIQ; 
physical function) 
PF  0 
 290 
Sleep quality where decrement = 
improvement 
PF  0 
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 291 Brief Pain Inventory (BPI) intensity 
subscale  (disability domain) 
PF 0 
 292 Modified 8-item Arthritis Self-Efficacy 
Scale total (coping/cognitive appraisal) 
C&CA 1 
 293 Chronic Pain Coping Inventory 
pacing(coping/cognitive appraisal) 
C&CA 1 
 294 Quebec back pain disability scale (any 
language version) disability 
PF 0 
 295 Patient specific complaints (visual 
analogue scale) (disability) 
PF 0 
 296 Short version Photograph Series of Daily 
Activities (PHODA-SeV) (coping/cognitive 
appraisal) 
PF 1 
EXCLUDE 297 RT3 Tri-Axial Research Tracker (activity 
levels)  
6.4 DECIDED TO EXCLUDE  
 
PF 1 
 298 chronic pain acceptance questionnaire – 
activity engagement subscale 
(coping/cognitive appraisal) 
C&CA 1 
 299 Positive and negative affect schedule 
(PANS) positive affect subscale 
EF 1 
 300 Positive and negative affect schedule 
(PANS) negative affect subscale 
EF 0 
 301 Pain self-efficacy scale (PSEQ; coping 
cognitive appraisal) 
C&CA 1 
 302 Depression and Anxiety Stress Scales 
(DASS) depression subscale 
EF 0 
 303 Depression and Anxiety Stress Scales 
(DASS) anxiety subscale 
EF 0 
 304 Arthritis self-efficacy scale overall 
(coping/cognitive appraisal) 
C&CA 1 
 305 Dyadic adjustment scale (role functioning) PF 1 
 306 Minnesota Multiphasic Personality 
Inventory (MMPI) Somatization subscale 
(domain) 
EF 0 
 307 PARS (Spouse related community 
adjustment 
PF 1 
NB. 278 separate outcome measures were used in the final pre-post analysis once those 
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whose direction could not be ascertained had been removed and duplicates merged. 
Measurement_direction 0 decrement is improvement   
 1 increment is improvement    
measurement_domain 1 coping/cognitive appraisal   
  2 mood   
  3 disability   
  4 pain behaviour (includes beh. activity, 
may do post hoc analysis) 
  
  5 pain experience   
  6 social role functioning   
  7 health and social care use   
  8 (physiology/fitness - unlikely to use)   
  9 unclear   
IMMPACT/coping cog 
appraisal domain 
1 
Pain experience 
  
 2 Physical functioning   
 3 Emotional functioning   
 4 Coping and cognitive appraisal   
 5 TBC   
 6 Pain behaviour    
measurement_source 1 patient   
  2 spouse/family   
  3  researcher blind   
  4  researcher not blind   
  5 not stated   
reactivity_measure 0 low (eg patient rated)   
  1 high (eg non patient rated)   
  2 unclear   
specficity_measure 0 low (eg not related to target problem)   
  1 high (eg related to target problem)   
  2 unclear   
effect_sizes_recorded 0 no   
  1 yes   
  2 unclear   
ITT_analyses_conducted 0 no   
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  1 yes   
  2 unclear   
RCI_calculated 0 no   
  1 yes   
  2 unclear   
t_of_pre_post_change     
correlation_pre_post_ch
ange 
 
 
  
outcome_data_page_nu
mbers 
 
 
  
mean_pre_treatment     
SD_pre_treatment     
n_pre_treatment     
mean_post_treatment     
SD_post_treatment     
n_post_treatment     
time_to_follow_up_1 1 1 week after post treatment   
  2 2 weeks after post treatment   
  3 3 weeks after post treatment   
  4 4 weeks after post treatment   
  5 5 weeks after post treatment   
  6 6 weeks after post treatment   
 12 12 weeks after post-treatment    
 14 14weeks after post treatment    
 16 4 months after post treatment    
  26 6 months after post treatment   
 36 9 months post-treatment    
 52 Year after post treatment   
 60 15 months post treatment   
 104 2 year after post treatment   
mean_follow_up_1     
SD_follow_up_1     
n_follow_up_1     
time_to_follow_up_2 1 1 week after post treatment   
  2 2 weeks after post treatment   
  3 3 weeks after post treatment   
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Value Label   
  4 4 weeks after post treatment   
  5 5 weeks after post treatment   
  6 6 weeks after post treatment   
 12 12 weeks after post treatment    
 14 14weeks after post treatment    
 16 4 months after post treatment    
 26 6 months after post treatment   
 36 9 months post treatment    
 52 Year after post treatment   
 60 15 months post treatment   
 78 18 months post treatment   
 104 2 year after post treatment   
mean_follow_up_2     
SD_follow_up_2     
n_follow_up_2     
(same as above for 
follow up 3 too)  
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Appendix 6: Survey Round One, Outcome Domains (study 3) 
 
In order that I am able to describe the composition of this expert panel, it would be helpful if 
you could complete the following 'about you' questions. These will not be connected to your 
subsequent survey responses in any way. 
1.  Please record your current profession and job title (if this is different) in the below space 
   
2.  How long ago did you achieve your professional qualification?    
3.  For how many years have you worked within this PMP?    
4.  Are you male or female?    
Thank you for providing this information. 
Survey 1: Assessing the importance of particular outcome domains   
This survey asks you to consider a number of potential outcome domains that PMPs could 
employ. This list is based upon a number of suggestions within the research literature in 
addition to the collective responses within the previous PMP survey. At this stage I would like 
you to consider these domains and rate the importance of each one. I would also like you to 
consider and comment upon the definition of each domain which has been provided and, if 
applicable, suggest specific measures within each domain that you rate as important. I 
appreciate that not all measures will be of relevance to your professional role, but would like 
you to consider the multi-disciplinary nature of PMPs within your ratings and 
recommendations. 
5.  Potential Outcome Domain   
a. Coping or cognitive appraisal        
 b. Mood        
 c. Disability        
 d. Pain behaviour or activity        
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 e. Pain experience        
 f. Social role functioning        
 g. Physiology or fitness  
Indicate whether you think it is:  
very important    
somewhat important     
unimportant, or     
definitely not important  
to measure these domains within your PMP.  
Please select the 'More Info' box (to the right) to view domain definitions, and use the space 
below to comment upon these. 
If you have indicated that this domain is important, please use the below space to recommend 
specific measures. 
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Appendix 7: Survey Round Two, Outcome Domains (study 3) 
 
In order that I am able to describe the composition of this expert panel, it would be helpful if 
you could complete the following 'about you' questions. 
These will not be connected to your subsequent survey responses in any way. 
1.  Please record your current profession and job title (if this is different) in the below space 
   
2.  How long ago did you achieve your professional qualification?    
3.  For how many years have you worked within this PMP?    
4.  Are you male or female?    
Thank you for providing this information. 
The second survey   
This survey asks you to consider the collective responses to the previous survey and suggest 
improvements to domain definitions. It also asks you to consider the collective ratings of 
importance assigned to these domains, and decide whether you agree that each domain 
should be included. Finally, it asks you to consider the outcome measures suggested in the 
previous survey, and assign each one to a domain. I appreciate that not all measures will be of 
relevance to your professional role, but would like you to consider the multi-disciplinary nature 
of PMPs within your responses. 
Domain definitions and importance   
5.  Coping or cognitive appraisal: e.g. measures of cognitive strategies and appraisals used to 
manage pain. 
One expert suggested that repeating the words 'cognitive' and 'appraisal' made this definition 
unclear. Others implied the importance of measures within this domain, including 
catastrophising, changes to thinking patterns as indicated by re-appraisal of the situation, self-
efficacy and fear of movement. 
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Please use the below space to record your views upon these comments and how this domain 
could be defined.    
In the previous survey, 91.7% of experts (n=11) rated this domain as very important, and 8.3% 
(n=1) as somewhat important. 
With this in mind and your reflections upon the definition above, do you think that PMPs 
should definitely measure outcomes within this domain? 
Yes, No   
6.  Mood: e.g. depressive state, anxious state. 
Experts suggested that the examples used were useful but restrictive and that experiences 
such as anger and frustration should also be incorporated, with one suggestion that response 
to mood may be more significant than mood itself. 
Please use the below space to record your views upon these comments and how this domain 
could be defined.    
In the previous survey, two-thirds of experts (n=8) rated this domain as very important, with 
the remaining third (n=4) rating it as somewhat important. 
With this in mind and your reflections upon the definition above, do you think that PMPs 
should definitely measure outcomes within this domain? 
Yes, No   
7. Disability: e.g. activities of daily living, impact on health and lifestyle. 
Only one expert commented on the definition itself. Others suggested that it was fundamental 
to assess disability, with a contrasting view that PMP patients may have inaccurate views of the 
extent of their disability and therefore measuring it may not be meaningful. 
Please use the below space to record your views upon these comments and how this domain 
could be defined. 
In the previous survey, two-thirds (n=8) rated disability as very important to measure, with 
25% (n=3) viewing it as somewhat important and 8.3% (n=1) as unimportant. 
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With this in mind and your reflections upon the definition as above, do you think that PMPs 
should definitely measure outcomes within this domain? 
Yes, No   
8.  Pain behaviour or activity: e.g. behavioural acts associated with pain, including distance able 
to walk etc. 
Several experts suggested that the amalgamation of pain behaviour and activity was logical, 
with a contrasting view that they should be classed separately. The view that the definition was 
too vague and should be more specific, perhaps including fear-avoidance related behaviours, 
help-seeking and healthcare use was also expressed, with one additional view that the level of 
importance assigned to the domain may be dependent on the domain definitions themselves. 
Please use the below space to record your views upon these comments and how this domain 
could be defined. 
In the previous survey, two-thirds of experts (n=8) rated this domain as 'very important, with 
25% (n=3) and 8.3% (n=1) rating it as somewhat important and unimportant respectively. 
With this in mind and your reflections upon the definition above, do you think that PMPs 
should definitely measure outcomes within this domain? 
Yes, No   
9.  Pain experience: e.g. ratings of pain intensity, sensation and unpleasantness. 
This was the domain which led to the least consensus. Experts commented that pain 
experience is hard to define due to its subjectivity, and therefore that it may be a less 
important domain to measure within PMPs, particularly as treatment progresses. 
Please use the below space to record your views upon these comments and how this domain 
could be defined.    
In the previous survey, 25% (n=3) rated this domain as very important, 50% (n=6) as somewhat 
important, 16.7% (n=2) and 8.3% (n=1) as unimportant and definitely not important 
respectively. 
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With this in mind and your reflections upon the definition above, do you think that PMPs 
should definitely measure outcomes within this domain? 
Yes, No   
10.  Social Role Functioning: e.g. assessments of the ability of the person to function in various 
social roles, including familial, leisure and employment related roles. 
There was a general view that it would be more appropriate to re-name this domain 'role' 
functioning given that the definition incorporated home and family as well as work and leisure 
roles. There was also an expectation that outcomes within this domain may overlap with those 
in the pain behaviour and coping domains, and be of variable levels of importance depending 
on individual patients. 
Please use the below space to record your views upon these comments and how this domain 
could be defined.    
In the previous survey, two-thirds (n=8) of experts viewed this as a very important domain to 
measure, with 25% (n=3) and 8.3% (n=1) viewing it is somewhat important and unimportant 
respectively. 
With this in mind and your reflections upon the definition above, do you think that PMPs 
should definitely measure outcomes within this domain? 
Yes, No   
11.  Physiology/fitness: e.g. assessments of biological functioning and physical fitness. 
Several participants commented that timed walks may be applicable within this domain, and 
that it was a difficult domain to measure. 
Please use the below space to record your views upon these comments and how this domain 
could be defined. 
Participants in the previous survey varied greatly in terms of the importance they assigned to 
measures within this domain, with 25% (n=3) rating it as very important, 58.3% (n=7) as 
somewhat important and 16.7% (n=2) as unimportant. 
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With this in mind and your reflections upon the definition above, do you think that PMPs 
should definitely measure outcomes within this domain? 
Yes, No   
12.  In the first survey you suggested a number of outcome measures that would be useful 
within PMPs (listed below) but there was a lack of consensus regarding the domains within 
which particular measures were assigned. 
You are now invited to assign each measure that you are familiar with to the domain which you 
feel is most appropriate. 
Some measures comprise scales which are relevant to more than one domain, i.e. are multi-
dimensional. If you perceive a measure to be multi-dimensional, please select this and state 
the most appropriate domain for the total measure score, and suggest domains for the 
particular scales within the measure.    
Please state the most appropriate domain for the total measure score and the scales within 
this measure.  
N/A - I am not familiar with the measure     
Coping or cognitive appraisal     
Mood     
Disability     
Pain behaviour or activity     
Pain experience     
Social role functioning     
Physiology or fitness     
Multi-dimensional  
 a. Arm Rotation          
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 b. Beck Anxiety Inventory         
 c. Beck Depression Inventory        
 d. Brief Pain Inventory         
 e. Canadian Occupational Performance Measure activity scale    
 f. Canadian Occupational Performance Measure total    
 g. Chronic Pain Acceptance Questionnaire       
 h. Coping Strategies Questionnaire        
i. Fear Avoidance Beliefs Questionnaire       
 j. General Health Questionnaire-12        
13.      
 Please state the most appropriate domain for the total measure score and the scales within 
this measure.  
N/A - I am not familiar with the measure     
Coping or cognitive appraisal     
Mood     
Disability     
Pain behaviour or activity     
Pain experience     
Social role functioning     
Physiology or fitness     
Multi-dimensional  
 a. Hospital Anxiety and Depression Scale       
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 b. McGill short-form          
 c. Medication Count          
 d. Nottingham Health Profile        
 e. Observation (non-specified)        
 f. Oswestry Disability Index         
 g. Pain Catastrophising Scale        
 h. Pain Disability Questionnaire        
 i. Pain Self-Efficacy Questionnaire        
 j. Roland Morris Disability Questionnaire       
14.    Please state the most appropriate domain for the total measure score and the scales 
within this measure.   
  N/A - I am not familiar with the measure     
Coping or cognitive appraisal     
Mood     
Disability     
Pain behaviour or activity     
Pain experience     
Social role functioning     
Physiology or fitness     
Multi-dimensional  
 a. Short-Form 8 total          
 b. Short-Form 36 total         
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 c. Short- Form-36 Bodily Pain        
 d. Sickness Impact Profile          
e. Sit and reach         
f. Sit to stand          
 g. Tampa Scale for Kinesophobia        
 h. Visual Analogue Scale distress        
 i. Visual Analogue Scale interference       
 j. Walking  
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Appendix 8: Survey Round Two Summary (study 3) 
Dear colleague, 
In recent months you have been a member of an expert panel of thirteen whose initial task 
was to generate a list of outcome measures of use within Pain Management Programmes 
(PMPs) by completing electronic surveys; conducted in line with the Delphi method. The data 
from two surveys has now been analysed, and I am writing to you with a summary of the 
results and to confirm that this part of my research is now complete. 
The results of the first survey demonstrated a broad consensus regarding the utility of specific 
outcome domains, but more variability with regard to the domain definitions and assignment 
of measures to domains; congruent within a recently published review of measures for people 
with chronic pain (reference supplied). The purpose of the second survey was therefore 
amended, and it sought more clarification regarding domain definitions and the assignment of 
measures.  
Of the 77% of experts who completed the second survey (n=10) there was a general consensus 
(defined as 70% agreement) that measures within the domains of coping and cognitive 
appraisal, mood, disability and social role functioning should definitely be measured within 
PMPs. There was a lack of consensus, however, as to whether measures within the domains of 
pain behaviour, pain experience and physiology/fitness should be incorporated, and upon the 
most useful manner in which each domain could be defined. Overall, experts agreed that the 
value of a measure should be determined by the context and the specific aims of a PMP, and 
that overlap between domains should not preclude the use of any measure.  
As a consequence of these results I have updated a review of the literature regarding outcome 
domains within chronic pain, and the results of both will ultimately inform the manner in which 
data from Randomised Controlled Trials (RCTs) is aggregated within the meta-analysis that I 
will conduct in the coming months.  
I would like to take this opportunity to thank you for your participation; it has been much 
appreciated. If you have any further queries regarding this research, or would like a copy of my 
thesis when it is complete then please let me know and I will be happy to forward it to you.  
Yours faithfully, 
Grania Fenton (contact details supplied) 
